Synthesis of Multi-Functional Building Blocks from Acetylene Containing a Amino Acids by Esseveldt, B.C.J. van
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/19510
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
  
 
 
 
 
Synthesis of Multi-Functional Building Blocks 
from Acetylene-Containing α-Amino Acids 
  
 
 
 
 
Synthesis of Multi-Functional Building Blocks 
from Acetylene-Containing α-Amino Acids 
 
 
 
 
 
Een wetenschappelijke proeve op het gebied van de 
Natuurwetenschappen, Wiskunde & Informatica 
 
 
 
 
 
 
 
 
Proefschrift 
 
 
ter verkrijging van de graad van doctor aan de Radboud Universiteit Nijmegen 
op gezag van de Rector Magnificus prof. dr. C. W. P. M. Blom, 
volgens besluit van het College van Decanen in het openbaar te verdedigen 
op donderdag 14 oktober 2004 des namiddags om 1.30 uur precies 
 
 
 
 
 
 
door 
 
Bart Cornelis Johannes van Esseveldt 
 
geboren op 6 november 1974 te Deurne 
 
 
 
  
Promotor: Prof. dr. F. P. J. T. Rutjes 
 
Copromotor: Dr. F. L. van Delft 
 
Manuscriptcommissie: Prof. dr. R. J. M. Nolte 
 Prof. dr. H. E. Schoemaker (DSM Research, Geleen) 
 Prof. dr. B. Zwanenburg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De uitgave van dit proefschrift werd mede gerealiseerd met financiële steun van de J. E. 
Jurriaanse Stichting, Rotterdam. 
 
Omslag: Lidwien van der Horst & John Slippens, Afdeling Grafische Vormgeving, 
Faculteit NWI, Radboud Universiteit Nijmegen 
Realisatie: Ponsen & Looijen bv, Wageningen 
 
ISBN 90-9018409-0 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aan mijn ouders 
 
  
CONTENTS 
 
 
CHAPTER 1 ACETYLENE-CONTAINING α-AMINO ACIDS 
 
1.1 Introduction 1 
1.2 Side Chain Modifications 2 
1.3 Cyclization Reactions of the Amino Acids 10 
1.4 Miscellaneous Modifications 14 
1.5 Biosynthetic Applications 19 
1.6 Purpose and Outline of this Investigation 20 
1.7 References 20 
 
 
CHAPTER 2 SYNTHESIS OF NOVEL TRYPTOPHAN ANALOGUES 
 
2.1 Introduction 23 
2.2 Tryptophan Analogues 24 
2.3 Attempted Pd-Catalyzed Indole Formation 26 
2.4 Cyclizations of Several Functionalized Cyclization Precursors 28 
2.5 Metal-Catalyzed Synthesis of Tryptophan Analogues 31 
2.6 Conclusions 35 
2.7 Acknowledgments 35 
2.8 Experimental Section 36 
2.9 References 48 
 
 
CHAPTER 3 FUNCTIONALIZED BUILDING BLOCKS FROM  
 ACETYLENE-CONTAINING α-AMINO ACIDS 
 
3.1 Introduction 51 
3.2 Pd-Catalyzed Pyrroline Formation 53 
3.3 Mechanistic Aspects 55 
3.4 Cyclizations of Several Functionalized Cyclization Precursors 57 
3.5 Metal-Catalyzed Lactone Formation 61 
3.6 Reactions with the Pyrrolines 63 
3.7 Conclusions 65 
3.8 Acknowledgments 65 
3.9 Experimental Section 66 
3.10 References 77 
 
 
  
CHAPTER 4 5-SUBSTITUTED PROLINE ANALOGUES 
 
4.1 Introduction 79 
4.2 Metal-Catalyzed Pyrroline Formation 81 
4.3 Ag-Catalyzed Cyclizations of Several Functionalized 83 
 Cyclization Precursors 
4.4 Synthesis of Pyridyl-Substituted Pyrrolines 86 
4.5 Hydrogenation to 5-Substituted Proline Analogues 89 
4.6 Conclusions 90 
4.7 Acknowledgments 90 
4.8 Experimental Section 91 
4.9 References 98 
 
 
CHAPTER 5 FUNCTIONALIZED HETEROCYCLIC ENEDIYNES 
 
5.1 Introduction 101 
5.2 Preparation of Functionalized Azaenediynes 104 
5.3 Preliminary Studies toward Enediyne-Containing Dipeptides 106 
5.4 Conclusions 109 
5.5 Acknowledgments 109 
5.6 Experimental Section 109 
5.7 References 115 
 
 
SUMMARY 117 
 
SAMENVATTING 121 
 
PUBLICATIONS & ORAL COMMUNICATIONS 125 
 
DANKWOORD 127 
 
CURRICULUM VITAE 129 
  
LIST OF ABBREVIATIONS 
 
 
Ac acetyl HRMS high resolution mass 
AIBN azoisobutyronitrile  spectrum 
aq aqueous IR infra red 
Ar aryl J coupling constant (in NMR) 
Bn benzyl LDA lithium diisopropylamide 
Boc tert-butyloxycarbonyl m multiplet (in NMR) 
br broad (in NMR) Me methyl 
tBu tert-butyl min minute(s) 
nBu n-butyl mp melting point 
Cbz benzyloxycarbonyl Ms methanesulfonyl 
CI chemical ionization (in MS) MS mass spectrometry 
d doublet (in NMR) NBS N-bromosuccinimide 
dba dibenzylideneacetone NMM N-methylmorpholine 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene NMR nuclear magnetic resonance 
DCC dicyclohexylcarbodiimide NOE nuclear Overhauser effect 
DDQ dichloro dicyano quinone Nu nucleophile 
DIBAL-H diisobutylaluminum hydride PG protective group 
DIPEA diisopropylethylamine Ph phenyl 
DMAP 4-(dimethylamino)pyridine iPr isopropyl 
DMB 2,4-dimethoxybenzyl nPr n-propyl 
DME 1,2-dimethoxyethane rt room temperature 
DMF N,N-dimethylformamide Rf retention factor 
DMT-MM 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)- rac racemic 
 4-methylmorpholinium chloride s singlet (in NMR) 
EDCI 1-(3-dimethylaminopropyl)- t triplet (in NMR) 
 3-ethylcarbodimide THF tetrahydrofuran 
ee enantiomeric excess Ts para-toluenesulfonyl 
EI electron impact (in MS) Tf trifluoromethanesulfonyl 
equiv equivalent TBDMS tert-butyldimethylsilyl 
Et ethyl TLC thin layer chromatography 
Fmoc 9-fluorenylmethoxycarbonyl TFA trifluoroacetic acid 
FT Fourier transform TFAA trifluoroacetic anhydride 
h hour(s) TBDPS tert-butyldiphenylsilyl 
HOBt 1-hydroxybenzotriazole TES triethylsilyl 
HPLC high pressure liquid TBAF tetrabutylammonium fluoride 
 chromatography 
1 
 
CHAPTER 1 
 
ACETYLENE-CONTAINING α-AMINO ACIDS 
 
 
1.1 Introduction 
 
Acetylene-containing α-amino acids such as 1-3 comprise a class of unsaturated 
amino acids that, in contrast to the proteinogenic α-amino acids, are not encountered in 
nature as constituents of proteins. Some of these so-called non-proteinogenic amino acids, 
however, do occur in nature and have been isolated at least in one of the enantiomeric forms 
from natural sources. 
 
1 2 3
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(S)-Propargylglycine (1), for example, was found in the mushroom Amanita 
pseudoporphyria1 and was also isolated from a Streptomyces strain.2 It possesses antibacterial 
activity and was reported to be an inhibitor of several pyridoxal phosphate-dependent 
enzymes.3 The homologous (S)-homopropargylglycine (2) was isolated from the Japanese 
mushroom Cortinarius claricolor and showed antibiotic activity against Bacillus subtilis B-50.4 
In addition to the proteinogenic α-amino acids, the acetylene-containing amino acids 
1-3 offer novel synthetic opportunities to the (bio)organic chemist, since the non-natural 
functionality in the side chain provides an inert ‘handle’ for novel structural modifications of 
the amino acids itself as well as peptides incorporating these amino acids. Therefore, the 
aforementioned amino acids have gained considerable interest in recent years as target in 
various synthetic approaches.5 Moreover, the acetylenic amino acids 1-3 and other related 
unsaturated α-amino acids have become increasingly important as building blocks in 
synthetic routes, which is reflected by the number of applications of such amino acids that 
have been reported in the literature.6 
In view of the increased importance in (bio)synthetic chemistry, this introductory 
chapter will give an overview of synthetic applications of acetylene-containing non-
proteinogenic α-amino acids that have appeared in the recent literature (1999 to March 2004). 
In doing so, the examples in this review will be limited to applications of the (protected) 
amino acids itself, whereas applications of amino acid derivatives (e.g. the corresponding 
amino alcohols) will not be covered. At the end of this chapter, which serves to put the 
investigations in this thesis in a wider perspective, the purpose and outline of this thesis will 
be presented. 
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1.2 Side Chain Modifications 
 
A frequently used transformation on acetylenic amino acids is a cycloaddition 
process utilizing the unsaturation in the side chain. An interesting example of this topic was 
recently reported by Meldal and coworkers, who used the immobilized propargylglycine 
moiety 4 (connected to a PEGA800 resin) as substrate in the 1,3-dipolar cycloaddition with 
(substituted) azides (Scheme 1.1).7 
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A regiospecific Cu(I)-catalyzed cycloaddition led to the formation of the [1,2,3]-triazoles 5, 
which could be conveniently cleaved from the resin to afford the peptidotriazoles 6 with 
>95% conversion and purity. 
Kurth and coworker described a thermal approach for the cycloelimination of N3-
alkylated hydantoins from the solid phase, and exploited this methodology in the synthesis 
of novel isoxazoloimidazolidinediones (Scheme 1.2).8 Their solid phase pathway commenced 
with the immobilized propargylglycine derivative 7, which was connected to a Merrifield 
resin. 1,3-Dipolar cycloaddition of alkyn 7 with Mukaiyama-generated nitrile oxides 
provided the resin-bound isoxazoles 8. Subsequent deprotection of the Boc group with TFA, 
followed by reductive alkylation gave resins 9, which were reacted with several isocyanates 
to give the urea derivatives 10. The isoxazole-containing hydantoins 11 were released from 
the resin in 20-35% overall yields by simply heating in THF. 
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Scheme 1.2 
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In a similar fashion, thiohydantoins bearing an isoxazole moiety were prepared by 
the same group. The previously mentioned immobilized isoxazoles 8 were in a series of steps 
converted into the thioureas 12, which then underwent a thermally induced cycloelimination 
to liberate the thiohydantoins 13 in 30-40% overall yields (Scheme 1.3).9 
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In line with the previous examples, the group of Vederas used a 1,3-dipolar 
cycloaddition on propargylglycine derivative 14 as the key step in the synthesis of the 
vinylogous amides 20 and 21 (Scheme 1.4).10 The cycloaddition of 14 with oxime 15 under 
basic conditions afforded isoxazole 16 as a single regioisomer, which was treated with a 
catalytic amount of Mo(CO)6 to give vinylogous amide 17 in 65% yield. 
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Subsequent exposure of 17 to TFA gave a 1:1 mixture of cyclic and open-chain products 18 
and 19 in 90% yield. Hydrolysis of both compounds using LiOH gave the targeted 
vinylogous amides 20 and 21 (as its stable dilithium salt) in good yields, which were then 
evaluated as inhibitors of enzymes involved in bacterial lysine biosynthesis. 
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Besides the cycloaddition reactions, the acetylenic side chain of the amino acids can 
also be used for the introduction of an additional range of functional groups via the Pd-
catalyzed Sonogashira coupling. This reaction was employed by Lee et al. in the synthesis of 
a small library of thrombin inhibitors.11 Thus, the enantiopure Boc-protected 
propargylglycine 22 was reacted with amine 23 under standard peptide coupling conditions 
to give amide 24 in 52% yield (Scheme 1.5). Subsequent deprotection of the Boc group and 
sulfonylation of the resulting amine afforded the Sonogashira precursors 25, which were 
then coupled with a variety of aryl iodides to give the desired thrombin inhibitors 26 in good 
yields. 
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Scheme 1.5 
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At Procter and Gamble Pharmaceuticals, the Sonogashira reaction was used for the 
synthesis of the phenyl-substituted propargylglycine derivative 28, which served as a 
scaffold for the development of new matrix metalloprotease inhibitors.12 The Pd-catalyzed 
coupling of 27 with phenyl iodide gave the substituted counterpart in 72% yield. Compound 
28 was subsequently converted into the carboxylic acids 29, of which the inhibitory activity 
was evaluated (Scheme 1.6). 
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Researchers at Novartis Pharmaceuticals utilized the Sonogashira coupling in the 
synthesis of propargylglycine derivative 30 (Scheme 1.7). Thus, propargylglycine 27 was first 
coupled with methyl 3-bromobenzoate after which an enzymatic hydrolysis led to 30 in high 
enantioselectivity. Propargylglycine derivative 30 was then converted in a multi-step 
sequence into the dipeptidyl nitrile 31, which was tested as an inhibitor of the lysosomal 
cysteine protease cathepsin B.13 
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Scheme 1.7 
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Crisp and Jiang reported the use of the Sonogashira reaction in the functionalization 
of propargylglycine derivative 32 with the 9-substituted adenine 33.14 The Sonogashira 
coupling proceeded smoothly to give the substituted propargylglycine derivative 34, which 
was then used as amine coupling partner in reaction with diacid chloride 35 (Scheme 1.8). 
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The latter condensation led to the formation of compound 36 in 18% yield, which can be 
considered as a potential host for organic guests or as a ligand for metal cations. The 
intramolecular hydrogen bonding in 36 was studied by 1H NMR and FT-IR spectroscopy, 
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which indicated that the hydrogen bonding gives rise to a planar cis-conformation of the 
molecule. 
Whereas the acetylene function can be readily substituted with a variety of aryl and 
1-alkenyl groups via the Sonogashira coupling, the functionalization of the acetylenic side 
chain with simple alkyl groups is less straightforward. IJsselstijn et al. developed novel 
synthetic methodology for the introduction of alkyl substituents at the terminal acetylene 
using organozinc coupling reactions.15 The organozinc chemistry requires an iodo- or 
bromoacetylene as coupling partner; therefore, propargylglycine derivative 27 was first 
brominated using N-bromosuccinimide and a catalytic amount of AgNO3 to provide 37 in 
87% yield (Scheme 1.9). 
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Brominated propargylglycine 37 was then reacted with an in situ generated 
organozinc/copper species to give the amino acids 38 with different alkyl side chains in 
reasonable to good yields. 
The versatility of the acetylenic side chain in Pd-mediated modifications was further 
demonstrated by Castle and coworker in the asymmetric synthesis of tryptophan derivative 
41, which represents the central tryptophan residue of the bicyclic octapeptide Celogentin 
C.16 The key transformation in the synthesis of 41 was the Pd-catalyzed heteroannulation of 
TES-substituted propargylglycine derivative 39 and iodoaniline 40 (Scheme 1.10). 
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Under the basic heteroannulation conditions, tryptophan 41 was formed in 58% yield 
without loss of enantiopurity according to chiral HPLC analysis. 
An alternative way of modifying the acetylenic side chain was developed by the 
group of Danion. They showed that the enantiopure propargyl- and homopropargylglycine 
derivatives 14 and 42 could be transformed into the corresponding (E)-vinylboronic acids 43 
(Scheme 1.11). 
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The methodology involved a hydroboration with diisopinocampheylborane (Ipc2BH), 
followed by oxidation of the resulting boranes using acetaldehyde and hydrolysis leading to 
the geometrically pure boronic acids 43. The amino acids 43 could be deprotected in an 
almost quantitative manner to give the free amino acids 44 (Scheme 1.12). These compounds 
are potential mimics of (S)-arginine and were evaluated as active-site probes of the enzymes 
arginase and nitric oxide synthase.17 In addition, the boronic acids 43 readily underwent 
Suzuki-type couplings with aromatic or vinylic bromides to give the stereodefined 
unsaturated amino acids 45 in reasonable yields.18 
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Recently, propargylglycine has also been applied by Kotha et al. in a metathesis-based 
approach toward highly functionalized phenylalanine derivatives.19 In this method, 
propargylglycine derivative 46 served among others as substrate in a cross-enyne metathesis 
reaction with allyl acetate using the first generation Grubbs catalyst (47) to give the 1,3-diene 
48 in 45% yield. This diene subsequently underwent a Diels-Alder reaction with the 
indicated dienophile, followed by DDQ oxidation to afford the targeted phenylalanine 
derivative 49 (Scheme 1.13). 
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Scheme 1.13 
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The group of Pulley also synthesized several phenylalanine analogues starting from 
propargylglycine derivative 50 (Scheme 1.14).20 
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They used a benzannulation strategy that formally involved a [3+2+1] cycloaddition between 
aryloxy-substituted Fischer chromium carbenes of type 51 and the acetylenic side chain of 50. 
These cycloadditions led to the formation of diaryl ether containing phenylalanines 52 in 
somewhat moderate yields. 
Researchers at The Dow Chemical Company devised a concise and scaleable route to 
the enantiopure cis-allylglycine derivative 54 (Scheme 1.15), and its optical antipode, starting 
from 2-butyne-1,4-diol.21 
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One of the intermediates in the synthesis of compound 54 was propargylglycine derivative 
53, which could be conveniently transformed into target 54 via a stereoselective reduction 
using Lindlar’s catalyst. Allylglycine 54 was then converted to the natural product (–)-
bulgecinine (55). 
 
1.3 Cyclization Reactions of the Amino Acids 
 
1.3.1 Direct Cyclization via the Side Chain 
 
Knight and coworkers found that propargylglycine derivatives such as 56 smoothly 
undergo an iodine-mediated 5-endo-dig cyclization to give the corresponding iodinated 
proline derivative 57.22 Subsequent treatment of 57  with two equivalents of DBU in DMF at 
room temperature led to an elimination of p-toluenesulfinic acid to provide the iodopyrrole 
58 in 90% yield (Scheme 1.16). 
 
Scheme 1.16 
HN CO2Me
Ts
56 57 (74%)
N
Ts
CO2Me
I
I2, K2CO3
MeCN, rt
DBU
DMF, rt
58 (90%)
N
H
CO2Me
I
HN CO2Me
Ts 59 60
(50% over 2 steps)
MeCN, rt
61 (65%)
N
H
CO2Me
I
N
H
CO2Me
N
H
CO2Me
AcO OAc
N
H
CO2Me
O
1) I2, K2CO3
2) DBU, DMF, rt
Bu3SnH, AIBN
benzene, 80 °C
Pb(OAc)4
CHCl3, 60 °C
62 (95%)
1 N HCl, rt
63
N
O
MeO
NH
Cl
64
 
 
This procedure was applied by the same group in a synthetic approach toward the core of 
the natural product roseophilin (64, Scheme 1.16).23 In this approach, the appropriately 
substituted propargylglycine derivative 59 first underwent the previously mentioned 
iodocyclization, followed by elimination of the sulfonamide moiety to give iodopyrrole 60. 
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This compound was subjected to tributyltinhydride and AIBN to undergo a radical 
cyclization affording the annulated pyrrole 61 in 65% yield. Compound 61 was efficiently 
oxidized using lead(IV) acetate to give 62, which was hydrolyzed to the targeted ketone 63, 
representing the bicyclic core of roseophilin. 
 
1.3.2 Cyclizations Involving a Functional Group on the Nitrogen Atom 
 
Propargylglycine-derived enynes and diynes have been recognized by Kotha and 
coworker as versatile building blocks in the transition metal-mediated synthesis of 1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid (Tic) derivatives. For example, enyne 65 could be 
transformed via an enyne metathesis reaction using Grubbs catalyst 47 (viz. Scheme 1.13) into 
the pipecolic acid derivative 66 in 70% yield. This diene was then reacted in a Diels-Alder 
fashion with dimethyl acetylenedicarboxylate (DMAD), followed by DDQ oxidation 
resulting in the formation of Tic derivative 67 (Scheme 1.17).24a,c 
 
Scheme 1.17 
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The same researchers also reported an alternative approach toward Tic derivatives 
using a [2+2+2] cycloaddition reaction as the key step. A representative example is the 
cyclotrimerization of diyne 68 with 2-butyn-1,4-diol using Wilkinson’s catalyst, which led to 
the formation of Tic derivative 69 in 53% yield (Scheme 1.18).24b,c 
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Related to the enyne metathesis reaction in scheme 1.17 (65→66), the group of 
Chatani reported the transformation of propargylglycine-derived enynes 70 and 71 into the 
corresponding pipecolic acid derivatives (Scheme 1.19).25 In this reaction, the enyne 
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precursors underwent a GaCl3-catalyzed skeletal reorganization to give the products 72 and 
73 in 69 and 87% yields, respectively. 
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In the design of cyclic scaffolds which allow the functionalization at various sites, 
Bolton and coworker studied the intramolecular Heck cyclization on propargylglycine 
derivatives for the construction of substituted benzazepines (Scheme 1.20).26 
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Initially, they investigated a solution phase pathway toward benzazepine 76 starting from 
propargylglycine 74. Propargylglycine 74 was first converted into precursor 75, which was 
then subjected to typical Heck cyclization conditions. These conditions provided the desired 
lactam 76 in a somewhat low yield of 34%, together with the deiodinated precursor 77 as the 
major product in 65% yield. With both compounds in hand, the same researchers set out to 
translate the solution phase sequence to the solid phase. This pathway commenced with the 
Wang resin-linked Fmoc-protected propargylglycine 78 (Scheme 1.20), which was 
transformed in several steps into the immobilized precursor 79. In this case, subjection of 
compound 79 to similar cyclization conditions as used before in solution, afforded 
benzazepine 76 as the sole product in 63% overall yield after cleavage from the resin. 
The group of Rutjes investigated the viability of using ring-closing alkyne metathesis 
(RCAM) in the synthesis of cyclic dipeptides derived from acetylenic amino acids.15 
Dipeptide 83 was selected as substrate to test the RCAM and was obtained via coupling of 
the bishomopropargylglycine derivatives 81 and 82 in 87% yield (Scheme 1.21). Subjection of 
precursor 83 to the tungsten catalyst 84 afforded the corresponding 12-membered lactam 85 
in 64% yield (based on 50% conversion), thereby demonstrating the potential of RCAM in 
combination with these highly functionalized substrates. 
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This methodology was further elaborated by the groups of Overkleeft and Rutjes in 
the synthesis of cyclic β-turn mimetics.27 Among several examples, they prepared the 
acetylenic amino acid-containing oligopeptides 87 and 88 using standard solution phase 
peptide coupling procedures (Scheme 1.22). 
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Both peptidic diynes were then subjected to the same RCAM conditions affording the 
cyclic tetrapeptides 89 and 90 in 62 and 25% yields, respectively. The structure of compound 
90 was investigated by 2D NMR measurements and compared to its cystine-containing 
counterpart. This structural analysis indicated that the replacement of a disulfide bridge by 
an acetylene moiety gave rise to a more rigid cyclic peptide. 
 
1.4 Miscellaneous Modifications 
 
The group of Hiemstra studied the formation of 2,6-bridged piperazine-3-ones via 
cyclizations of (substituted) diketopiperazine-derived N-acyliminium ions.28 The starting 
diketopiperazines were synthesized from readily available amino acids and one of the 
sequences commenced with Boc-protected propargylglycine 91 (Scheme 1.23). 
Propargylglycine 91 was reacted with N-benzylglycine methyl ester under standard peptide 
coupling conditions affording dipeptide 92. Subsequent cleavage of the Boc group and 
treatment with base led to the formation of diketopiperazine 93 in 64% yield over two steps. 
Protection of the lactam nitrogen with a methoxycarbonyl group furnished 94, which was 
reduced using NaBH4 in methanol. The intermediate hydroxylactam was subjected to formic 
acid, which induced a cyclization via the acetylene moiety to give ketone 95 in 17% yield. 
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Scheme 1.23 
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Undheim and coworkers were involved in the development of conformationally 
constrained analogues of cystine (96). In the course of their studies, they became interested in 
the synthesis of the tricyclic bis-amino acid derivative 98 which can be considered as a very 
rigid cystine analogue (Scheme 1.24).29 The key step in the synthetic sequence toward 98 
concerned the construction of the tricyclic system. This was achieved by subjecting the 
acetylene tethered bis-propargylglycine derivative 97 to Grubbs catalyst 47 (viz. Scheme 
1.13), which led to a metathesis cascade reaction to give 98 in 58% yield. 
 
Scheme 1.24 
H2N CO2H MeO2C N
H
H
NMeO2C
Ac
Ac HN
Ac
CO2Me
HN
Ac
MeO2C
catalyst 47
toluene, 85 °C
96 97 98 (58%)
HO2C NH2
S
S
 
 
In collaboration with DSM Research, the groups of van Boom and Rutjes also aimed 
at the synthesis of conformationally restricted cystine isosteres.30 The constrained cystine 
analogues 102 and 103 were selected as target compounds and prepared via a RCAM 
strategy using enantiomerically pure propargylglycine derivative 99 as the starting material. 
A representative example of this approach is shown in Scheme 1.25, where two 
propargylglycine residues were first coupled with ethylene glycol to give the tethered 
system 100 in 84% yield. 
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Scheme 1.25 
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Subjection of precursor 100 to the tungsten-alkylidene complex 84 (viz. Scheme 1.21) 
gave the cyclic acetylene 101 in an acceptable yield. At this point, compound 101 was 
transformed into two different cystine isosteres containing either a (Z)-alkene or an alkyne 
functionality. Stereoselective reduction of acetylene 101, followed by hydrolysis of the ester 
linkages and cleavage of the Boc-protecting groups led to isostere 102 in 56% yield. 
Alternatively, immediate saponification of 101 with LiOH, followed by deprotection of the 
Boc groups provided the acetylenic isostere 103 in 85% over two steps. 
The group of Trost exploited a Ru-catalyzed hydrative diyne cyclization, which was 
previously developed in their laboratory, in the total synthesis of the tricyclic alkaloid (+)-
cylindricine C (109, Scheme 1.26).31 
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An important intermediate in the synthetic approach toward the natural product 109 
was diyne 104. This propargylglycine derivative was converted into precursor 105 in two 
steps, i.e., ester reduction, followed by protection of the resulting primary alcohol, which set 
the scene for the hydrative diyne cyclization. Thus, subjection of cyclization precursor 105 to 
5% [CpRu(MeCN)3]PF6 (106) led to a chemoselective formation of the desired ketone 107 in 
90% yield. An LDA-mediated aldol reaction between ketone 107 and heptanal was 
immediately followed by an elimination (MsCl, Et3N) to provide divinyl ketone 108 in 83% 
yield. Subsequent cleavage of the Boc group with TFA and basic work-up liberated the 
amine, which was refluxed in the presence of base to produce the tricyclic core of the natural 
product. Finally, removal of the TBDPS group using TBAF afforded (+)-cylindricine C in 90% 
yield over three steps. 
Without utilizing the acetylenic side chain for structural modifications, propargyl-
glycine has recently also been applied as building block in the synthesis of (biologically 
active) peptides or peptidomimetics. For example, researchers at Elan and Eli Lilly used 
propargylglycine 110 as starting material in the synthesis of the amino alcohol dipeptides 
114, which were designed to inhibit formation of β-amyloid peptide (Scheme 1.27).32 
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Propargylglycine 110 was first coupled with Boc-protected (S)-alanine to give dipeptide 111. 
Subsequent cleavage of the Boc group and coupling with acids 112 (R = Me or H) provided 
the N-terminated dipeptides 113. These esters were then reduced to the targeted amino 
alcohol analogues 114, which were screened for the desired biological activity. 
In order to investigate the importance of the terminal peptidic moiety for the 
biological activity of the natural antibiotic pyloricidin C (115), Hasuoka et al. prepared 
several pyloricidin C derivatives in which the terminal (S)-leucine residue was substituted 
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with various amino acids.33 As part of this study, they prepared derivative 116 in which the 
leucine moiety was replaced by (S)-propargylglycine. 
 
H2N
O
N
H
OH
OH
OH
OH
O
N
H
Ph
CO2H H2N
O
N
H
OH
OH
OH
OH
O
N
H
Ph
CO2H
115 116  
 
The propargylglycine containing derivative 116 was evaluated for its antibacterial activity 
against H. pylori NCTC11637, which turned out to be 30-fold higher than the activity of the 
parent compound pyloricidin C. 
At Pfizer, a variety of 2-pyridone-containing peptidomimetics were synthesized and 
tested as inhibitors of the human rhinovirus 3C protease.34 In several synthetic routes toward 
the targeted compounds, enantiopure propargylglycine 117 proved to be a versatile starting 
material, which is illustrated by the example in Scheme 1.28. 
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Thus, propargylglycine 117 was first converted into the α-hydroxy acid 118 in 66% yield. 
This compound was then esterified and transformed into the corresponding triflate 119, 
which was reacted with hydroxypyridine 120 to afford N-alkylated pyridone 121 in 71% 
yield over three steps. Subjection of methyl ester 121 to LiI in refluxing pyridine gave 
carboxylic acid 122, which was coupled with the deprotected amino alcohol 123 to provide 
compound 124. This product was oxidized using the Dess-Martin periodinane and the 
intermediate aldehyde underwent olefination to give 125 in 64% yield. Finally, oxidative 
removal of the DMB group led to the desired inhibitor 126 in good yield. 
 
1.5 Biosynthetic Applications 
 
To expand the scope of DNA-templated organic synthesis, the research group of Liu 
developed a novel DNA-template, the so-called T architecture.35 In contrast to previously 
used DNA-templates, the T architecture offered the possibility to perform two DNA-
templated reactions on a single template in one step. The viability of the T architecture in 
sequential DNA-templated reactions was for example demonstrated by combining the 
amine-linked T architecture with the complementary DNA-linked propargylglycine 127 and 
phenylazide 128 (Scheme1.29). 
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Subjection of a buffered solution of system 129 to DMT-MM led to amide formation, after 
which addition of CuSO4 and sodium ascorbate induced a 1,3-dipolar cycloaddition to give 
the triazole adduct 130 in 32% overall yield. 
The incorporation of non-proteinogenic amino acids into proteins is an important 
strategy in altering the chemical and physical properties of natural and artificial proteins. 
This can be achieved via conventional synthetic methods such as solid phase synthesis, 
however, one of the most efficient means concerns the in vivo translation of non-natural 
amino acids into proteins. The latter strategy utilizes the ability of the cell’s translation 
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machinery to incorporate structurally related analogues of the proteinogenic amino acids 
into proteins. The group of Tirrell has been actively involved in this field and they showed 
that several unsaturated methionine analogues could be efficiently incorporated into 
proteins using the translation system in methionine-depleted E. coli cells.36 Especially, 
homopropargylglycine (2) proved to be an excellent methionine surrogate, which could be 
incorporated into proteins with extents of substitution of methionine of up to 98%. 
 
1.6 Purpose and Outline of this Investigation 
 
This thesis details the development of novel synthetic methodology for the synthesis 
of biologically relevant functionalized heterocyclic compounds. The starting materials in 
these investigations are the acetylenic α-amino acids 1-3, which are readily accessible in our 
group in both enantiomeric forms via a chemoenzymatic procedure that has been developed 
in collaboration with DSM Research (Geleen, The Netherlands).37 
In this Chapter, an overview has been given of recent synthetic applications of 
acetylenic α-amino acids to show that these compounds have been broadly recognized as 
versatile building blocks in a variety of synthetic routes. 
Chapter 2 details the synthesis of both unsaturated proline derivatives and novel 
optically active tryptophan analogues via Pd- and Ag-catalyzed cyclization reactions of 
appropriately designed cyclization precursors. 
In Chapter 3, part of the chemistry described in Chapter 2 is applied in 
cycloisomerizations of substituted acetylene-containing amino acids, which leads to the 
formation of several enantiopure heterocyclic building blocks. 
Chapter 4 discloses a novel approach toward 5-aryl-substituted proline analogues 
involving a Ag-catalyzed 5-endo-dig cyclization of aryl-substituted acetylenic amino acids. 
In Chapter 5, enantiopure acetylene-containing amino acids are used as coupling 
partner in the construction of the enediyne system of novel functionalized heterocyclic 
enediynes using the Sonogashira coupling. 
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CHAPTER 2 
 
SYNTHESIS OF NOVEL TRYPTOPHAN ANALOGUES 
 
 
2.1 Introduction1 
 
Indoleamine 2,3-dioxygenase (IDO) is a heme containing glycoprotein that is widely 
distributed in mammalian tissue, including the brain, lung and small intestine. One of the 
functions of IDO in cells is the cleavage of the indole 2,3-double bond of (S)-tryptophan (1), 
using superoxide in the presence of free-radical generating systems, such as ascorbic acid 
and methylene blue. The product of this oxidative cleavage is (S)-N-formylkynurenine (2), 
which is subsequently hydrolyzed by a formamidase enzyme to give (S)-kynurenine (3, 
Scheme 2.1). 
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These two reactions are the first steps in the kynurenine pathway, which was first 
recognized as a major route for the metabolism of tryptophan to nicotinamide and its 
nucleotide conjugates in 1947.2 The kynurenine pathway contains a number of interesting 
enzymes that catalyze chemical reactions that are infrequently found in metabolism. 
Consequently, many of these transformations are still mechanistically poorly understood, 
such as the aforementioned IDO-catalyzed oxidative cleavage of tryptophan (1→2, Scheme 
2.1). 
The activity of the IDO enzyme can be induced by several factors,3 which results in 
depletion of available tryptophan, the least abundant of the essential amino acids required 
for cellular integrity. Hence, its reduced availability affects protein synthesis, genome 
replication and organismal growth. Increased IDO activity therefore leads to starvation of 
cells for tryptophan, which has a much more devastating effect on rapidly dividing cells, 
such as microbial pathogens and tumor cells. As a result, the IDO enzyme has apparent 
antimicrobial and antitumor properties. 
Another consequence of inducing IDO activity is an increase in the concentration of 
metabolites produced in the kynurenine pathway, such as quinolinic acid (4) and kynurenic 
acid (5), both of which are know to exhibit neurological activity.4 
 
 
Chapter 2 
 
24 
N
CO2H
CO2H N
OH
CO2H
4 5  
 
Quinolinic acid, for example, has been implicated as an etiological factor in a range of 
neurodegenerative diseases including AIDS-related dementia, Huntington’s disease and 
Lyme’s disease.5 Moreover, the upregulation of IDO activity, resulting consequently in the 
elevation of quinolinic acid concentrations, is observed in several inflammatory diseases 
including meningitis, septicemia and arthritis.6 Consequently, in the design of novel 
therapies to treat these diseases, the kynurenine pathway has been identified as an important 
target for drug action. Mechanistic work on the enzymes involved in the pathway has 
therefore been stimulated, to provide information so that specific and effective inhibitors can 
be designed. 
Especially, inhibitors of the IDO enzyme have important clinical implications as 
potential therapeutic agents, to study and to control the symptoms of the aforementioned 
diseases which are affected by the upregulation of IDO activity. In addition, potent and 
specific inhibitors of the IDO enzyme are valuable pharmacological tools to elucidate the 
biological importance of the kynurenine pathway in more detail and to better understand the 
chemistry of the IDO-catalyzed reactions. 
 
2.2 Tryptophan Analogues 
 
Tryptophan analogues constitute one class of IDO inhibitors and therefore a wide 
range of tryptophan analogues have already been examined as inhibitors of the IDO enzyme. 
For example, replacement of the indole nitrogen of tryptophan by both oxygen and sulfur 
gave analogues 6 and 7, respectively, which exhibited moderate inhibitory activity towards 
rabbit intestine IDO.7 
 
H2N CO2H
O
6 7
H2N CO2H
S
8
H2N CO2H
N Me
 
 
Based on studies focusing at the structural requirements for binding in the active site of the 
IDO enzyme, the N-methylated analogue 8 was prepared, which is the most potent 
tryptophan-based IDO inhibitor reported to date.8 Although several tryptophan analogues 
have exhibited inhibitory activity against the IDO enzyme, none of these compounds inhibit 
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IDO below micromolar levels. Consequently, highly potent inhibitors of human IDO (with 
low nanomolar affinity) are still required, and for this reason the synthesis of novel 
tryptophan analogues in an optically active form is necessary. 
In the continued effort to search for novel inhibitors of IDO, we envisaged that it may 
be of interest to synthesize three structurally related tryptophan analogues: (S)-
isotryptophan (9), (S)-homoisotryptophan (10) and (S)-bishomoisotryptophan (11). 
 
9 10 11
H2N CO2H H2N CO2HH2N CO2H
N
H
N
H
NH
 
 
Of these potentially biologically relevant α-amino acids, only isotryptophan itself has been 
previously prepared in optically active form. In that preparation,9 the synthesis proceeded 
via cyclization of the ortho-ethynylaniline 12 that was connected to a Schöllkopf chiral 
auxiliary. The key cyclization to the indole ring 13 was promoted by copper, which has also 
been reported as the catalyst of choice for the synthesis of other indole systems.10 The desired 
(S)-isotryptophan (9) was eventually obtained in 72% yield by acidic hydrolysis of 13, 
followed by subsequent saponification (Scheme 2.2). 
 
Scheme 2.2 
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H2N CO2H
N
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N
EtO
OEt
N
N
EtO
N
H
NH2
OEt
1)  1N HCl, THF, rt, 2 h
2)  1N NaOH, EtOH
     60 °C, 2 h
9 (72%)
DMF/ethylene glycol
(4:1 v/v), 95 °C, 20 h
CuI
 
 
In addition to copper, palladium catalysts11 have been frequently used in cyclization 
reactions of nitrogen nucleophiles onto alkenes and alkynes to provide nitrogen heterocycles 
such as pyrroles12 and indoles.13 However, to the best of our knowledge, Pd-catalyzed 
syntheses of 2-substituted indoles have only been conducted using relatively simple 2-
alkynylanilines as the cyclization precursors.13 
We envisaged that the tryptophan analogues 9-11 might be readily synthesized from 
the corresponding protected anilines 14 via such a Pd-catalyzed cyclization as the key step. 
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The anilines 14 should be easily accessible from the enantiomerically pure acetylene-
containing α-amino acids 15-17 (Scheme 2.3). 
 
Scheme 2.3 
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2.3 Attempted Pd-Catalyzed Indole Formation 
 
To probe the feasibility of forming the 2-substituted indole ring via an intramolecular 
Pd-catalyzed reaction, cyclization precursor 19 was synthesized starting from the racemic 
propargylglycine derivative 18.14 The Pd-catalyzed functionalization of propargylglycine 
derivatives with aromatic groups under Sonogashira-type coupling conditions has already 
been described by Crisp.15 A slight modification of the reported conditions led to a smooth 
coupling of 18 with 2-iodoaniline at room temperature affording precursor 19 in 88% yield 
(Scheme 2.4). 
 
Scheme 2.4 
HN CO2Me
Boc
HN CO2Me
Boc
NH2 N CO2Me
NH
2-iodoaniline
PdCl2(PPh3)2, CuI
Et2NH, Et2O
rt, 2 h
Boc
PdCl2(MeCN)2
MeCN
reflux, 3 h
18 19 (88%) 20 (65%)  
 
Interestingly, subjection of 19 to previously reported cyclization conditions13f did not lead to 
the anticipated formation of the corresponding indole system. Instead, an unexpected 
compound was formed as the sole product in 65% yield. Eventually, this product was 
unambiguously identified as the 5-membered cyclic imine 20 via an X-ray crystal structure 
determination (Fig. 2.1).16 
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Figure 2.1 PLATON17 drawing of the crystal structure of 20. 
 
After this surprising result, amino acid 19 was again subjected to the same reagents, 
but now at room temperature, resulting in the formation of the cyclic enamide 21 in 54% 
yield after column chromatography (Scheme 2.5). Subsequent treatment of this enamide with 
the same Pd-catalyst in refluxing acetonitrile led to a rapid conversion into the 
aforementioned pyrroline 20 in 70% yield. The latter conversion could also be accomplished 
by refluxing 21 in acetonitrile without the Pd-catalyst present, however, in that case the 
reaction did not go to completion even after prolonged reaction times of over 24 h. 
 
Scheme 2.5 
HN CO2Me
Boc
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PdCl2(MeCN)2
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19 21 (54%)
PdCl2(MeCN)2
MeCN, reflux, 30 min
BocNH2
N CO2Me
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Boc
20 (70%)
 
 
A plausible mechanism to explain the remarkable formation of pyrroline 20 from 
precursor 19, involves complexation of the Pd(II)-catalyst to the triple bond, possibly aided 
by coordination to the aniline nitrogen, giving rise to the π-complex 22 (Scheme 2.6). This 
renders the acetylene sufficiently electrophilic to undergo nucleophilic attack of the 
apparently more nucleophilic carbamate nitrogen to give the corresponding vinylpalladium 
intermediate 23. This species will undergo protonolysis of the Pd-C bond, thereby 
regenerating the Pd(II)-catalyst, to give cyclic enamide 21 as the intermediate product, which 
under the circumstances immediately reacts further to provide pyrroline 20 as the product. 
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Scheme 2.6 
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In this last step, the regenerated Pd-catalyst may possibly act as a Lewis acid by lowering the 
electron density of the double bond, thus facilitating intramolecular attack of the aniline 
nitrogen onto the Boc group. 
 
2.4 Cyclizations of Several Functionalized Cyclization Precursors 
 
Intrigued by the facile cycloisomerization of 19, we set out to further determine the 
scope of this reaction. Therefore, we prepared several cyclization precursors via Sonogashira 
couplings of protected propargylglycine 18 with (substituted) aryl iodides. The racemic 
substituted acetylenes 24-28 were thus obtained in good yields and subjected to 
PdCl2(MeCN)2 in MeCN at different temperatures (Table 2.1). 
Unfortunately, subjection of cyclization precursor 24 to the Pd-catalyst did not give 
any reaction at room temperature, while heating at reflux temperature led to rapid 
decomposition of the starting compound (entry 1). Subjection of the substituted acetylene 25 
to the Pd-catalyst at room temperature did not lead to the formation of the corresponding 
cyclic enamide. Instead, these conditions led to partial decomposition of the starting 
compound and unexpected formation of the hydrated product 29 as the sole product in a 
yield of 32% (entry 2). Subjection of 25 to the same conditions at reflux temperature also did 
not lead to a cyclization reaction. Moreover, these conditions led to even more 
decomposition of the starting material and slowed down the formation of ketone 29. 
Substitution of the aromatic ring with an ortho-methoxy substituent (viz. 26) did not result in 
cyclization either, but gave a similar reaction leading to ketone 30 as the major product in a 
somewhat lower yield of 19% (entry 3). 
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Table 2.1 
entry precursor (yield)a product yield (%)a
aIsolated yield after column chromatography.
HN CO2Me
Boc
HN CO2Me
Boc
NH2
HN CO2Me
Boc
OMe
HN CO2Me
Boc
HN
Ac
NHO
O
NH2
HN CO2Me
Boc
O
24 (84%)
29
decomposition
HN CO2Me
Boc
O
30
OMe
O
N
NH2
O
25 (87%)
26 (85%)
27 (81%)
28 (52%)
31
32
32
19
49
32
1
2
3
4
5
N CO2Me
NH Boc
Ac
 
 
Presumably, in these cases the internal acetylene undergoes a Pd-catalyzed hydration 
leading to the corresponding ketone. Similar regioselective Pd-catalyzed hydration of 
substituted acetylenes has been observed before, and the formation of for example ketone 29 
might be explained analogously to the reported mechanism18 (Scheme 2.7). 
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Scheme 2.7 
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Thus, the catalytic cycle presumably involves electrophilic activation of the triple bond by 
the Pd(II)-catalyst, followed by intramolecular nucleophilic attack of the ester function. The 
resulting vinylpalladium intermediate 33 then undergoes attack by water followed by 
subsequent protonolysis of the Pd-C bond to give eventually ketone 29 as its enol tautomer. 
In an attempt to improve the yield of ketone 29, the Pd-catalyzed hydration of acetylene 25 
was conducted again in the presence of a small amount of water, according to the literature 
procedure.18 These conditions, however, did not facilitate the formation of ketone 29, which 
was even isolated in a somewhat lower yield of 26%. 
In addition, the acetylated aniline 27 underwent cyclization at room temperature, 
resulting in the formation of the cyclic enamide 31 in 49% yield after column 
chromatography (entry 4). Furthermore, we converted cyclization precursor 19 into the more 
restricted oxazolidinone analogue 28 in two steps, i.e., ester reduction with LiBH4 in THF 
followed by oxazolidinone formation in 52% yield (Scheme 2.8). Subjection of the cyclic 
carbamate 28 to the Pd-catalyst at reflux temperature led to the formation of the 
corresponding bicyclic product 32 in a somewhat lower isolated yield of 32% (entry 5). 
 
Scheme 2.8 
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Boc
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The results shown in Table 2.1 indicate that the presence of the ortho-aniline nitrogen 
atom in the precursor is crucial for the cycloisomerization to occur, which is in line with the 
proposed mechanism. This fact significantly reduces the scope of this cyclization, so that this 
line of research was not pursued any further. 
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2.5 Metal-Catalyzed Synthesis of Tryptophan Analogues 
 
Next, we set out to investigate the feasibility of forming the 2-substituted indole 
system starting from the homologous optically active homo- and bishomopropargylglycine 
derivatives 36 and 37, respectively, via the same pathway as used before. In order to do so, 
the amino acids 15-17 were first converted into the corresponding methyl esters and 
protected to give the optically active Boc-protected amino acids 35-37 (Scheme 2.9). 
 
Scheme 2.9 
H2N CO2H
n
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17 n = 3
HN CO2Me
n
35 n = 1 (81%)
36 n = 2 (61%)
37 n = 3 (74%)
Boc
1)  SOCl2 , MeOH
     0 °C → reflux, 4 h
2)  Boc2O, NaHCO3
     dioxane/H2O 
     (1:1 v/v), rt, 4 h
 
 
The Pd-catalyzed Sonogashira coupling of 36 and 37 with 2-iodoaniline afforded the 
cyclization precursors 38 and 39 in 79 and 78% yield, respectively (Scheme 2.10). To our 
satisfaction, treatment of 38 with the Pd-catalyst in refluxing acetonitrile led to a rapid 
conversion into homoisotryptophan derivative 40 in 60% yield after chromatography. Under 
the same conditions, bishomoisotryptophan derivative 41 was also obtained in a reasonable 
yield of 55%. Furthermore, we proved in both cases using chiral HPLC (Chiralcel OJ) that no 
(partial) racemization had taken place during the whole synthetic sequence. 
 
Scheme 2.10 
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These results actually point out that the applied cyclization conditions are suitable for 
the formation of the desired 2-substituted indole system. However, the mode of cyclization is 
strongly dependent on the side chain length of the cyclization precursor. To verify this 
reasoning, the suitably protected biscarbamate 43 was synthesized in two steps from the 
enantiopure propargylglycine derivative 35 (Scheme 2.11). The presence of the additional 
Boc group in this precursor should prevent the cyclization via the carbamate nitrogen, 
thereby leaving the aniline nitrogen as the only reactive nucleophile. 
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Scheme 2.11 
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Indeed, subjection of precursor 43 to the same Pd-catalyst in refluxing acetonitrile led to an 
activation of the aniline nitrogen, which cyclized onto the triple bond affording 
isotryptophan derivative 44 as the sole product without loss of enantiopurity according to 
chiral HPLC (Chiralcel OD). 
In order to circumvent the use of the second Boc group on the carbamate nitrogen, we 
also searched for a catalyst that would effect a selective cyclization into the 2-substituted 
indole system, without interference of the carbamate nitrogen in the cyclization process. 
Based on methodology that had simultaneously been developed in related studies (see: 
Chapter 4), it soon became apparent to us that AgOTf, silver has a high affinity for double 
bonds and much less for heteroatoms such as nitrogen, might be the catalyst of choice in 
effecting such a selective cyclization. In order to probe the feasibility of selective indole 
formation via a Ag-catalyzed cyclization, precursor 45 was synthesized from the enantiopure 
propargylglycine derivative 35 (Scheme 2.12). 
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Subjection of precursor 45 to the Ag-catalyst in acetonitrile at room temperature did not give 
any reaction. However, we were pleased to see that heating the reaction mixture at reflux 
temperature indeed led to a slow but clean conversion of the starting compound into 
isotryptophan derivative 46, which was isolated in an improved yield of 75% after column 
chromatography. 
Additionally, we converted the racemic Ts-protected propargylglycine derivative 4714 
via Sonogashira coupling with 2-iodoaniline into precursor 48, which was also subjected to 
AgOTf in refluxing acetonitrile affording isotryptophan derivative 49 in an excellent yield of 
86% after chromatography. Luckily, tryptophan analogue 49 appeared to be a crystalline 
solid suitable for an X-ray crystal structure determination, proving the formation of the 2-
substituted indole system (Fig. 2.2).16 
 
 
Figure 2.2 PLATON17 drawing of the crystal structure of 49. 
 
Encouraged by these results, we set out to apply this methodology in the synthesis of 
2-substituted benzo[b]furans, which might give us the opportunity to also access the oxygen 
containing counterparts of tryptophan analogues 9-11 (see: Scheme 2.3). In order to 
investigate the feasibility of forming a 2-substituted benzo[b]furan via a similar 
intramolecular Pd- or Ag-catalyzed reaction, the racemic propargylglycine derivative 47 was 
first reacted with 2-iodophenol under Sonogashira coupling conditions to afford the 
appropriate precursor 50 (Scheme 2.13). 
 
Scheme 2.13 
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To our surprise, these conditions led to the formation of a 4:1 mixture of the expected 
precursor 50 and the desired tryptophan analogue 51 in a combined yield of 80%. Without 
separation, we subjected the obtained mixture to AgOTf in refluxing acetonitrile to see 
whether this catalyst would effect cyclization of phenol 50 into benzofuran 51. 
Unfortunately, refluxing the mixture for more than 20 h in the presence of AgOTf did not 
lead to an increase in the conversion of 50 into 51 as judged by TLC. Obviously, this behavior 
can be explained by the lower nucleophilicity of the phenol compared to the previously used 
anilines. In line with this reasoning, we added Et2NH (1 equiv) to the reaction mixture to see 
if this would facilitate the formation of benzofuran 51. Indeed, the addition of Et2NH led to a 
rapid conversion of phenol 50 into benzofuran 51, however, the reaction did not go to 
completion and also led to partial decomposition of the remaining phenol. 
Considering these results, we again turned our attention to the Sonogashira reaction 
of propargylglycine derivative 47 with 2-iodophenol (Scheme 2.13). We envisaged that a 
modification of the applied conditions, i.e. using Et2NH as base and solvent at reflux 
temperature, might be beneficial to the formation of tryptophan analogue 51. Thus, 
subjection of acetylene 47 to these modified conditions led to the formation of a mixture of 
phenol 50 and benzofuran 51 in an improved ratio in favor of 51 in a combined yield of 71% 
(Scheme 2.14). 
 
Scheme 2.14 
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After this result, it became apparent to us that it would be feasible to convert 
propargylglycine derivative 47 completely into tryptophan analogue 51 if the reaction 
mixture would be refluxed for more than 2 h. To achieve this tandem cross-coupling 
cyclization process,19 we first converted enantiomerically pure propargylglycine 15 into 
propargylglycine derivative 52 by esterification using thionyl chloride in MeOH and 
subjection to pyridine and p-toluenesulfonyl chloride in CH2Cl2. Acetylene 52 was 
subsequently reacted with 2-iodophenol under the aforementioned modified Sonogashira 
conditions to give initially the intermediate phenol 53, which was after 4 h completely 
consumed to give the enantiopure tryptophan analogue 54 as the sole product in 74% yield 
(Scheme 2.15). 
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Scheme 2.15 
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2.6 Conclusions 
 
In this chapter the short and efficient preparation of novel optically active tryptophan 
analogues with potential biological activity towards the IDO enzyme is described. The 
aniline-containing homo- and bishomopropargylglycine derivatives 38 and 39 underwent a 
rapid Pd-catalyzed cyclization to afford the corresponding tryptophan analogues 40 and 41 
in reasonable yields. In contrast to these results, treatment of the aniline-containing 
propargylglycine derivative 19 with the same Pd-catalyst led to an unexpected 
cycloisomerization affording pyrroline 20. In addition, some insight was gained regarding 
the scope and limitations of the observed cycloisomerization. 
Furthermore, in the case of the enantiopure cyclization precursor 45 we demonstrated 
the possibility of circumventing the Pd-catalyzed cycloisomerization by the selective 
construction of tryptophan analogue 46 via a Ag-catalyzed indole formation. Finally, we 
explored the possibility to apply the developed methodology in the synthesis of 2-subsituted 
benzo[b]furans. This led to modified conditions in the Sonogashira reaction of 
propargylglycine derivative 52 with 2-iodophenol, allowing the direct synthesis of 
tryptophan analogue 54 via a tandem cross-coupling cyclization process. 
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2.8 Experimental Section 
 
General information. All reactions were carried out under an atmosphere of 
nitrogen, unless stated otherwise. Infrared (IR) spectra were obtained using an ATI Mattson 
Genesis Series FTIR spectrometer and wavelengths are reported in cm-1. Optical rotations 
were measured on a Perkin-Elmer 241 polarimeter, using concentrations (c) in g/100 mL in 
the indicated solvents. 1H and 13C nuclear magnetic resonance (NMR) spectra were 
determined in CDCl3, unless indicated otherwise, using a Bruker DMX300 (300 MHz) 
spectrometer. Chemical shifts (δ) are given in ppm downfield from tetramethylsilane. HRMS 
measurements were carried out using a Fisons (VG) Micromass 7070E or a Finnigan 
MAT900S instrument. Flash chromatography was performed with Acros Organics silica gel 
(0.035-0.070 nm) using the indicated solvent (mixture). Rf values were obtained by using thin 
layer chromatography (TLC) on silica gel-coated glass plates (Merck silica gel 60 F254) with 
the aforementioned solvent (mixture), unless noted otherwise. Melting points were 
determined with a Büchi melting point B-545 apparatus. THF and Et2O were distilled from 
sodium and benzophenone. Heptane, EtOAc and CH2Cl2 were distilled from CaH2. Et2NH 
was distilled from and stored over KOH. If necessary, other solvents were distilled from the 
appropriate drying agents prior to use. Unless stated otherwise, all commercially available 
reagents were used as received. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-4-pentynoate (35). A suspension 
of 15 (1.00 g, 8.84 mmol) in MeOH (30 mL) was treated dropwise at 0 °C with 
SOCl2 (1.4 mL, 19.0 mmol) and heated at reflux for 4 h. The reaction mixture 
was concentrated in vacuo to give the crude amino ester as the HCl-salt. The 
crude residue was dissolved in dioxane/water (80 mL, 1:1 v/v), NaHCO3 (2.23 g, 26.5 mmol) 
and Boc2O (3.88 g, 17.8 mmol) were added and the reaction mixture stirred for 4 h at room 
temperature. Dioxane was evaporated in vacuo and the remaining aqueous solution was 
extracted with EtOAc (3 × 25 mL). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. Purification by chromatography (EtOAc/heptane 1:6) afforded 35 
(1.62 g, 7.13 mmol, 81%) as a colorless oil. Rf 0.65 (EtOAc/heptane 1:1); [α]D +47.7 (c 1.1, 
CH2Cl2); IR (neat) 3298, 2978, 1745, 1712, 1504, 1437; 1H NMR (300 MHz, CDCl3) δ 5.32 (br d, J 
= 6.6 Hz, 1H), 4.46 (m, 1H), 3.76 (s, 3H), 2.73 (br m, 2H), 2.03 (t, J = 2.1 Hz, 1H), 1.45 (s, 9H,); 
13C NMR (75 MHz, CDCl3) δ 170.9, 154.9, 80.3, 78.6, 71.7, 52.8, 52.1, 28.6, 23.1; HRMS (CI) 
calcd for C11H18NO4 (MH+) 228.1236, found 228.1236. 
 
 
 
HN CO2Me
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Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-hexynoate (36). Following the 
same procedure as for 35, (S)-homopropargylglycine 16 (0.98 g, 7.71 mmol) 
was protected and purified by chromatography (EtOAc/heptane 1:6) to afford 
36 (1.14 g, 4.72 mmol, 61%) as a white solid. Rf 0.24 (EtOAc/heptane 1:4); [α]D 
+9.9 (c 1.0, CH2Cl2); mp 59.0 °C; IR (neat) 3367, 3253, 2983, 1732, 1676, 1512; 1H 
NMR (300 MHz, CDCl3) δ 5.24 (br d, J = 6.9 Hz, 1H), 4.39 (m, 1H), 3.75 (s, 3H), 2.28 (dt, J = 
2.7, 7.5 Hz, 2H), 2.05 (m, 1H), 2.01 (t, J = 2.4 Hz, 1H), 1.89 (m, 1H), 1.45 (s, 9H); 13C NMR (75 
MHz, CDCl3) δ 172.7, 155.3, 82.8, 80.0, 69.3, 52.8, 52.4, 31.5, 28.3, 14.9; HRMS (CI) calcd for 
C12H20NO4 (MH+) 242.1392, found 242.1395. 
 
Methyl (2S)-2-[tert-butoxycarbonyl)amino]-6-heptynoate (37). Following the 
same procedure as for 35, (S)-bishomopropargylglycine 17 (1.00 g, 7.08 mmol) 
was protected and purified by chromatography (EtOAc/heptane 1:6) to afford 
37 (1.33 g, 5.21 mmol, 74%) as a colorless oil. Rf 0.20 (EtOAc/heptane 1:4); [α]D 
+71.7 (c 1.0, CH2Cl2); IR (neat) 3296, 2953, 1741, 1712, 1504; 1H NMR (300 MHz, 
CDCl3) δ 5.03 (br d, J = 6.9 Hz, 1H), 4.31 (m, 1H), 3.75 (s, 3H), 2.23 (dt, J = 2.4, 6.9 Hz, 2H), 
1.96 (t, J = 2.7 Hz, 1H), 1.91 (m, 1H), 1.80-1.53 (m, 3H), 1.45 (s, 9H); 13C NMR (75 MHz, CDCl3) 
δ 172.9, 155.2, 83.4, 80.0, 69.1, 53.2, 52.5, 32.0, 28.6, 24.6, 18.4; HRMS (CI) calcd for C13H22NO4 
(MH+) 256.1549, found 256.1549. 
 
Methyl (2S)-2-{[(4-methylphenyl)sulfonyl]amino}-4-pentynoate (52). A 
suspension of 15 (500 mg, 4.42 mmol) in MeOH (20 mL) was treated dropwise 
at 0 °C with SOCl2 (0.7 ml, 9.5 mmol) and heated at reflux for 4 h. The reaction 
mixture was concentrated in vacuo to give the crude amino ester as the HCl-
salt. The crude residue was suspended in CH2Cl2 (75 mL), pyridine (2.2 mL, 28.4 mmol) and 
p-TsCl (1.68 g, 8.81 mmol) were added and the reaction mixture was stirred for 65 h at room 
temperature. Saturated aqueous CuSO4 (100 mL) was added to the reaction mixture and the 
layers were separated. The aqueous layer was extracted with CH2Cl2 (3 × 50 mL) and the 
combined organic layers were washed with saturated aqueous NaHCO3 (50 mL), brine (50 
mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
chromatography (EtOAc/heptane 1:3) to afford 52 (970 mg, 3.45 mmol, 78%) as a white solid. 
Rf 0.28 (EtOAc/heptane 1:2); [α]D +16.5 (c 1.0, CH2Cl2); mp 83.2 °C; IR (neat) 3261, 2950, 1705, 
1593, 1433; 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 8.1 Hz, 2H), 7.27 (d, J = 8.1 Hz, 2H), 5.45 
(d, J = 9.0 Hz, 1H), 4.10 (m, 1H), 3.60 (s, 3H), 2.66 (m, 2H), 2.41 (s, 3H), 2.02 (t, J = 2.7 Hz, 1H); 
13C NMR (75 MHz, CDCl3) δ 169.8, 143.7, 136.7, 129.6, 127.1, 77.6, 72.4, 54.2, 53.1, 24.4, 21.9; 
HRMS (EI) calcd for C13H15NO4S 281.0722, found 281.0722. 
 
General procedure A for the Sonogashira cross-coupling reactions. To a solution of 
the acetylene-containing amino acid, aryl halide (1.2 equiv) and Et2NH (5 equiv) in Et2O, CuI 
(10 mol%) and the Pd-catalyst (5 mol%) were added. The mixture was stirred at room 
temperature under N2-atmosphere for the indicated time. The reaction mixture was poured 
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into a saturated aqueous solution of NH4Cl and after separation of the organic layer the 
aqueous layer was extracted with Et2O (2 ×). The combined organic layers were washed with 
brine, dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography to afford the pure product. 
 
Methyl 2-[(tert-butoxycarbonyl)amino]-5-phenyl-4-pentynoate (25). 
According to general procedure A, to a solution of 18 (384 mg, 1.69 mmol), 
iodobenzene (417 mg, 0.49 mmol) and Et2NH (0.88 mL, 8.50 mmol) in Et2O 
(18 mL), CuI (33 mg, 0.17 mmol) and PdCl2(PPh3)2 (60 mg, 0.09 mmol) 
were added and the resulting mixture was stirred for 2 h. Work-up and 
purification by chromatography (EtOAc/heptane 1:6) afforded 25 (448 mg, 
1.48 mmol, 87%) as a yellow oil. Rf 0.28 (EtOAc/heptane 1:4); IR (neat) 3375, 2977, 1747, 1716, 
1598; 1H NMR (300 MHz, CDCl3) δ 7.38 (m, 2H), 7.28 (m, 3H), 5.42 (d, J = 8.3 Hz, 1H), 4.56 
(m, 1H), 3.79 (s, 3H), 2.95 (m, 2H), 1.46 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 171.1, 154.9, 
131.5, 128.0, 127.6, 122.8, 83.7, 83.4, 79.8, 52.3, 52.1, 28.1, 23.6; HRMS (EI) calcd for C17H21NO4 
303.1471, found 303.1471. 
 
Methyl 2-[(tert-butoxycarbonyl)amino]-5-(2-methoxyphenyl)-4-penty-
noate (26). According to general procedure A, to a solution of 18 (411 mg, 
1.81 mmol), 2-iodoanisole (524 mg, 2.24 mmol) and Et2NH (0.93 mL, 8.50 
mmol) in Et2O (18 mL), CuI (35 mg, 0.18 mmol) and PdCl2(PPh3)2 (64 mg, 
0.09 mmol) were added and the resulting mixture was stirred for 2 h. 
Work-up and purification by chromatography (EtOAc/heptane 1:4) afforded 26 (509 mg, 
1.53 mmol, 85%) as a yellow oil. Rf 0.21; 1H NMR (300 MHz, CDCl3) δ 7.28 (m, 2H), 6.85 (m, 
2H), 5.69 (d, J = 8.9 Hz, 1H), 4.58 (m, 1H), 3.86 (s, 3H), 3.75 (s, 3H), 3.01 (m, 2H), 1.46 (s, 9H). 
 
Methyl 5-[2-(acetylamino)phenyl]-2-[(tert-butoxycarbonyl)amino]-4-
pentynoate (27). According to general procedure A, to a solution of 18 
(367 mg, 1.62 mmol), N1-(2-iodophenyl)acetamide (465 mg, 1.78 mmol) 
and Et2NH (0.84 mL, 8.16 mmol) in Et2O (18 mL), CuI (32 mg, 0.17 mmol) 
and PdCl2(PPh3)2 (57 mg, 0.08 mmol) were added and the resulting 
mixture was stirred for 2 h. Work-up and purification by chromatography (EtOAc/heptane 
1:2) afforded 27 (471 mg, 1.31 mmol, 81%) as a colorless oil. Rf 0.21; IR (neat) 3329, 2980, 1738, 
1693, 1579, 1518, 1444; 1H NMR (300 MHz, CDCl3) δ 8.25 (s, 1H), 8.22 (s, 1H), 7.20 (m, 2H), 
6.88 (m, 1H), 5.64 (d, J = 8.2 Hz, 1H), 4.52 (m, 1H), 3.68 (s, 3H), 2.93 (dd, J = 5.0, 17.2 Hz, 1H), 
2.83 (dd, J = 5.9, 17.0 Hz, 1H), 2.22 (s, 3H), 1.33 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 171.5, 
169.1, 155.2, 139.3, 131.5, 129.0, 123.0, 119.8, 111.8, 90.7, 80.1, 79.0, 52.5, 52.1, 28.0, 24.2, 24.0; 
HRMS (EI) calcd for C19H24N2O5 360.1685, found 360.1674. 
 
4-[3-(2-Aminophenyl)-2-propynyl]-1,3-oxazolan-2-one (28). To a 
solution of 19 (535 mg, 1.68 mmol) in THF (20 mL), LiBH4 (73 mg, 3.36 
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mmol) was added at 0 °C. The reaction mixture was allowed to reach room temperature and 
stirred for 24 h. Upon completion, the reaction mixture was quenched by adding water (1 
mL) and stirred further for 15 min at room temperature, after which time the mixture was 
poured into water (30 mL). The aqueous solution was extracted with EtOAc (100 mL) and the 
organic layer was washed with water (2 × 30 mL), brine (2 × 30 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by chromatography (EtOAc/heptane 
1:1) to afford the corresponding amino alcohol 34 (386 mg, 1.33 mmol, 79%) as a light-yellow 
oil. 1H NMR (300 MHz, CDCl3) δ 7.21 (d, J = 7.6 Hz, 1H), 7.05 (m, 1H), 6.63 (m, 2H), 5.34 (d, J 
= 8.6 Hz, 1H), 4.31 (br s, 2H), 3.86 (br s, 1H), 3.71 (m, 3H), 2.71 (d, J = 6.1 Hz, 2H), 1.43 (s, 9H). 
To a solution of amino alcohol 34 (366 mg, 1.26 mmol) in THF (30 mL), NaH (52 mg of a 60% 
dispersion in mineral oil, 1.31 mmol) was added. The reaction mixture was heated at reflux 
for 22 h, diluted with MeOH (3 mL) and concentrated in vacuo. The crude product was 
purified by chromatography (EtOAc/heptane 3:1) to afford 28 (179 mg, 0.83 mmol, 66%) as a 
light-yellow solid. Rf 0.13 (EtOAc/heptane 2:1); mp 147.2 °C; IR (neat) 3352, 1732, 1614; 1H 
NMR (300 MHz, CDCl3) δ 7.24 (dd, J = 1.7, 8.3 Hz, 1H), 7.11 (dt, J = 1.6, 7.7 Hz, 1H), 6.67 (m, 
2H), 5.68 (br s, 1H), 4.57 (dd, J = 8.3, 8.9 Hz, 1H), 4.28 (dd, J = 4.6, 8.9 Hz, 1H), 4.13 (m, 3H), 
2.76 (dd, J = 1.4, 5.6 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 157.3, 150.8, 132.5, 129.9, 123.5, 
118.1, 114.6, 88.3, 81.2, 69.4, 66.0, 26.7; HRMS (EI) calcd for C12H12N2O2 216.0899, found 
216.0898. 
 
Methyl (2S)-6-(2-aminophenyl)-2-[(tert-butoxycarbonyl)amino]-5-hexyno-
ate (38). According to general procedure A, to a solution of 36 (518 mg, 2.15 
mmol), 2-iodoaniline (565 mg, 2.58 mmol) and Et2NH (1.12 mL, 10.7 mmol) 
in Et2O (20 mL), CuI (40 mg, 0.21 mmol) and PdCl2(PPh3)2 (75 mg, 0.107 
mmol) were added and the resulting mixture was stirred for 2 h. Work-up 
and purification by chromatography (EtOAc/heptane 1:3) afforded 38 (562 
mg, 1.69 mmol, 79%) as a light-brown oil. Rf 0.27 (EtOAc/heptane 1:2); [α]D 
+4.9 (c 1.0, CH2Cl2); IR (neat) 3461, 3369, 2975, 1734, 1701, 1617; 1H NMR (300 
MHz, CDCl3) δ 7.20 (dd, J = 1.4, 7.7 Hz, 1H), 7.03 (m, 1H), 6.60 (m, 2H), 5.33 (br d, J = 8.5 Hz, 
1H), 4.50 (br m, 1H), 4.32 (br s, 2H), 3.69 (s, 3H), 2.53 (t, J = 6.9 Hz, 2H), 2.11 (m, 1H), 1.92 (m, 
1H), 1.42 (s, 9H); 13C NMR (75 MHz,CDCl3) δ 172.9, 155.4, 148.2, 132.0, 129.0, 117.3, 114.1, 
107.9, 93.1, 79.8, 78.3, 52.6, 52.3, 31.5, 28.2, 16.0; HRMS (EI) calcd for C18H24N2O4 332.1736, 
found 332.1734. 
 
Methyl (2S)-7-(2-aminophenyl)-2-[(tert-butoxycarbonyl)amino]-6-hep-
tynoate (39). According to general procedure A, to a solution of 37 (322 
mg, 1.26 mmol), 2-iodoaniline (337 mg, 1.54 mmol) and Et2NH (0.67 mL, 
6.43 mmol) in Et2O (18 mL), CuI (27 mg, 0.14 mmol) and PdCl2(PPh3)2 
(49 mg, 0.07 mmol) were added and the resulting mixture was stirred 
for 2 h. Work-up and purification by chromatography (EtOAc/heptane 
1:3) afforded 39 (341 mg, 0.98 mmol, 78%) as a yellow oil. Rf 0.26 
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(EtOAc/heptane 1:2); [α]D +10.8 (c 1.0, CH2Cl2); IR (neat) 3356, 2978, 1738, 1712, 1614, 1493, 
1454; 1H NMR (300 MHz, CDCl3) δ 7.22 (dd, J = 1.2, 7.5 Hz, 1H), 7.07 (m, 1H), 6.65 (m, 2H), 
5.02 (br m, 1H), 4.32 (br m, 1H), 4.15 (s, 2H), 3.75 (s, 3H), 2.52 (t, J = 6.9 Hz, 1H), 2.30 (t, J = 6.6 
Hz, 1H), 2.08-1.56 (m, 4H), 1.46 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 172.9, 155.2, 147.3, 132.0, 
128.9, 117.8, 114.2, 108.6, 94.4, 80.1, 77.9, 53.3, 52.5, 32.2, 28.6, 25.1, 19.6; HRMS (EI) calcd for 
C19H26N2O4 346.1893, found 346.1900. 
 
Methyl (2S)-5-(2-aminophenyl)-2-[di(tert-butoxycarbonyl)amino]-4-
pentynoate (43). To a solution of 35 (274 mg, 1.21 mmol) in MeCN (5 
mL), DMAP (46 mg, 0.38 mmol) and Boc2O (528 mg, 2.42 mmol) were 
added and the resulting mixture was stirred at room temperature for 
20 h. Upon completion, the reaction mixture was concentrated in vacuo 
and purified by chromatography (EtOAc/heptane 1:9) to afford 42 (360 
mg, 1.10 mmol, 91%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 5.16 (dd, J = 6.6, 8.4 Hz, 
1H), 3.72 (s, 3H), 2.93 (m, 2H), 1.96 (t, J = 2.7 Hz, 1H), 1.50 (s, 18H). According to general 
procedure A, to a solution of biscarbamate 42 (337 mg, 1.03 mmol), 2-iodoaniline (272 mg, 
1.24 mmol) and Et2NH (0.55 mL, 5.26 mmol) in Et2O (18 mL), CuI (22 mg, 0.12 mmol) and 
PdCl2(PPh3)2 (37 mg, 0.05 mmol) were added and the resulting mixture was stirred for 2 h. 
Work-up and purification by chromatography (EtOAc/heptane 1:4) afforded 43 (394 mg, 
0.94 mmol, 91%) as a brown oil. Rf 0.15; [α]D −89.2 (c 0.5, CH2Cl2); IR (neat) 3465, 3373, 2980, 
1790, 1743, 1695, 1616; 1H NMR (300 MHz, CDCl3) δ 7.17 (dd, J = 1.2, 7.5 Hz, 1H), 7.03 (dt, J = 
1.5, 8.1 Hz, 1H), 6.59 (m, 2H), 5.22 (dd, J = 6.3, 9.3 Hz, 1H), 4.21 (s, 2H), 3.75 (s, 3H), 3.25 (dd, J 
= 6.3, 17.4 Hz, 1H), 3.18 (dd, J = 9.3, 17.4 Hz, 1H), 1.48 (s, 18H); 13C NMR (75 MHz, CDCl3) δ 
169.8, 169.4, 151.8, 151.5, 148.0, 132.1, 129.1, 117.4, 114.0, 108.0, 90.6, 83.6, 79.4, 73.5, 67.4, 57.0, 
52.6, 28.3, 21.9 HRMS (EI) calcd for C22H30N2O6 418.2104, found 418.2099. 
 
Methyl (2S)-5-(2-aminophenyl)-2-[(tert-butoxycarbonyl)amino]-4-penty-
noate (45). According to general procedure A, to a solution of 35 (303 mg, 
1.33 mmol), 2-iodoaniline (351 mg, 1.60 mmol) and Et2NH (0.70 mL, 6.73 
mmol) in Et2O (18 mL), CuI (28 mg, 0.15 mmol) and PdCl2(PPh3)2 (47 mg, 
0.07 mmol) were added and the resulting mixture was stirred for 2 h. 
Work-up and purification by chromatography (EtOAc/heptane 1:3) afforded 45 (356 mg, 
1.12 mmol, 84%) as a light-brown oil. Rf 0.28 (EtOAc/heptane 1:2); [α]D +82.2 (c 0.5, CH2Cl2); 
IR (neat) 3369, 2978, 1743, 1711, 1618, 1493; 1H NMR (300 MHz, CDCl3) δ 7.17 (dd, J = 1.5, 7.6 
Hz ,1H), 7.04 (m, 1H), 6.59 (m, 2H), 5.57 (br d, J = 8.3 Hz, 1H), 4.56 (m, 1H), 4.31 (s, 2H), 3.73 
(s, 3H), 2.95 (d, J = 5.2 Hz, 2H), 1.42 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 171.6, 155.1, 148.2, 
131.9, 129.3, 117.3, 114.1, 107.3, 88.8, 80.4, 80.0, 52.5, 52.3, 28.1, 24.1; HRMS (EI) calcd for 
C17H22N2O4 318.1580, found 318.1580. 
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Methyl 5-(2-aminophenyl)-2-{[(4-methylphenyl)sulfonyl]amino}-4-pen-
tynoate (48). According to general procedure A, to a solution of 47 (402 
mg, 1.43 mmol), 2-iodoaniline (377 mg, 1.72 mmol) and Et2NH (0.75 mL, 
7.20 mmol) in Et2O (18 mL), CuI (29 mg, 0.15 mmol) and PdCl2(PPh3)2 (50 
mg, 0.07 mmol) were added and the resulting mixture was stirred for 2 h. 
Work-up and purification by chromatography (EtOAc/heptane 1:2) afforded 48 (473 mg, 
1.27 mmol, 89%) as a light-brown oil. Rf 0.16; IR (neat) 3377, 3275, 1739, 1616, 1493; 1H NMR 
(300 MHz, CDCl3) δ 7.75 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 8.2 Hz, 2H), 7.13 (m, 2H), 6.65 (m, 
2H), 5.51 (d, J = 8.9 Hz, 1H), 4.22 (m, 3H), 3.61 (s, 3H), 2.94 (d, J = 5.2 Hz, 2H), 2.41 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 170.5, 148.3, 143.6, 136.7, 131.9, 129.5, 129.4, 127.0, 117.3, 114.3, 107.2, 
88.1, 80.9, 54.5, 52.7, 25.0, 21.3; HRMS (EI) calcd for C19H20N2O4S 372.1144, found 372.1145. 
 
General procedure B for the Pd- and Ag-catalyzed cyclization reactions. To a 
solution of the cyclization precursor in MeCN, the catalyst (10 mol%) was added. The 
mixture was stirred at reflux temperature under N2-atmosphere for the indicated time. The 
reaction mixture was concentrated in vacuo and purified by flash chromatography to afford 
the pure product. 
 
Methyl 5-{2-[(tert-butoxycarbonyl)amino]phenyl}-3,4-dihydro-2H-2-
pyrrolecarboxylate (20). According to general procedure B, to a 
solution of 19 (340 mg, 1.07 mmol) in MeCN (10 mL), PdCl2(MeCN)2 
(28 mg, 0.11 mmol) was added and the resulting mixture was stirred 
for 3 h. Purification by chromatography (EtOAc/heptane 1:6) afforded 20 (222 mg, 0.70 
mmol, 65%) as a white solid. An X-ray crystal structure determination was carried out after 
recrystallization from hexane. Rf 0.45 (EtOAc/heptane 1:2); mp 78.0 °C; IR (neat) 2980, 1734, 
1720, 1604, 1576, 1522, 1446; 1H NMR (300 MHz, CDCl3) δ 11.9 (s, 1H), 8.42 (d, J = 8.4 Hz, 1H), 
7.40 (m, 2H), 6.96 (t, J = 8.3 Hz, 1H), 4.99 (m, 1H), 3.78 (s, 3H), 3.25-3.00 (m, 2H), 2.35-2.09 (m, 
2H), 1.52 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 177.4, 172.9, 153.5, 140.9, 131.9, 130.5, 120.8, 
118.5, 118.4, 79.7, 74.4, 52.2, 36.9, 28.3, 25.1; HRMS (EI) calcd for C17H22N2O4 318.1580, found 
318.1576. 
 
 
 
 
 
 
 
Crystallographic data for 20: 
Crystal color    transparent colorless 
Crystal shape    rather regular thick platelet 
Crystal size    0.31 × 0.23 × 0.11 mm 
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Empirical formula   C17H22N2O4 
Formula weight   318.37 
Temperature    293(2) K 
Radiation/Wavelength  MoKα (graphite mon.)/0.71073 Å 
Crystal system, space group  Triclinic, P-1 
Unit cell dimensions   a = 5.9502(6) Å; α = 76.621(12)° 
25 reflections    b = 9.4955(8) Å; β = 79.367(8)° 
10.268 < θ < 12.154   c = 16.0415(19) Å; γ = 77.358(10)° 
Volume    851.76(16) Å3 
Z, Calculated density   2, 1.241 Mg/m3 
Absorption coefficient  0.089 mm-1 
Diffractometer/scan   Enraf-Nonius CAD4/ω-2θ 
F(000)    340 
θ range for data collection  2.82 to 27.47° 
Index ranges    −7<=h<=0, −12<=k<=12, −20<=l<=20 
Reflections collected/unique  4278/3904 [R(int) = 0.0409] 
Reflections observed   1352 ([Io>2σ(Io)]) 
Absorption correction   Semi-empirical from ψ-scans 
Range of relat. transm. factors  1.150 and 0.860 
Refinement method   Full-matrix least-squares on F2 
Computing    SHELXL-97 (Sheldrick, 1997) 
Data/restraints/parameters  3904/0/297 
Goodness-of-fit on F2   1.005 
SHELXL-97 weight parameters 0.063700, 0.000000 
Final R indices [I>2σ(I)]  R1 = 0.0710, wR2 = 0.1262 
R indices (all data)   R1 = 0.2243, wR2 = 0.1757 
Extinction coefficient   0.013(4) 
Largest diff. peak and hole  0.157 and −0.174 e.A-3 
 
Table 2.2 Bond lengths of the non-hydrogen atoms (Å) of 20 (standard deviations) 
O(1)-C(12) 1.342(4) N(2)-C(12) 1.351(4) C(6)-C(7) 1.406(5) 
O(1)-C(13) 1.480(4) N(2)-C(11) 1.405(4) C(7)-C(8) 1.367(5) 
O(2)-C(12) 1.208(4) C(2)-C(17) 1.517(5) C(8)-C(9) 1.360(6) 
O(3)-C(17) 1.307(4) C(2)-C(3) 1.518(6) C(9)-C(10) 1.371(5) 
O(3)-C(18) 1.444(6) C(3)-C(4) 1.508(6) C(10)-C(11) 1.391(5) 
O(4)-C(17) 1.185(4) C(4)-C(5) 1.496(5) C(13)-C(16) 1.507(5) 
N(1)-C(5) 1.285(4) C(5)-C(6) 1.474(4) C(13)-C(14) 1.512(5) 
N(1)-C(2) 1.472(4) C(6)-C(11) 1.391(4) C(13)-C(15) 1.523(5) 
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Table 2.3 Bond angles of the non-hydrogen atoms (°) of 20 (standard deviations) 
C(12)-O(1)-C(13) 121.1(3) C(11)-C(6)-C(7) 117.8(3) O(2)-C(12)-N(2) 126.6(4) 
C(17)-O(3)-C(18) 117.5(4) C(11)-C(6)-C(5) 123.9(3) O(1)-C(12)-N(2) 108.1(3) 
C(5)-N(1)-C(2) 109.3(3) C(7)-C(6)-C(5) 118.2(3) O(1)-C(13)-C(16) 101.5(3) 
C(12)-N(2)-C(11) 127.3(3) C(8)-C(7)-C(6) 122.4(4) O(1)-C(13)-C(14) 111.7(3) 
N(1)-C(2)-C(17) 108.3(3) C(9)-C(8)-C(7) 118.5(5) C(16)-C(13)-C(14) 111.4(4) 
N(1)-C(2)-C(3) 106.2(3) C(8)-C(9)-C(10) 121.3(5) O(1)-C(13)-C(15) 108.1(3) 
C(17)-C(2)-C(3) 114.8(4) C(9)-C(10)-C(11) 120.7(4) C(16)-C(13)-C(15) 112.0(4) 
C(4)-C(3)-C(2) 104.9(3) C(10)-C(11)-C(6) 119.2(4) C(14)-C(13)-C(15) 111.8(4) 
C(5)-C(4)-C(3) 102.5(4) C(10)-C(11)-N(2) 121.8(4) O(4)-C(17)-O(3) 123.0(4) 
N(1)-C(5)-C(6) 123.0(3) C(6)-C(11)-N(2) 119.0(3) O(4)-C(17)-C(2) 125.3(4) 
N(1)-C(5)-C(4) 114.8(3) O(2)-C(12)-O(1) 125.4(3) O(3)-C(17)-C(2) 111.8(3) 
C(6)-C(5)-C(4) 122.2(3)     
 
1-(tert-Butyl) 2-methyl 5-(2-aminophenyl)-2,3-dihydro-1H-1,2-pyr-
roledicarboxylate (21). According to general procedure B, to a 
solution of 19 (424 mg, 1.33 mmol) in MeCN (10 mL), PdCl2(MeCN)2 
(35 mg, 0.13 mmol) was added and the resulting mixture was stirred 
for 2 h. Purification by chromatography (EtOAc/heptane 1:3) afforded 21 (227 mg, 0.71 
mmol, 54%) as a white solid. Rf 0.27; mp 139.1 °C; IR (neat) 3442, 3357, 2972, 1730, 1668, 1649, 
1603, 1402; 1H NMR (300 MHz, CDCl3) δ 7.06 (m, 2H), 6.59 (m, 2H), 5.00 (dd, J = 2.1, 3.5 Hz, 
1H), 4.92 (dd, J = 2.5, 11.2 Hz, 1H), 4.50 (br s, 2H), 3.77 (s, 3H), 3.07 (ddd, J = 2.1, 11.2, 18.9 Hz, 
1H), 2.53 (dt, J = 3.5, 17.0 Hz, 1H), 1.14 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 173.7, 152.1, 
145.3, 142.4, 129.2, 129.0, 119.1, 116.6, 114.2, 108.4, 80.5, 60.5, 52.6, 32.0, 27.7; HRMS (EI) calcd 
for C17H22N2O4 318.1580, found 318.1583. 
 
Methyl 2-[(tert-butoxycarbonyl)amino]-5-oxo-5-phenylpentanoate (29). 
According to general procedure B, to a solution of 25 (438 mg, 1.44 mmol) in 
MeCN (16 mL), PdCl2(MeCN)2 (37 mg, 0.14 mmol) was added and the 
resulting mixture was stirred at room temperature for 70 h. Purification by 
chromatography (EtOAc/heptane 1:4) afforded 29 (149 mg, 0.46 mmol, 32%) 
as a light-yellow solid. Rf 0.39 (EtOAc/heptane 1:2); mp 109.4 °C; IR (neat) 
3359, 1736, 1699, 1680, 1599, 1514, 1448; 1H NMR (300 MHz, CDCl3) δ 7.92 (d, J = 7.2 Hz, 2H), 
7.48 (m, 3H), 5.14 (br d, J = 7.2 Hz, 1H), 4.37 (m, 1H), 3.73 (s, 3H), 3.08 (m, 2H), 2.30 (m, 1H), 
2.08 (m, 1H), 1.41 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 198.5, 172.7, 155.3, 136.6, 133.1, 128.5, 
128.0, 80.1, 53.3, 52.6, 34.8, 28.6, 27.3; HRMS (CI) calcd for C17H24NO5 (MH+) 322.1654, found 
322.1659. 
 
Methyl 2-[(tert-butoxycarbonyl)amino]-5-(2-methoxyphenyl)-5-oxo-penta-
noate (30). According to general procedure B, to a solution of 26 (504 mg, 
1.51 mmol) in MeCN (14 mL), PdCl2(MeCN)2 (39 mg, 0.15 mmol) was added 
and the resulting mixture was stirred at room temperature for 24 h. 
Purification by chromatography (EtOAc/heptane 1:4) afforded 30 (102 mg, 
0.29 mmol, 19%) as a white solid. Rf 0.18 (EtOAc/heptane 1:3); 1H NMR (300 
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MHz, CDCl3) δ 7.68 (d, J = 1.9 Hz, 1H), 7.46 (m, 1H), 6.98 (m, 2H), 5.17 (br d, J = 7.7 Hz, 1H), 
4.34 (m, 1H), 3.90 (s, 3H), 3.74 (s, 3H), 3.09 (m, 2H), 2.22 (m, 1H), 2.05 (m, 1H), 1.42 (s, 9H). 
 
1-(tert-Butyl) 2-methyl 5-[2-(acetylamino)phenyl]-2,3-dihydro-1H-
1,2-pyrroledicarboxylate (31). According to general procedure B, to a 
solution of 27 (376 mg, 1.04 mmol) in MeCN (14 mL), PdCl2(MeCN)2 
(29 mg, 0.11 mmol) was added and the resulting mixture was stirred 
for 2 h. Purification by chromatography (EtOAc/heptane 1:3) 
afforded 31 (184 mg, 0.51 mmol, 49%) as a white solid. Rf 0.25 (EtOAc/heptane 1:2); mp 108.7 
°C; IR (neat) 3357, 2974, 1738, 1684, 1643, 1581, 1524, 1443; 1H NMR (300 MHz, CDCl3) δ 8.69 
(br s, 1H), 8.44 (d, J = 8.3 Hz, 1H), 7.27 (m, 1H), 7.16 (dd, J = 1.6, 7.6 Hz, 1H) 6.97 (m, 1H), 5.07 
(dd, J = 2.0, 3.4 Hz, 1H), 4.98 (dd, J = 2.3, 11.0 Hz, 1H), 3.82 (s, 3H), 3.12 (ddd, J = 2.0, 11.0, 
17.0 Hz, 1H), 2.55 (dt, J = 2.9, 17.0 Hz, 1H), 2.24 (s, 3H), 1.08 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 173.7, 169.3, 151.4, 140.9, 136.8, 128.9, 128.4, 122.6, 122.5, 119.7, 110.2, 81.3, 60.6, 52.9, 
32.3, 27.6, 24.7; HRMS (EI) calcd for C19H24N2O5 360.1685, found 360.1682. 
 
5-(2-Aminophenyl)-7,7a-dihydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one (32). 
According to general procedure B, to a solution of 28 (120 mg, 0.56 mmol) 
in MeCN (10 mL), PdCl2(MeCN)2 (14 mg, 0.05 mmol) was added and the 
resulting mixture was stirred for 2 h. Purification by chromatography 
(EtOAc/heptane 2:1) afforded 32 (38 mg, 0.18 mmol, 32%) as a light-yellow 
oil. Rf 0.19; IR (neat) 3462, 3356, 1745, 1616, 1491, 1454; 1H NMR (300 MHz, CDCl3) δ 7.28 (dd, 
J = 1.5, 7.5 Hz, 1H), 7.13 (dt, J = 1.8, 7.7 Hz, 1H), 6.71 (m, 2H), 5.45 (t, J = 2.7 Hz, 1H), 4.79 (m, 
1H), 4.67 (t, J = 8.7 Hz, 1H), 4.21 (dd, J = 6.6, 8.7 Hz, 1H), 4.16 (br s, 2H), 2.73 (m, 2H); 13C 
NMR (75 MHz, CDCl3) δ 157.4, 145.0, 141.3, 130.0, 129.9, 118.3, 116.4, 116.3, 112.1, 69.9, 59.9, 
36.0; HRMS (EI) calcd for C12H12N2O2 216.0899, found 216.0891. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-4-(1H-2-indolyl)butanoate (40). 
According to general procedure B, to a solution of 38 (556 mg, 1.67 mmol) in 
MeCN (16 mL), PdCl2(MeCN)2 (43 mg, 0.17 mmol) was added and the 
resulting mixture was stirred for 30 min. Purification by chromatography 
(EtOAc/heptane 1:4) afforded 40 (334 mg, 1.00 mmol, 60%) as a light-brown 
oil. Rf 0.14 (EtOAc/heptane 1:3); [α]D −26.8 (c 0.5, CH2Cl2); IR (neat) 3381, 2954, 
1693, 1504, 1454; 1H NMR (300 MHz, CDCl3) δ 9.15 (br s, 1H), 7.50 (d, J = 7.5 
Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.06 (m, 2H), 6.22 (s, 1H), 5.22 (br d, J = 8.1 Hz, 1H), 4.43 (br 
m, 1H), 3.67 (s, 3H), 2.82 (m, 2H), 2.14 (m, 1H), 1.93 (m, 1H), 1.47 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 172.7, 155.9, 138.2, 136.0, 128.6, 121.0, 119.7, 119.4, 110.8, 99.9, 80.7, 52.8, 52.7, 34.5, 
28.6, 24.3; HRMS (EI) calcd for C18H24N2O4 332.1736, found 332.1727. 
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Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-(1H-2-indolyl)pentanoate 
(41). According to general procedure B, to a solution of 39 (226 mg, 0.65 
mmol) in MeCN (12 mL), PdCl2(MeCN)2 (17 mg, 0.07 mmol) was added 
and the resulting mixture was stirred for 30 min. Purification by 
chromatography (EtOAc/heptane 1:4) afforded 41 (125 mg, 0.36 mmol, 
55%) as a light-brown oil. Rf 0.17 (EtOAc/heptane 1:3); [α]D +5.2 (c 0.5, 
CH2Cl2); IR (neat) 3377, 2949, 1734, 1691, 1504, 1456; 1H NMR (300 MHz, 
CDCl3) δ 8.30 (br s, 1H), 7.49 (d, J = 7.2 Hz, 1H), 7.25 (m, 1H), 7.05 (m, 2H), 6.20 (s, 1H), 5.11 
(br d, J = 7.2 Hz, 1H), 4.40 (br m, 1H), 3.72 (s, 3H), 2.79 (m, 2H), 1.91-1.65 (m, 4H), 1.47 (s, 9H); 
13C NMR (75 MHz, CDCl3) δ 172.9, 155.5, 138.9, 135.9, 128.6, 120.9, 119.7, 119.4, 110.4, 99.6, 
80.3, 53.0, 52.5, 32.8, 28.6, 27.5, 25.5; HRMS (EI) calcd for C19H26N2O4 346.1893, found 
346.1894. 
 
Methyl (2S)-2-[di(tert-butoxycarbonyl)amino]-3-(1H-2-indolyl)propa-
noate (44). According to general procedure B, to a solution of 43 (327 mg, 
0.78 mmol) in MeCN (12 mL), PdCl2(MeCN)2 (20 mg, 0.08 mmol) was 
added and the resulting mixture was stirred for 3 h. Purification by 
chromatography (EtOAc/heptane 1:6) afforded 44 (170 mg, 0.41 mmol, 
52%) as a white solid. Rf 0.28 (EtOAc/heptane 1:3); mp 143.0 °C; [α]D −99.9 (c 1.0, CH2Cl2); IR 
(neat) 3392, 2983, 1743, 1726, 1685, 1456; 1H NMR (300 MHz, CDCl3) δ 8.45 (s, 1H), 7.47 (d, J = 
8.1 Hz, 1H), 7.24 (d, J = 7.7 Hz, 1H), 7.04 (m, 2H), 6.25 (d, J = 1.2 Hz, 1H), 5.15 (t, J = 6.9 Hz, 
1H), 3.75 (s, 3H), 3.61 (dd, J = 6.6, 15.0 Hz, 1H), 3.28 (dd, J = 7.2, 15.0 Hz, 1H), 1.40 (s, 18H); 
13C NMR (75 MHz, CDCl3) δ 171.1, 151.7, 136.1, 134.9, 128.5, 121.2, 119.9, 119.5, 110.6, 101.8, 
83.6, 58.4, 52.7, 30.1, 28.2; HRMS (EI) calcd for C22H30N2O6 418.2104, found 418.2105. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-2-indolyl)propanoate 
(46). According to general procedure B, to a solution of 45 (351 mg, 1.10 
mmol) in MeCN (12 mL), AgOTf (29 mg, 0.11 mmol) was added and the 
resulting mixture was stirred for 20 h. Purification by chromatography 
(EtOAc/heptane 1:3) afforded 46 (261 mg, 0.82 mmol, 75%) as a light-yellow 
oil. Rf 0.29 (EtOAc/heptane 1:2); [α]D +46.8 (c 1.0, CH2Cl2); IR (neat) 3378, 2976, 1692, 1498; 1H 
NMR (300 MHz, CDCl3) δ 8.27 (s, 1H), 7.51 (d, J = 7.5 Hz, 1H), 7.28 (m, 1H), 7.08 (m, 2H), 6.25 
(d, J = 1.5 Hz, 1H), 5.13 (br d, J = 10.8 Hz, 1H), 4.63 (br m, 1H), 3.74 (s, 3H), 3.27 (d, J = 5.4 Hz, 
2H), 1.45 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 172.3, 155.2, 136.2, 133.3, 128.4, 121.5, 120.0, 
119.7, 110.7, 102.0, 80.5, 53.4, 52.8, 31.6, 28.6; HRMS (EI) calcd for C17H22N2O4 318.1580, found 
318.1578. 
 
Methyl 3-(1H-2-indolyl)-2-{[(4-methylphenyl)sulfonyl]amino}propanoate 
(49). According to general procedure B, to a solution of 48 (360 mg, 0.97 
mmol) in MeCN (12 mL), AgOTf (25 mg, 0.10 mmol) was added and the 
resulting mixture was stirred for 20 h. Purification by chromatography 
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(EtOAc/heptane 1:3) afforded 49 (310 mg, 0.83 mmol, 86%) as a white solid. An X-ray crystal 
structure determination was carried out after recrystallization from Et2O. Rf 0.37 
(EtOAc/heptane 1:1); mp 146.3 °C; IR (neat) 3356, 3239, 1714, 1593, 1450, 1429; 1H NMR (300 
MHz, CDCl3) δ 8.26 (s, 1H), 7.64 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 7.8 Hz, 1H), 7.15 (m, 3H), 7.05 
(m, 2H), 6.14 (t, J = 1.2 Hz, 1H), 5.33 (d, J = 5.7 Hz, 1H), 4.21 (br d, J = 5.1 Hz, 1H) 3.56 (s, 3H), 
3.24 (d, J = 5.1 Hz, 2H), 2.38 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 171.8, 143.8, 136.2, 136.0, 
132.4, 129.6, 128.2, 127.1, 121.6, 120.0, 119.7, 110.9, 102.0, 56.0, 53.0, 32.2, 21.8; HRMS (EI) calcd 
for C19H20N2O4S 372.1144, found 372.1144. 
 
 
 
 
 
 
 
 
Crystallographic data for 49: 
Crystal color    transparent colorless 
Crystal shape    regular fragment 
Crystal size    0.18 × 0.16 × 0.08 mm 
Empirical formula   C19H20N2O4S 
Formula weight   372.43 
Temperature    208(2) K 
Radiation/Wavelength  MoKα (graphite mon.)/0.71073 Å 
Crystal system, space group  Triclinic, P-1 
Unit cell dimensions   a = 10.6303(5) Å; α = 73.937(5)° 
109156 reflections   b = 11.7369(8) Å; β = 88.550(6)° 
3.560 < θ < 27.500   c = 15.9793(11) Å; γ = 75.558(5)° 
Volume    1853.3(2) Å3 
Z, Calculated density   4, 1.335 Mg/m3 
Absorption coefficient  0.201 mm-1 
Diffractometer/scan   Nonius KappaCCD/area detector ϕ and ω scan 
F(000)    784 
θ range for data collection  3.56 to 27.50° 
Index ranges    −13<=h<=13, −15<=k<=15, −20<=l<=20 
Reflections collected/unique  109156/8481 [R(int) = 0.1937] 
Reflections observed   4836 ([Io>2σ(Io)]) 
Absorption correction   None 
Refinement method   Full-matrix least-squares on F2 
Computing    SHELXL-97 (Sheldrick, 1997) 
Data/restraints/parameters  8481/68/585 
Goodness-of-fit on F2   1.016 
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SHELXL-97 weight parameters 0.066500, 0.298900 
Final R indices [I>2σ(I)]  R1 = 0.0624, wR2 = 0.1269 
R indices (all data)   R1 = 0.1316, wR2 = 0.1455 
Largest diff. peak and hole  0.680 and −0.332 e.A-3 
 
Table 2.4 Bond lengths of the non-hydrogen atoms (Å) of 49 (standard deviations) 
S(1)-O(4) 1.4099(19) C(2)-C(3) 1.514(4) C(10)-C(11) 1.368(4) 
S(1)-O(3) 1.433(2) C(3)-C(4) 1.528(4) C(11)-C(12) 1.391(4) 
S(1)-N(1) 1.628(3) C(4)-C(5) 1.482(4) C(13)-C(18) 1.382(4) 
S(1)-C(13) 1.757(3) C(5)-C(6) 1.361(4) C(13)-C(14) 1.386(4) 
O(1)-C(2) 1.312(3) C(6)-C(7) 1.428(4) C(14)-C(15) 1.369(5) 
O(1)-C(1) 1.450(3) C(7)-C(12) 1.400(3) C(15)-C(16) 1.383(5) 
O(2)-C(2) 1.212(3) C(7)-C(8) 1.407(4) C(16)-C(17) 1.393(4) 
N(1)-C(3) 1.447(3) C(8)-C(9) 1.372(4) C(16)-C(19) 1.498(4) 
N(2)-C(5) 1.372(3) C(9)-C(10) 1.394(4) C(17)-C(18) 1.371(4) 
N(2)-C(12) 1.373(3)     
 
Table 2.5 Bond angles of the non-hydrogen atoms (°) of 49 (standard deviations) 
O(4)-S(1)-O(3) 120.35(14) C(2)-C(3)-C(4) 107.3(2) N(2)-C(12)-C(11) 130.1(2) 
O(4)-S(1)-N(1) 108.70(13) C(5)-C(4)-C(3) 116.1(3) N(2)-C(12)-C(7) 107.5(2) 
O(3)-S(1)-N(1) 103.87(13) C(6)-C(5)-N(2) 108.4(2) C(11)-C(12)-C(7) 122.4(2) 
O(4)-S(1)-C(13) 107.39(12) C(6)-C(5)-C(4) 130.2(3) C(18)-C(13)-C(14) 119.6(3) 
O(3)-S(1)-C(13) 108.28(13) N(2)-C(5)-C(4) 121.1(2) C(18)-C(13)-S(1) 119.9(2) 
N(1)-S(1)-C(13) 107.66(13) C(5)-C(6)-C(7) 108.0(2) C(14)-C(13)-S(1) 120.4(2) 
C(2)-O(1)-C(1) 117.2(2) C(12)-C(7)-C(8) 118.7(3) C(15)-C(14)-C(13) 120.1(3) 
C(3)-N(1)-S(1) 120.03(19) C(12)-C(7)-C(6) 106.5(2) C(14)-C(15)-C(16) 121.3(3) 
C(5)-N(2)-C(12) 109.7(2) C(8)-C(7)-C(6) 134.8(3) C(15)-C(16)-C(17) 117.9(3) 
O(2)-C(2)-O(1) 124.1(3) C(9)-C(8)-C(7) 118.8(3) C(15)-C(16)-C(19) 121.1(3) 
O(2)-C(2)-C(3) 122.6(2) C(8)-C(9)-C(10) 121.1(3) C(17)-C(16)-C(19) 121.0(3) 
O(1)-C(2)-C(3) 113.3(2) C(11)-C(10)-C(9) 121.7(3) C(18)-C(17)-C(16) 121.4(3) 
N(1)-C(3)-C(2) 114.8(2) C(10)-C(11)-C(12) 117.3(3) C(17)-C(18)-C(13) 119.7(3) 
N(1)-C(3)-C(4) 111.4(2)     
 
Methyl (2S)-3-benzo[b]furan-2-yl-2-{[(4-methylphenyl)sulfonyl]amino}-
propanoate (54). According to general procedure A, to a solution of 52 (344 
mg, 1.22 mmol), 2-iodophenol (333 mg, 1.51 mmol) in Et2NH (18 mL), CuI 
(24 mg, 0.13 mmol) and PdCl2(PPh3)2 (45 mg, 0.06 mmol) were added and 
the resulting mixture was stirred at reflux temperature for 4 h. Work-up and 
purification by chromatography (EtOAc/heptane 1:2) afforded 54 (337 mg, 0.90 mmol, 74%) 
as a light-yellow solid. Rf 0.23; mp 118.2 °C; [α]D +5.7 (c 1.0, CH2Cl2); IR (neat) 3252, 2954, 
1744, 1593, 1454, 1429, 1416; 1H NMR (300 MHz, CDCl3) δ 7.60 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 
6.6 Hz, 1H), 7.30-7.08 (m, 5H), 6.41 (d, J = 0.9 Hz, 1H), 5.36 (d, J = 9.0 Hz, 1H), 4.32 (m, 1H), 
3.57 (s, 3H) 3.19 (d, J = 5.7 Hz, 2H), 2.33 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 170.7, 154.7, 
152.1, 143.5, 136.5, 129.4, 128.2, 127.0, 123.9, 122.7, 120.6, 110.9, 105.5, 54.7, 53.0, 32.9, 21.8; 
HRMS (EI) calcd for C19H19NO5S 373.0984, found 373.0986. 
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CHAPTER 3 
 
FUNCTIONALIZED BUILDING BLOCKS FROM 
ACETYLENE-CONTAINING α-AMINO ACIDS 
 
 
3.1 Introduction 
 
The synthesis of functionalized heterocycles is an important goal in organic chemistry 
because such ring systems are frequently used as versatile building blocks in the synthesis of 
pharmaceuticals and natural products.1 Amongst well-established approaches, 
intramolecular Pd-catalyzed cyclizations of heteronucleophiles onto alkynes provide a 
convenient method for preparing such heterocycles.2 For example, acetylenes tethered with 
oxygen nucleophiles, in the form of carboxylic acids or alcohols, are excellent substrates for 
Pd-catalyzed cyclizations to give 5- or 6-membered lactones or cyclic ethers, respectively.3 
Representative for these types of reactions is the intramolecular hydrocarboxylation of the 
triple bond of 4-pentynoic acid (1) which gave the unsaturated lactone 2 upon treatment with 
PdCl2(MeCN)2 in the presence of a catalytic amount of base (Scheme 3.1).3c 
 
Scheme 3.1 
2 (100%)1
O
PdCl2(MeCN)2
Et3N, MeCN
reflux
CO2H
O
 
 
Alkynyl amines and amides also undergo efficient intramolecular cyclizations 
mediated by palladium.4 As an example, alkyn 3 cyclized in a good yield to the 5-membered 
cyclic imine 4 upon exposure to a Pd(II)-catalyst (Scheme 3.2). In a similar fashion, the 
corresponding 6-membered imines could also be obtained. 
 
Scheme 3.2 
4 (70%)3
H2N
Nn-C7H15
n-C7H15
PdCl2(MeCN)2
H2O, MeCN
reflux, 5 hMe
Me
 
 
Recently, similar Pd-catalyzed cyclizations have been conducted in the group of 
Rutjes using enantiomerically pure acetylene-containing amino acids as the substrates. Such 
trifunctional amino acids, containing both an oxygen and a nitrogen nucleophile, gave upon 
suitable protection access to a variety of enantiopure substituted lactones, as well as to the 
corresponding nitrogen heterocycles.5 The tosylamide 5, for example, cyclized in the 
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presence of Pd(OAc)2 at room temperature to the 5-membered lactone 7 without detectable 
loss of enantiopurity (Scheme 3.3). The catalytic cycle presumably involves electrophilic 
activation of the triple bond by Pd(II), followed by nucleophilic attack of the carboxylate 
function. The resulting vinylpalladium intermediate 6 undergoes protonolysis of the Pd-C 
bond leading to lactone 7 and regeneration of the Pd(II)-catalyst. 
 
Scheme 3.3 
7 (66%)5
Et3N, THF
rt, 1 h
CO2HHN
Ts
O
O
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Ts
Pd(OAc)2
Pd X
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O
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Similarly, cyclizations with nitrogen as the nucleophile were carried out using 8 and 
the homologous precursor 9 as the substrates (Scheme 3.4). 
 
Scheme 3.4 
10 (65%)
K2CO3, THF
60 °C, 4 h
Pd(OAc)2/2PPh3
HN CO2Me
n
8 n = 1
9 n = 2
Ts
N
Ts
CO2Me N
Ts
CO2Me
Pd2(dba)3/2PPh3
K2CO3, THF
60 °C, 1 h
11 (54%)n = 1 n = 2
 
 
In the case of propargylglycine derivative 8, the 5-membered endocyclic enamide 10 was 
formed in 65% yield using 10 mol% of the catalyst and 5 equiv of K2CO3. Under virtually the 
same conditions, homopropargylglycine derivative 9 cyclized in a 5-exo fashion to the 5-
membered exocyclic enamide 11 in a somewhat lower yield of 54%. 
In both cases, the use of in situ formed Pd(0)-catalysts resulted in the formation of the 
cyclization products, while Pd(II) is required as an intermediate. Therefore, it has been 
hypothesized that these reactions start with oxidative addition of the relatively acidic NH-
bond onto Pd to form a Pd-H species (viz. 12 in Scheme 3.5).5 Then, intramolecular insertion 
of the triple bond can take place, which depending on the chain length can result in a 
vinylpalladium species that either contains an endocyclic (13) or an exocyclic (14) double 
bond. Eventually, reductive elimination will regenerate Pd(0) to provide the enamides 10 
and 11. 
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Scheme 3.5 
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Ts
CO2Me
Pd2(dba)3/2PPh3
K2CO3, THF
60 °C, 1 h
11
n
PdH N
Ts
CO2Me
N
Ts
CO2Me
12
N
Ts
CO2Me
n = 1 n = 2 Pd
H
Pd
H
13 14  
 
We anticipated that this methodology might be readily extended to the substituted 
precursors 16. This should lead to the formation of the 2,5-disubstituted pyrrolines 15, a 
novel set of amino acid-derived building blocks, which might be valuable precursors to 
access various 5-substituted proline derivatives (Scheme 3.6). 
 
Scheme 3.6 
815 16
HN CO2Me
N CO2Me
R
R
HN CO2Me
TsTs
Ts
 
 
The precursors 16 should be easily accessible from enantiopure propargylglycine derivative 
8 (see: Chapter 2), whose relatively inert side chain offers the possibility to introduce a range 
of aromatic6 and aliphatic7 groups via transition metal-mediated processes. 
 
3.2 Pd-Catalyzed Pyrroline Formation 
 
In order to probe the feasibility of pyrroline formation via a Pd-catalyzed cyclization, 
precursor 18 was synthesized from the racemic propargylglycine derivative 17 (see: Chapter 
2) via a Sonogashira-type8 coupling with iodobenzene affording 18 in 84% yield (Scheme 3.7). 
Interestingly, subsequent subjection of 18 to previously reported cyclization conditions5 did 
not lead to the anticipated formation of the phenyl-substituted pyrroline. Instead, a complex 
mixture of products was obtained, from which elimination product 19, being the major 
product, could be isolated as a single geometrical isomer in 19% yield. 
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Scheme 3.7 
HN CO2Me
Ts
HN CO2Me
Ts
iodobenzene
PdCl2(PPh3)2, CuI
Et2NH, Et2O
rt, 2 h
Pd(PPh3)4, K2CO3
DMF, 80 °C, 18 h
17 18 (84%)
MeO2C NH2
19 (19%)  
 
The formation of 19 is most likely the result of base-mediated elimination of p-
toluenesulfinic acid,9 followed by isomerization of the imine double bond to the 
thermodynamically more stable enamine position. The double bond of 19 was assigned the 
sterically least hindered (Z)-geometry after conducting 1H NMR NOE experiments. In line 
with this reasoning, the same conversion could even be accomplished in a cleaner fashion by 
heating 18 in DMF in the presence of K2CO3, without the Pd-catalyst present, leading to the 
formation of 19 in 70% yield (based on recovered starting material). 
Having observed these results, we turned our attention to the conditions reported in 
Chapter 2, i.e. PdCl2(MeCN)2 in refluxing acetonitrile. To our satisfaction, subjection of 18 to 
these conditions led to the rapid formation of pyrroline 20 as the sole product in 51% yield 
after column chromatography (Scheme 3.8). 
 
Scheme 3.8 
HN CO2Me
Ts
PdCl2(MeCN)2
MeCN, reflux, 2 h
18 20 (51%)
N
Ts
CO2Me
HN CO2Me
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O
PdCl2(MeCN)2
MeCN, rt, 20 h
20 (34%)
21 (15%)  
 
In addition, subjection of 18 to the same catalyst at room temperature also led to the 
formation of cyclized product 20, albeit that the reaction was significantly slower. In this 
case, as a result of a competitive reaction, ketone 21 was formed as a side product in 15% 
yield. According to the results described in Section 2.4, the formation of the latter product 
might be explained via a Pd-catalyzed hydration of acetylene 18. 
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Encouraged by the facile cycloisomerization of 18, we also subjected acetylene 22, 
obtained in 91% yield starting from propargylglycine derivative 17 and 2-iodoaniline, to 
PdCl2(MeCN)2 in refluxing acetonitrile (Scheme 3.9). 
 
Scheme 3.9 
HN CO2Me
Ts
PdCl2(MeCN)2
MeCN, reflux, 1 h
22 (91%) 23 (57%)
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Ts
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As expected, treatment of 22 with the aforementioned catalyst led to the rapid formation of 
the cyclic enamide 23 in 57% yield. Interestingly, exposure of 22 to the same conditions at 
room temperature gave rise to the formation of 23 in 51% yield after prolonged reaction 
times of over several days, but in this case formation of the corresponding ketone was not 
observed. 
These results indicate that, in contrast to the Boc-protected cyclization precursors in 
Section 2.4, the presence of an ortho-aniline nitrogen atom in the Ts-protected precursors is 
not crucial for the cycloisomerization to occur. In case of the Boc-protected (see: Section 2.3) 
and Ts-protected aniline-substituted precursors, the presence of the aniline nitrogen seems to 
prevent ketone formation at room temperature. This might be explained by assuming that 
complexation of Pd to the triple bond, possibly aided by coordination to the aniline nitrogen, 
favors the nucleophilic attack of the sulfonamide or carbamate nitrogen leading exclusively 
to the formation of the corresponding Ts- or Boc-protected cyclic enamide. 
 
3.3 Mechanistic Aspects 
 
The formation of pyrroline 20 can be explained by complexation of the Pd(II)-catalyst 
to the triple bond to give the π-complex 24. The substituted acetylene is now sufficiently 
electrophilic for nucleophilic attack of the nitrogen atom to give the corresponding 
vinylpalladium intermediate 25. This intermediate undergoes protonolysis of the Pd-C bond 
to regenerate Pd(II) and give 20 as the product (Scheme 3.10). 
Clearly, the sulfonamide nitrogen in precursor 18 is nucleophilic enough to effect the 
cyclization both at room temperature or under reflux conditions which eventually leads to 
pyrroline 20. This outcome is, however, markedly different from the results reported in 
Section 2.4, in which the analogous Boc-protected compound did not show any cyclization. 
This difference might be explained by the fact that the relatively acidic sulfonamide NH in 18 
is to a larger extent dissociated under the applied conditions than the less acidic carbamate 
NH in the corresponding Boc-protected precursor. This leads to a more nucleophilic nitrogen 
in the case of the Ts-protected precursor 18 and thus to the formation of the cyclized product. 
Chapter 3 
 
56 
Scheme 3.10 
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The requirement of Pd(II) as a reactive intermediate in the cyclization of 18 into 
pyrroline 20 was demonstrated in two additional experiments, in which 18 was first 
subjected to Pd(PPh3)4 in refluxing acetonitrile. Under these conditions, no reaction was 
observed after 24 h in the presence of the Pd(0)-catalyst and the starting material was fully 
recovered (Scheme 3.11). 
 
Scheme 3.11 
HN CO2Me
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18 20
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or:
 
 
Moreover, subjection of 18 to AgOTf in refluxing acetonitrile (see: Chapters 2 and 4) did not 
lead to the formation of pyrroline 20 but gave an almost quantitative recovery of the starting 
material. The latter experiment indicates that the formation of pyrroline 20 can not be simply 
attributed to an electrophilic activation of the triple bond followed by nucleophilic attack of 
the sulfonamide moiety, but seems to involve the intermediacy of vinylpalladium species 25 
(see: Scheme 3.10). 
We envisaged that compound 22 could be a suitable precursor to prove the 
intermediacy of a vinylpalladium species such as 26. Possibly, trapping of this species via 
insertion of CO in the Pd-C bond, followed by intramolecular nucleophilic attack of the 
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aniline nitrogen onto the formed acylpalladium species would lead to the tricyclic system 27 
(Scheme 3.12). 
 
Scheme 3.12 
HN CO2Me
Ts
PdCl2(MeCN)2, CO
MeCN, reflux
15 min
22
NH2 N CO2Me
Ts
Pd
X
26
NH2
N CO2Me
Ts
23 (56%)
NH2
27
HN
O
N
CO2Me
Ts
 
 
These conditions did not lead to the formation of compound 27, but instead an unusually 
rapid conversion of the starting material was observed affording the known pyrroline 23 
within 15 min as the sole product in 56% yield after column chromatography. Presumably, 
the presence of CO in the reaction mixture leads, via ligand exchange, to the formation of a 
more reactive Pd-catalyst, which is responsible for the rapid conversion of 22 into cyclic 
enamide 23. 
 
3.4 Cyclizations of Several Functionalized Cyclization Precursors 
 
With the cycloisomerizations of compounds 18 and 22 in hand, we decided to further 
explore the scope and limitations of the cyclizations. Therefore, we prepared a variety of 
cyclization precursors via Sonogashira couplings between propargylglycine derivative 17 
and several (substituted) aryl iodides. The substituted acetylenes 28-33 were thus obtained in 
good yields and subjected to PdCl2(MeCN)2 in refluxing acetonitrile (Table 3.1). 
Subjection of precursor 28, substituted with an electron donating methoxy group, led 
to the formation of the corresponding cyclic enamide 34 in 49% yield (entry 1). Likewise, the 
p-methyl substituted precursor 29 underwent cyclization to give pyrroline 35 in 50% yield 
(entry 2). In contrast to these results, not shown in Table 3.1, the cyclization of the precursor 
derived from propargylglycine derivative 17 and p-nitrophenyl iodide did not lead to the 
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corresponding cyclized product, indicating that the cyclization is sensitive to electronic 
effects. 
 
Table 3.1 
entry precursor (yield)a pyrroline yield (%)a
1
aIsolated yield after column chromatography.
HN CO2Me
Ts 28 (80%) 34
49
2
N
HN CO2Me
Ts  29 (82%) 35
50
3
N
HN CO2Me
Ts 30 (81%) 36
68
4
N
37
5
HN CO2Me
Ts 31 (81%)
44
N
HN CO2Me
Ts 32 (78%) 38
51
NF
F
OMe
Ts
CO2Me
Me
CO2Me
Ts
Me
Me CO2Me
TsMe
CO2Me
Ts
CO2Me
Ts
6
HN CO2Me
Ts 33 (79%) 39
48
N
Ts
CO2Me
MeO
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The 1-naphthyl-substituted acetylene 31 as well as 32, containing a pharmaceutically relevant 
fluorophenyl substituent, both underwent cyclization affording pyrrolines 37 and 38 in 44 
and 51% yield, respectively (entries 4 and 5). Interestingly, the sterically more hindered 
precursor 30 cyclized relatively cleanly, leading to the cyclic enamide 36 in an acceptable 
yield of 68% (entry 3). Crystallization of this product afforded good quality crystals that 
were subjected to an X-ray crystal structure analysis, thereby unambiguously confirming its 
structure (Fig. 3.1).10 
 
 
Figure 3.1 PLATON11 drawing of the crystal structure of 36. 
 
We also wished to verify that no (partial) racemization had taken place in the cyclization 
process, to ensure that this sequence is suitable for the synthesis of enantiopure proline 
derivatives. Thus, the enantiomerically pure cyclization precursor 33 was subjected to the 
Pd-catalyst in refluxing acetonitrile. This provided the pyrroline 39 as the sole product in 
48% yield (entry 6), without detectable loss of enantiopurity according to chiral HPLC 
analysis (Chiralcel OD). 
Unfortunately, in addition to the cyclizations shown in Table 3.1, the enantiopure 2-
pyridyl-substituted precursor 40, obtained in 76% yield from propargylglycine derivative 
(R)-17 and 2-iodopyridine,did not undergo a cyclization but gave after refluxing for several 
hours in the presence of the Pd(II)-catalyst substantial recovery of the starting material 
(Scheme 3.13). 
 
Scheme 3.13 
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Likewise, the 3-pyridyl-substituted analogue of 40 did not undergo cyclization either. 
Presumably, in both cases, this behavior could be attributed to the electron deficient nature 
of the pyridyl moiety, which is in line with the results obtained before. On the other hand, it 
may not be ruled out that this outcome is due to the fact that the pyridyl group strongly 
binds to the palladium, thus inhibiting the catalyst. 
Additionally, we investigated the possible cyclization of the homologous precursor 
42, obtained in 80% yield from enantiomerically pure homopropargylglycine derivative 9, 
using the same methodology (Scheme 3.14). 
 
Scheme 3.14 
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It appeared that extension of the side chain of the precursor was fatal to the cyclization 
reaction. Compound 42 did not undergo the anticipated 5-exo-dig cyclization, but instead 
slowly decomposed under the applied conditions. 
In order to study the influence of the ester group on the pyrroline formation, the 
enantiopure amino acid 44 was converted into the corresponding protected amino alcohol 
46. Thus, ester reduction of 44 with LiBH4 in THF gave amino alcohol 45 in 88% yield, which 
was subsequently protected with TBDMSCl to afford silyl ether 46 in 95% yield after column 
chromatography (Scheme 3.15). 
 
Scheme 3.15 
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First, the unprotected amino alcohol 45 was subjected to PdCl2(MeCN)2 in refluxing 
acetonitrile. These conditions led to the formation of a complex mixture of products from 
which pyrroline 47 could be isolated as the major product in a poor yield of 10% (Scheme 
3.16). 
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Scheme 3.16 
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Ts
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47 R = H (10%)
48 R = TBDMS
N
TsOR
PdCl2(MeCN)2
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Treatment of the protected amino alcohol 46 under the same conditions did not lead to an 
improvement of the yield of the corresponding pyrroline, but gave a mixture of 
unidentifiable products. Apparently, the enamides 47 and 48 are less stable than the ester 
substituted counterparts and readily decompose under the applied conditions. This might be 
explained by the fact that reduction of the electron withdrawing ester function presumably 
leads to a more nucleophilic enamide which is easily protonated and therefore more 
susceptible to decomposition. 
In summary, the yields of the cyclization reactions turned out to be somewhat low. 
This might be attributed to the instability of the enamides that are formed in these reactions. 
The relatively vulnerable enamides are likely to be prone to decomposition under the 
applied conditions, which is underlined by the fact that TLC analysis always showed 
complete conversion and that the starting material was not recovered in these reactions. 
 
3.5 Metal-Catalyzed Lactone Formation 
 
In addition to the cyclizations using the sulfonamide nitrogen as the nucleophile, we 
wanted to investigate the possibility of using the carboxylic acid as the nucleophile, which 
might give access to a variety of substituted lactones. In order to probe the feasibility of 
lactone formation via a Pd-catalyzed cyclization, precursor 18 was first saponified providing 
the free acid 49 in 95% yield (Scheme 3.17). 
 
Scheme 3.17 
HN CO2Me
Ts
HN CO2H
Ts
THF/H2O
 (1:1 v/v) , rt, 20 h
18 49 (95%)
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Subjection of 49 to the previously used cyclization conditions did not give the anticipated 
formation of lactone 50. Instead, the starting material slowly underwent decomposition 
under the applied conditions. 
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The precedence of several literature examples regarding the Ag-catalyzed cyclization 
of acetylenic alcohols and acids,12 drew our attention again to the previously mentioned Ag-
catalyst. Thus, the enantiomerically pure precursor 51 was exposed to AgOTf in refluxing 
acetonitrile (Scheme 3.18). 
 
Scheme 3.18 
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To our satisfaction, these conditions led to a slow but clean formation of lactone 52, although 
the reaction did not go to completion even after prolonged reaction times of over 24 h. 
Nevertheless, after refluxing for 24 h in the presence of the Ag-catalyst, compound 52 could 
be isolated as the sole product in 64% yield. Lactone 52 turned out to be a crystalline solid 
suitable for X-ray crystal structure determination, proving the formation of the 5-membered 
ring and the (Z)-geometry of the exocylic double bond (Fig. 3.2). 
 
 
Figure 3.2 PLATON11 drawing of the crystal structure of 52. 
 
Analogous to what is known from literature,12 the mechanism of the formation of 52 
presumably involves electrophilic activation of the triple bond by the Ag-catalyst, followed 
by nucleophilic attack of the carboxylate function. The nucleophile attacks the triple bond 
trans with respect to the Ag-catalyst which might explain the formation of the (Z)-double 
bond. Interestingly, the stereospecific formation of 52 is in nice contrast to the previously 
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reported formation of similar lactones with (E)-geometry of the exocyclic double bond via 
oxypalladation of propargylglycine derivatives in the presence of iodobenzene.5 
Encouraged by this result, we also applied the aforementioned conditions on amino 
alcohol 45 to see whether the Ag-catalyst would effect cyclization of the alcohol onto the 
triple bond to give the corresponding cyclic ether 53. Thus, compound 45 was subjected to 
AgOTf in refluxing acetonitrile (Scheme 3.19). 
 
Scheme 3.19 
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Unfortunately, this reaction led to quantitative recovery of the starting material. Apparently, 
the alcohol itself is not sufficiently nucleophilic to effect cyclization. This is probably due to 
the fact that the alcohol is not acidic enough to be (partly) dissociated under the applied 
conditions, which is the case for the corresponding carboxylic acid. 
 
3.6 Reactions with the Pyrrolines 
 
In order to explore the synthetic opportunities of the obtained pyrrolines, we set out 
to investigate some methods to functionalize the double bond. Firstly, we investigated the 
reduction of the enantiopure pyrroline 39 to the corresponding saturated proline derivative 
54. Therefore, pyrroline 39 was first subjected to straightforward hydrogenation conditions 
using Pd on carbon under a hydrogen atmosphere (Scheme 3.20). Disappointingly, these 
conditions did not lead to the desired reduction of the enamide moiety, but instead gave 
partial decomposition of the starting material, probably as a result of hydrogenolysis at the 
benzylic position. The reluctance of pyrroline 39 to undergo a catalytic hydrogenation might 
be explained by the crystal structure of pyrroline 36 (see: Fig. 3.1). This structure clearly 
shows the shielding of the enamide double bond by the p-toluenesulfonamide moiety from 
the bottom side of the molecule and the methyl ester from the top side, which may severely 
hamper the approach of the double bond to the catalyst surface. 
We then turned our attention to reported conditions,5 involving the reduction of 
pyrroline 39 via the intermediate N-sulfonyliminium ion 55.13 This was accomplished by 
using a mixture of triethylsilane (5 equiv), trifluoroacetic acid (5 equiv) and trifluoroacetic 
anhydride (5 equiv). The initially formed tertiary iminium ion was captured by the hydride 
donor to give proline derivatives 56 and 57 as a 9:1 mixture of diastereoisomers as 
determined by 1H NMR in a combined yield of 74% (Scheme 3.20). 
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Scheme 3.20 
 
39 54
57
N
Ts
CO2MeN
Ts
CO2Me
55
N
Ts
CO2Me
56
N
Ts
CO2Me N
Ts
CO2Me+
Et3SiH, TFA
TFAA, CH2Cl2
0 °C → rt, 1.5 h
H2, Pd/C
EtOAc, rt, 20 h
56 / 57 = 9 : 1 (74%)  
 
Luckily, proline derivative 56 could be obtained in pure form by repeated column 
chromatography and crystallization, after which its structure was unambiguously identified 
by means of X-ray crystal structure analysis (Fig. 3.3).10 This result clearly established the cis-
configuration of both substituents in the major isomer. 
 
 
Figure 3.3 PLATON11 drawing of the crystal structure of 56. 
 
The use of triphenylsilane as a more bulky hydride source under the same conditions did not 
lead to an improvement of the diastereoisomeric ratio, in fact the proline derivatives 56 and 
57 were then obtained as a 7.5:1 mixture of isomers in a somewhat lower combined yield of 
67% after column chromatography. 
Besides the addition of the small hydride nucleophile, we also investigated the 
possible introduction of a larger nucleophile via the tertiary N-sulfonyliminium 55 using a 
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mixture of allyltrimethylsilane (10 equiv), trifluoroacetic acid (5 equiv) and trifluoroacetic 
anhydride (5 equiv, Scheme 3.21). 
 
Scheme 3.21 
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These conditions did not afford the allylated product 58 but led to the formation of a mixture 
of unidentifiable products. The formation of side products can be easily understood, 
considering the difficulty of nucleophilic attack on the tertiary iminium ion.14 As a result of 
this reluctancy of the tertiary cation 55 to undergo nucleophilic attack by more sterically 
hindered nucleophiles, further investigations to add nucleophiles were not carried out. 
 
3.7 Conclusions 
 
In this chapter, several metal-catalyzed cyclization reactions with acetylene-
containing amino acids are detailed. The synthesis of 2,5-disubstituted pyrrolines can be 
achieved via a 5-endo-dig Pd-catalyzed cyclization of suitably protected acetylene-containing 
amino acids in reasonable yields. In the case of amino acid 33, it has also been demonstrated 
that this pathway proceeds without detectable racemization. Furthermore, in the case of 51 
we have shown the possibility of using the carboxylic acid function as the nucleophile in a 
Ag-catalyzed cyclization leading to lactone 52. 
Finally, we explored a few methods to derivatize pyrroline 39 and demonstrated the 
feasibility of converting this pyrroline in an efficient manner into the corresponding 
saturated 5-substituted proline derivatives 56 and 57. 
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3.9 Experimental Section 
 
General information. For general experimental details, see Section 2.8. 
 
General procedure A for the Sonogashira cross-coupling reactions. For a general 
procedure, see Section 2.8. 
 
Methyl 5-(4-methoxyphenyl)-2-{[(4-methylphenyl)sulfonyl]amino}-
4-pentynoate (28). According to general procedure A, to a solution of 
17 (404 mg, 1.43 mmol), 4-iodoanisole (405 mg, 1.73 mmol) and 
Et2NH (0.74 mL, 7.23 mmol) in Et2O (18 mL), CuI (28 mg, 0.15 mmol) 
and PdCl2(PPh3)2 (51 mg, 0.07 mmol) were added and the resulting 
mixture was stirred for 3 h. Work-up and purification by 
chromatography (EtOAc/heptane 1:3) afforded 28 (440 mg, 1.14 mmol, 80%) as a light-
yellow solid. Rf 0.25 (EtOAc/heptane 1:2); mp 138.6 °C; IR (neat) 3338, 1745, 1603, 1506, 1452, 
1435; 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 8.3 Hz, 2H), 7.27 (m, 4H), 6.80 (d, J = 8.5 Hz, 
2H), 5.44 (d, J = 9.1 Hz, 1H), 4.19 (m, 1H), 3.80 (s, 3H), 3.62 (s, 3H), 2.90 (dd, J = 4.8, 17.0 Hz, 
1H), 2.83 (dd, J = 5.2, 16.8 Hz, 1H), 2.40 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 170.4, 159.6, 
143.8, 137.0, 133.2, 129.7, 127.3, 114.9, 113.9, 84.2, 81.3, 55.3, 54.6, 52.9, 25.1, 21.6; HRMS (EI) 
calcd for C20H21NO5S 387.1140, found 387.1140. 
 
Methyl 5-(4-methylphenyl)-2-{[(4-methylphenyl)sulfonyl]amino}-4-
pentynoate (29). According to general procedure A, to a solution of 17 
(402 mg, 1.43 mmol), 4-iodotoluene (395 mg, 1.81 mmol) and Et2NH 
(0.74 mL, 7.23 mmol) in Et2O (18 mL), CuI (28 mg, 0.15 mmol) and 
PdCl2(PPh3)2 (51 mg, 0.07 mmol) were added and the resulting mixture 
was stirred for 3 h. Work-up and purification by chromatography 
(EtOAc/heptane 1:3) afforded 29 (435 mg, 1.17 mmol, 82%) as an orange solid. Rf 0.19; 1H 
NMR (300 MHz, CDCl3) δ 7.75 (d, J = 8.3 Hz, 2H), 7.25 (m, 4H), 7.08 (d, J = 8.0 Hz, 2H), 5.45 
(d, J = 8.8 Hz, 1H), 4.18 (dt, J = 5.3, 9.0 Hz, 1H), 3.62 (s, 3H), 2.91 (dd, J = 4.8, 16.8 Hz, 1H), 
2.83 (dd, J = 5.5, 17.0 Hz, 1H), 2.40 (s, 3H), 2.33 (s, 3H). 
 
Methyl 5-(2-methylphenyl)-2-{[(4-methylphenyl)sulfonyl]amino}-4-pen-
tynoate (30). According to general procedure A, to a solution of 17 (412 
mg, 1.46 mmol), 2-iodotoluene (391 mg, 1.79 mmol) and Et2NH (0.77 mL, 
7.42 mmol) in Et2O (18 mL), CuI (29 mg, 0.15 mmol) and PdCl2(PPh3)2 (52 
mg, 0.07 mmol) were added and the resulting mixture was stirred for 2 h. 
Work-up and purification by chromatography (EtOAc/heptane 1:4) afforded 30 (437 mg, 
1.18 mmol, 81%) as a light-yellow solid. Rf 0.23 (EtOAc/heptane 1:3); mp 95.0 °C; IR (neat) 
3269, 1728, 1597, 1487, 1444, 1362; 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.4 Hz, 2H), 7.16 
(m, 6H), 5.46 (d, J = 8.7 Hz, 1H), 4.19 (dt, J = 5.0, 8.8 Hz, 1H), 3.63 (s, 3H), 2.98 (dd, J = 4.6, 17.0 
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Hz, 1H), 2.90 (dd, J = 5.3, 16.8 Hz, 1H), 2.40 (s, 3H), 2.34 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
170.1, 143.6, 140.0, 136.8, 132.0, 129.6, 129.3, 128.1, 127.1, 125.4, 122.4, 86.6, 83.2, 54.7, 53.1, 
25.5, 21.9, 21.0; HRMS (EI) calcd for C20H21NO4S 371.1191, found 371.1199. 
 
Methyl 2-{[(4-methylphenyl)sulfonyl]amino}-5-(1-naphthyl)-4-penty-
noate (31). According to general procedure A, to a solution of 17 (302 
mg, 1.08 mmol), 1-iodonaphthalene (354 mg, 1.39 mmol) and Et2NH 
(0.58 mL, 5.57 mmol) in Et2O (18 mL), CuI (20 mg, 0.11 mmol) and 
PdCl2(PPh3)2 (40 mg, 0.06 mmol) were added and the resulting mixture 
was stirred for 2 h. Work-up and purification by chromatography 
(EtOAc/heptane 1:4) afforded 31 (356 mg, 0.87 mmol, 81%) as a light-yellow oil. Rf 0.23 
(EtOAc/heptane 1:3); IR (neat) 3265, 3060, 2949, 1739, 1597, 1496, 1435; 1H NMR (300 MHz, 
CDCl3) δ 8.18 (d, J = 6.9 Hz, 1H), 7.74 (m, 4H), 7.45 (m, 4H), 7.23 (m, 2H), 5.48 (d, J = 8.7 Hz, 
1H), 4.27 (m, 1H), 3.64 (s, 3H), 2.98 (m, 2H), 2.36 (s, 3H). 
 
Methyl 5-(4-fluorophenyl)-2-{[(4-methylphenyl)sulfonyl]amino}-4-
pentynoate (32). According to general procedure A, to a solution of 17 
(404 mg, 1.44 mmol), 1-fluoro-4-iodobenzene (395 mg, 1.78 mmol) and 
Et2NH (0.77 mL, 7.40 mmol) in Et2O (18 mL), CuI (29 mg, 0.15 mmol) 
and PdCl2(PPh3)2 (53 mg, 0.08 mmol) were added and the resulting 
mixture was stirred for 2 h. Work-up and purification by 
chromatography (EtOAc/heptane 1:3) afforded 32 (420 mg, 1.12 mmol, 78%) as a light-
yellow solid. Rf 0.29 (EtOAc/heptane 1:2); mp 120.0 °C; IR (neat) 3344, 2968, 1741, 1599, 1504, 
1450, 1433; 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.3 Hz, 2H), 7.27 (m, 4H), 6.94 (m, 2H), 
5.41 (d, J = 8.9 Hz, 1H), 4.16 (dt, J = 4.4, 8.9 Hz, 1H), 3.61 (s, 3H), 2.90 (dd, J = 4.8, 17.0 Hz, 
1H), 2.83 (dd, J = 5.3, 16.7 Hz, 1H), 2.40 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 170.0, 163.9, 
160.6, 143.7, 136.8, 133.6, 133.5, 129.7, 127.1, 115.7, 115.4, 83.3, 82.6, 54.6, 53.1, 25.4, 21.9; HRMS 
(EI) calcd for C19H18NO4FS 375.0941, found 375.0943. 
 
Methyl (2R)-2-{[(4-methylphenyl)sulfonyl]amino}-5-phenyl-4-pentyno-
ate (33). According to general procedure A, to a solution of (R)-17 (452 mg, 
1.61 mmol), iodobenzene (400 mg, 1.96 mmol) and Et2NH (0.83 mL, 8.07 
mmol) in Et2O (18 mL), CuI (33 mg, 0.17 mmol) and PdCl2(PPh3)2 (56 mg, 
0.08 mmol) were added and the resulting mixture was stirred for 2 h. 
Work-up and purification by chromatography (EtOAc/heptane 1:3) 
afforded 33 (452 mg, 1.26 mmol, 79%) as a light-yellow solid. Rf 0.34 (EtOAc/heptane 1:2); 
[α]D −14.1 (c 1.0, CH2Cl2); mp 100.4 °C; IR (neat) 3279, 2929, 1746, 1721; 1H NMR (300 MHz, 
CDCl3) δ 7.76 (d, J = 8.3 Hz, 2H), 7.29 (m, 7H), 5.46 (d, J = 8.9 Hz, 1H), 4.19 (dt, J = 5.2, 8.9 Hz, 
1H), 3.63 (s, 3H), 2.89 (m, 2H), 2.40 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 170.4, 143.8, 137.0, 
131.7, 129.7, 128.3, 128.2, 127.2, 122.8, 84.2, 82.9, 54.5, 52.9, 25.0, 21.5; HRMS (EI) calcd for 
C19H19NO4S 357.1035, found 357.1028. 
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Methyl (2R)-2-{[(4-methylphenyl)sulfonyl]amino}-5-(2-pyridyl)-4-penty-
noate (40). According to general procedure A, to a solution of (R)-17 (380 
mg, 1.35 mmol), 2-iodopyridine (332 mg, 1.62 mmol) and Et2NH (0.71 mL, 
6.86 mmol) in Et2O (18 mL), CuI (29 mg, 0.15 mmol) and PdCl2(PPh3)2 (47 
mg, 0.07 mmol) were added and the resulting mixture was stirred for 2 h. 
Work-up and purification by chromatography (EtOAc/heptane 2:1) 
afforded 40 (365 mg, 1.02 mmol, 76%) as a white solid. Rf 0.26; [α]D −12.8 (c 0.5, CH2Cl2); mp 
131.4 °C; IR (neat) 3032, 2857, 1732, 1587, 1562, 1468, 1427; 1H NMR (300 MHz, CDCl3) δ 8.51 
(m, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.59 (dt, J = 1.8, 7.8 Hz, 1H), 7.25 (m, 4H) 5.54 (br s, 1H), 4.19 
(br s, 1H), 3.62 (s, 3H), 2.95 (dd, J = 4.8, 16.8 Hz, 1H), 2.88 (dd, J = 5.4, 16.8 Hz, 1H), 2.40 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 169.9, 149.7, 143.6, 142.7, 136.8, 136.0, 129.6, 127.2, 127.1, 
122.8, 83.7, 83.5, 54.4, 53.1, 25.2, 21.8; HRMS (EI) calcd for C18H18N2O4S 358.0987, found 
358.0989. 
 
Methyl (2S)-2-{[(4-methylphenyl)sulfonyl]amino}-6-phenyl-5-hexynoate (42). 
According to general procedure A, to a solution of 9 (345 mg, 1.17 mmol), 
iodobenzene (294 mg, 1.44 mmol) and Et2NH (0.61 mL, 5.89 mmol) in Et2O (18 
mL), CuI (22 mg, 0.12 mmol) and PdCl2(PPh3)2 (42 mg, 0.06 mmol) were added 
and the resulting mixture was stirred for 3 h. Work-up and purification by 
chromatography (EtOAc/heptane 1:3) afforded 42 (348 mg, 0.94 mmol, 80%) 
as a light-yellow oil. Rf 0.29 (EtOAc/heptane 1:2); 1H NMR (300 MHz, CDCl3) 
δ 7.71 (d, J = 8.1 Hz, 2H), 7.34 (m, 2H), 7.24 (m, 5H), 5.30 (d, J = 8.7 Hz, 1H) 
4.06 (m, 1H), 3.52 (s, 3H), 2.50 (dt, J = 1.8, 7.2 Hz, 2H), 2.37 (s, 3H), 1.99 (m, 2H); 13C NMR (75 
MHz, CDCl3) δ 171.6, 143.6, 136.4, 131.5, 129.6, 128.1, 127.8, 127.3, 123.4, 87.8, 81.9, 55.0, 52.9, 
32.5, 21.8, 15.9. 
 
N-[(1S)-1-({[1-(tert-butyl)-1,1-dimethylsilyl]oxy}methyl]-4-phenyl-3-
buty-nyl]-4-methyl-1-benzenesulfonamide (46). To a solution of 44 (352 
mg, 0.99 mmol) in THF (20 mL), LiBH4 (2M in THF, 1.0 mL, 2.0 mmol) 
was added at 0 °C. The reaction mixture was allowed to reach room 
temperature and stirred for 20 h. Upon completion, the reaction mixture 
was quenched by adding water (1 mL) and stirred further for 15 min at room temperature, 
after which time the mixture was poured into water (30 mL). The aqueous solution was 
extracted with EtOAc (100 mL) and the organic layer was washed with water (2 × 30 mL), 
brine (2 × 30 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by chromatography (EtOAc/heptane 1:2) to afford the amino alcohol 45 (288 mg, 
0.87 mmol, 88%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 8.4 Hz, 2H), 7.25 
(m, 7H), 5.07 (d, J = 7.8 Hz, 1H), 3.71 (m, 2H), 3.50 (m, 1H), 2.63 (dd, J = 5.4, 17.1 Hz, 1H), 2.54 
(dd, J = 6.9, 17.1 Hz, 1H), 2.38 (s, 3H), 2.04 (t, J = 5.7 Hz, 1H). To a solution of amino alcohol 
45 (184 mg, 0.56 mmol) in CH2Cl2 (8 mL), Et3N (0.09 mL, 0.65 mmol), DMAP (69 mg, 0.57 
mmol) and TBDMSCl (109 mg, 0.72 mmol) were added at 0 °C. The reaction mixture was 
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allowed to reach room temperature and stirred for 21 h. Upon completion, the reaction 
mixture was diluted with CH2Cl2 (10 mL) and washed with water (2 × 5 mL), brine (5 mL), 
dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
chromatography (EtOAc/heptane 1:9) to afford silyl ether 46 (234 mg, 0.53 mmol, 95%) as a 
colorless oil. Rf 0.12; [α]D +61.2 (c 0.5, CH2Cl2); IR (neat) 3270, 2946, 2924, 2850, 1593, 1485, 
1463, 1437, 1411; 1H NMR (300 MHz, CDCl3) δ 7.77 (d, J = 8.4 Hz, 2H), 7.22 (m, 7H), 4.98 (d, J 
= 7.8 Hz, 1H), 3.76 (dd, J = 3.6, 9.9 Hz, 1H) 3.49 (m, 2H), 2.70 (dd, J = 4.8, 16.8 Hz, 1H), 2.56 
(dd, J = 7.8, 16.8 Hz, 1H), 2.40 (s, 3H), 0.88 (s, 9H), 0.05 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 
143.3, 137.6, 131.5, 129.7, 128.2, 128.0, 127.0, 123.1, 85.2, 83.1, 63.3, 53.8, 26.1, 22.9, 21.8, 18.6, -
5.1; HRMS (EI) calcd for C24H33NO3SSi 443.1950, found 443.1955. 
 
General procedure B for the Pd- and Ag-catalyzed cyclization reactions. For a 
general procedure, see Section 2.8. 
 
Methyl (Z)-2-amino-5-phenyl-2-penten-4-ynoate (19). To a solution of 
18 (418 mg, 1.17 mmol) in DMF (20 mL), K2CO3 (808 mg, 5.85 mmol) 
and Pd(PPh3)4 (71 mg, 0.06 mmol) were added and the reaction 
mixture was stirred at 80 °C. Upon completion, the reaction mixture 
was poured into saturated aqueous NaHCO3 (40 mL) and the aqueous 
solution was extracted with Et2O (3 × 30 mL). The combined organic layers were washed 
with brine (30 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by chromatography (EtOAc/heptane 1:9) to afford 19 (45 mg, 0.22 mmol, 19%) as a 
yellow solid. Rf 0.23; IR (neat) 3448, 3354, 1705, 1614, 1591, 1487, 1441; mp 49.4 °C; 1H NMR 
(300 MHz, CDCl3) δ 7.44 (m, 2H), 7.31 (m, 3H), 5.59 (s, 1H), 4.57 (br s, 2H), 3.82 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 164.0, 141.2, 131.1, 128.3, 128.1, 123.4, 100.3, 86.6, 85.7, 52.8; HRMS 
(EI) calcd for C12H11NO2 201.0790, found 201.0792. 
 
Methyl 2-{[(4-methylphenyl)sulfonyl]amino}-5-oxo-5-phenylpentanoate 
(21). According to general procedure B, to a solution of 18 (353 mg, 0.99 
mmol) in MeCN (14 mL), PdCl2(MeCN)2 (26 mg, 0.10 mmol) was added and 
the resulting mixture was stirred at room temperature for 24 h. Purification 
by chromatography (EtOAc/heptane 1:3) afforded 20 (123 mg, 0.34 mmol, 
34%) as a white solid and 21 (57 mg, 0.15 mmol, 15%) as a white solid. Rf 0.24 
(EtOAc/heptane 1:2); mp 132.1 °C; IR (neat) 3274, 3049, 2907, 1735, 1675, 1588, 1446; 1H NMR 
(300 MHz, CDCl3) δ 7.89 (d, J = 8.4 Hz, 2H), 7.66 (d, J = 8.4 Hz, 2H), 7.54 (m, 1H), 7.43 (m, 
2H), 7.22 (d, J = 8.6 Hz, 2H), 5.26 (d, J = 8.4 Hz, 1H), 4.00 (br m, 1H), 3.52 (s, 3H), 3.11 (m, 2H), 
2.36 (s, 3H), 2.27 (m, 1H), 1.96 (m, 1H); 13C NMR (75 MHz, CDCl3) δ 198.3, 171.8, 143.6, 136.5, 
136.3, 133.2, 129.6, 128.5, 128.0, 127.2, 55.3, 52.9, 34.3, 27.7, 21.9; HRMS (EI) calcd for 
C19H21NO5S 375.1140, found 375.1145. 
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Methyl 5-(2-aminophenyl)-1-[(4-methylphenyl)sulfonyl]-2,3-dihy-
dro-1-H-2-pyrrolecarboxylate (23). According to general procedure 
B, to a solution of 22 (487 mg, 1.31 mmol) in MeCN (14 mL), 
PdCl2(MeCN)2 (35 mg, 0.14 mmol) was added and the resulting mixture was stirred for 1 h. 
Purification by chromatography (EtOAc/heptane 1:2) afforded 23 (279 mg, 0.75 mmol, 57%) 
as an orange solid. Rf 0.24; mp 166.0 °C; IR (neat) 3450, 3365, 1749, 1730, 1630,  1597, 1491, 
1454; 1H NMR (300 MHz, CDCl3) δ 7.54 (d, J = 8.5 Hz, 2H), 7.25 (d, J = 7.9 Hz, 2H), 7.07 (m, 
2H), 6.63 (m, 2H), 5.24 (dd, J = 2.5, 3,3 Hz, 1H), 5.03 (dd, J = 3.9, 8.5 Hz, 1H), 4.65 (s, 2H), 3.83 
(s, 3H), 2.56 (m, 2H), 2.43 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 172.5, 146.3, 144.2, 142.9, 134.4, 
130.3, 129.7, 129.5, 127.9, 116.9, 116.8, 115.5, 115.2, 62.6, 53.0, 32.5, 21.6; HRMS (EI) calcd for 
C19H20N2O4S 372.1144, found 372.1141. 
 
Methyl 5-(4-methoxyphenyl)-1-[(4-methylphenyl)sulfonyl]-2,3-
dihydro-1H-2-pyrrolecarboxylate (34). According to general 
procedure B, to a solution of 28 (371 mg, 0.96 mmol) in MeCN 
(12 mL), PdCl2(MeCN)2 (27 mg, 0.10 mmol) was added and the resulting mixture was stirred 
for 1 h. Purification by chromatography (EtOAc/heptane 1:3) afforded 34 (182 mg, 0.47 
mmol, 49%) as a light-yellow solid. Rf 0.31 (EtOAc/heptane 1:2); mp 97.5 °C; IR (neat) 1734, 
1604, 1564, 1514, 1421; 1H NMR (300 MHz, CDCl3) δ 7.53 (d, J = 8.2 Hz, 2H), 7.47 (d, J = 8.6 
Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 5.24 (dd, J = 1.9, 3,4 Hz, 1H), 4.90 
(dd, J = 2.1, 9.5 Hz, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 2.54 (ddd, J = 2.3, 3.6, 17.0 Hz, 1H), 2.43 (s, 
3H), 2.28 (ddd, J = 1.9, 9.7, 17.0 Hz, 1H); 13C NMR (75 MHz, C6D6) δ 171.3, 145.2, 143.2, 138.4, 
135.1, 130.1, 129.3, 128.7, 128.1, 127.0, 114.0, 63.9, 52.3, 32.6, 21.4, 21.3; HRMS (EI) calcd for 
C20H21NO5S 387.1140, found 387.1134. 
 
Methyl 5-(4-methylphenyl)-1-[(4-methylphenyl)sulfonyl]-2,3-di-
hydro-1H-2-pyrrolecarboxylate (35). According to general 
procedure B, to a solution of 29 (415 mg, 1.12 mmol) in MeCN (12 
mL), PdCl2(MeCN)2 (29 mg, 0.11 mmol) was added and the resulting mixture was stirred for 
1 h. Purification by chromatography (EtOAc/heptane 1:4) afforded 35 (208 mg, 0.56 mmol, 
50%) as a white solid. Rf 0.23 (EtOAc/heptane 1:3); mp 129.5 °C; IR (neat) 2943, 1730, 1595, 
1473; 1H NMR (300 MHz, CDCl3) δ 7.54 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 7.26 (d, J = 
7.8 Hz, 2H), 7.15 (d, J = 7.8 Hz, 2H), 5.30 (dd, J = 2.1, 3,6 Hz, 1H), 4.89 (dd, J = 2.1, 9.5 Hz, 1H), 
3.81 (s, 3H), 2.55 (ddd, J = 2.3, 3.6, 17.0 Hz, 1H), 2.43 (s, 3H), 2.37 (s, 3H), 2.28 (ddd, J = 2.1, 9.5, 
17.0 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 171.7, 144.7, 144.1, 138.7, 134.0, 129.6, 129.4, 128.5, 
127.7, 127.5, 114.4, 63.3, 52.7, 32.4, 21.5, 21.3; HRMS (EI) calcd for C20H21NO4S 371.1191, found 
371.1190. 
 
Methyl 5-(2-methylphenyl)-1-[(4-methylphenyl)sulfonyl]-2,3-dihy-
dro-1H-2-pyrrolecarboxylate (36). According to general procedure B, 
to a solution of 30 (429 mg, 1.15 mmol) in MeCN (12 mL), 
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PdCl2(MeCN)2 (30 mg, 0.12 mmol) was added and the resulting mixture was stirred for 1 h. 
Purification by chromatography (EtOAc/heptane 1:6) afforded 36 (292 mg, 0.79 mmol, 68%) 
as a white solid. An X-ray crystal structure determination was carried out after 
recrystallization from Et2O. Rf 0.30 (EtOAc/heptane 1:4); mp 117.7 °C; IR (neat) 2951, 1749, 
1594, 1446, 1352; 1H NMR (300 MHz, CDCl3) δ 7.43 (d, J = 8.1 Hz, 2H), 7.15 (m, 6H), 5.10 (dd, 
J = 2.1, 3,0 Hz, 1H), 5.02 (dd, J = 4.2, 9.6 Hz, 1H), 3.82 (s, 3H), 2.69 (m, 2H), 2.38 (s, 3H), 2.33 (s, 
3H); 13C NMR (75 MHz, C6D6) δ 171.8, 144.1, 143.3, 138.7, 136.6, 132.1, 130.6, 130.4, 129.3, 
129.0, 128.2, 125.2, 113.6, 62.8, 52.4, 33.1, 21.5, 20.8; HRMS (EI) calcd for C20H21NO4S 371.1191, 
found 371.1195. 
 
 
 
 
 
 
 
 
Crystallographic data for 36: 
Crystal color    transparent colorless 
Crystal shape    regular 
Crystal size    0.31 × 0.31 × 0.25 mm 
Empirical formula   C20H21NO4S 
Formula weight   371.44 
Temperature    293(2) K 
Radiation/Wavelength  MoKα (graphite mon.)/0.71073 Å 
Crystal system, space group  Monoclinic, P21/c 
Unit cell dimensions   a = 7.5605(6) Å, α = 90° 
54858 reflections   b = 10.4918(17) Å, β = 91.192(6)° 
5.050 < θ < 27.500   c = 22.511(3) Å, γ = 90° 
Volume    1785.2(4) Å3 
Z, Calculated density   4, 1.382 Mg/m3 
Absorption coefficient  0.207 mm-1 
Diffractometer/scan   Enraf-Nonius CAD4/area detector and ω scan 
F(000)    784 
θ range for data collection  5.05 to 27.50° 
Index ranges    −9<=h<=9, −13<=k<=13, −29<=l<=28 
Reflections collected/unique  54858/4062 [R(int) = 0.0746] 
Reflections observed   3315 ([Io>2σ(Io)]) 
Absorption correction   none 
Refinement method   Full-matrix least-squares on F2 
Computing    SHELXL-97 (Sheldrick, 1997) 
N
O
O
2
34
5
1014
13
12
11
O2
20
S1
O1
21
22
15
16
6
O4
O3
7SO O
N1
23
26
24
25
Chapter 3 
 
72 
Data/restraints/parameters  4062/0/319 
Goodness-of-fit on F2   1.108 
SHELXL-97 weight parameters 0.048600, 1.276700 
Final R indices [I>2σ(I)]  R1 = 0.0587, wR2 = 0.1175 
R indices (all data)   R1 = 0.0795, wR2 = 0.1241 
Largest diff. peak and hole  0.439 and −0.359 e.A-3 
 
Table 3.2 Bond lengths of the non-hydrogen atoms (Å) of 36 (standard deviations) 
S(1)-O(1) 1.4218(16) C(2)-C(3) 1.535(3) C(14)-C(15) 1.390(3) 
S(1)-O(2) 1.4271(16) C(3)-C(4) 1.489(3) C(15)-C(16) 1.494(4) 
S(1)-N(1) 1.6579(17) C(4)-C(5) 1.323(3) C(20)-C(21) 1.382(3) 
S(1)-C(20) 1.757(2) C(5)-C(10) 1.477(3) C(20)-C(25) 1.384(3) 
N(1)-C(5) 1.451(3) C(10)-C(11) 1.397(3) C(21)-C(22) 1.377(4) 
N(1)-C(2) 1.486(3) C(10)-C(15) 1.401(3) C(22)-C(23) 1.382(4) 
O(3)-C(6) 1.307(3) C(11)-C(12) 1.376(3) C(23)-C(24) 1.376(4) 
O(3)-C(7) 1.447(3) C(12)-C(13) 1.372(4) C(23)-C(26) 1.506(4) 
O(4)-C(6) 1.192(3) C(13)-C(14) 1.371(4) C(24)-C(25) 1.379(3) 
C(2)-C(6) 1.515(3)     
 
Table 3.3 Bond angles of the non-hydrogen atoms (°) of 36 (standard deviations) 
O(1)-S(1)-O(2) 119.62(10) C(5)-C(4)-C(3) 112.2(2) C(14)-C(15)-C(10) 117.3(2) 
O(1)-S(1)-N(1) 106.89(9) C(4)-C(5)-N(1) 110.62(18) C(14)-C(15)-C(16) 120.0(2) 
O(2)-S(1)-N(1) 105.69(9) C(4)-C(5)-C(10) 126.71(19) C(10)-C(15)-C(16) 122.6(2) 
O(1)-S(1)-C(20) 108.40(10) N(1)-C(5)-C(10) 122.67(17) C(21)-C(20)-C(25) 120.5(2) 
O(2)-S(1)-C(20) 109.21(10) O(4)-C(6)-O(3) 124.0(2) C(21)-C(20)-S(1) 119.99(18) 
N(1)-S(1)-C(20) 106.24(9) O(4)-C(6)-C(2) 121.4(2) C(25)-C(20)-S(1) 119.42(16) 
C(5)-N(1)-C(2) 105.99(15) O(3)-C(6)-C(2) 114.6(2) C(22)-C(21)-C(20) 118.7(2) 
C(5)-N(1)-S(1) 118.13(14) C(11)-C(10)-C(15) 119.3(2) C(21)-C(22)-C(23) 121.8(2) 
C(2)-N(1)-S(1) 116.28(13) C(11)-C(10)-C(5) 116.8(2) C(24)-C(23)-C(22) 118.4(2) 
C(6)-O(3)-C(7) 116.5(2) C(15)-C(10)-C(5) 123.8(2) C(24)-C(23)-C(26) 120.8(3) 
N(1)-C(2)-C(6) 111.51(18) C(12)-C(11)-C(10) 121.7(2) C(22)-C(23)-C(26) 120.8(3) 
N(1)-C(2)-C(3) 105.04(17) C(13)-C(12)-C(11) 119.1(3) C(23)-C(24)-C(25) 121.2(2) 
C(6)-C(2)-C(3) 109.82(18) C(14)-C(13)-C(12) 119.8(3) C(24)-C(25)-C(20) 119.4(2) 
C(4)-C(3)-C(2) 101.89(18) C(13)-C(14)-C(15) 122.8(3)   
 
Methyl 1-[(4-methylphenyl)sulfonyl]-5-(1-naphthyl)-2,3-dihydro-
1H-2-pyrrolecarboxylate (37). According to general procedure B, to a 
solution of 31 (332 mg, 0.81 mmol) in MeCN (12 mL), PdCl2(MeCN)2 
(21 mg, 0.08 mmol) was added and the resulting mixture was stirred 
for 2 h. Purification by chromatography (EtOAc/heptane 1:4) afforded 37 (145 mg, 0.36 
mmol, 44%) as a white solid. Rf 0.27 (EtOAc/heptane 1:3); mp 133.9 °C; IR (neat) 3047, 2951, 
1751, 1641, 1595, 1506, 1437; 1H NMR (300 MHz, CDCl3) δ 8.18 (m, 1H), 7.71 (m, 2H), 7.35 (m, 
6H), 6.88 (d, J = 8.1 Hz, 2H), 5.32 (dd, J = 2.1, 3.3 Hz, 1H), 5.22 (dd, J = 3.9, 10.8 Hz, 1H), 3.91 
(s, 3H), 2.95 (dd, J = 2.1, 10.8, 16.8 Hz, 1H), 2.77 (dt, J = 3.6, 17.1 Hz, 1H), 2.24 (s, 3H); 13C 
NMR (75 MHz, C6D6) δ 172.1, 144.6, 143.3, 134.7, 131.7, 128.1, 127.8, 127.7, 127.3, 126.2, 126.1, 
125.9, 125.6, 124.6, 124.2, 124.0, 114.9, 61.9, 52.9, 33.5, 21.7; HRMS (EI) calcd for C23H21NO4S 
407.1191, found 407.1191. 
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Methyl 5-(4-fluorophenyl)-1-[(4-methylphenyl)sulfonyl]-2,3-dihy-
dro-1H-2-pyrrolecarboxylate (38). According to general procedure 
B, to a solution of 32 (320 mg, 0.85 mmol) in MeCN (12 mL), 
PdCl2(MeCN)2 (22 mg, 0.08 mmol) was added and the resulting mixture was stirred for 2 h. 
Purification by chromatography (EtOAc/heptane 1:3) afforded 38 (163 mg, 0.43 mmol, 51%) 
as a white solid. Rf 0.30 (EtOAc/heptane 1:2); mp 93.3 °C; IR (neat) 2951, 1736, 1597, 1502, 
1437; 1H NMR (300 MHz, CDCl3) δ 7.52 (m, 4H), 7.26 (d, J = 8.7 Hz, 2H), 7.02 (t, J = 8.7 Hz, 
2H), 5.31 (dd, J = 2.1, 3,6 Hz, 1H), 4.91 (dd, J = 2.1, 9.3 Hz, 1H), 3.81 (s, 3H), 2.55 (ddd, J = 2.4, 
3.6, 17.1 Hz, 1H), 2.42 (s, 3H), 2.31 (ddd, J = 1.5, 9.3, 17.1 Hz, 1H); 13C NMR (75 MHz, CDCl3) 
δ 171.8, 164.8, 161.5, 144.4, 143.9, 134.1, 129.7, 129.7, 129.6, 128.7, 128.7, 127.9, 115.2, 114.9, 
63.4, 53.0, 32.7, 21.7; HRMS (EI) calcd for C19H18NO4SF 375.0941, found 375.0930. 
 
Methyl (2R)-1-[(4-methylphenyl)sulfonyl]-5-phenyl-2,3-dihydro-1H-
2-pyrrolecarboxylate (39). According to general procedure B, to a 
solution of 33 (396 mg, 1.11 mmol) in MeCN (12 mL), PdCl2(MeCN)2 
(29 mg, 0.11 mmol) was added and the resulting mixture was stirred for 2 h. Purification by 
chromatography (EtOAc/heptane 1:3) afforded 39 (192 mg, 0.53 mmol, 48%) as a white solid. 
Rf 0.36 (EtOAc/heptane 1:2); [α]D +82.9 (c 1.0, CH2Cl2); mp 88.3 °C; IR (neat) 2947, 1736, 1595, 
1493, 1444; 1H NMR (300 MHz, CDCl3) δ 7.54 (m, 4H), 7.29 (m, 5H), 5.35 (dd, J = 2.1, 3,6 Hz, 
1H), 4.91 (dd, J = 2.1, 9.3 Hz, 1H), 3.81 (s, 3H), 2.56 (ddd, J= 2.4, 3.6, 17.1 Hz, 1H), 2.42 (s, 3H), 
2.31 (ddd, J = 2.1, 9.6, 17.1 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 171.9, 144.9, 144.2, 134.2, 
132.6, 129.6, 129.0, 128.0, 128.0, 127.9, 115.3, 63.5, 53.0, 32.7, 21.7; HRMS (EI) calcd for 
C19H19NO4S 357.1035, found 357.1032. 
 
{(2S)-1-[(4-Methylphenyl)sulfonyl]-5-phenyl-2,3-dihydro-1H-2-pyrrol-
yl}methanol (47). According to general procedure B, to a solution of 45 
(276 mg, 0.84 mmol) in MeCN (10 mL), PdCl2(MeCN)2 (22 mg, 0.08 
mmol) was added and the resulting mixture was stirred for 2 h. 
Purification by chromatography (EtOAc/heptane 1:4) afforded 47 (26 mg, 0.08 mmol, 10%) 
as a white solid. Rf 0.15; IR (neat) 3304, 3058, 2915, 1649, 1593, 1489, 1433; 1H NMR (300 MHz, 
CDCl3) δ 7.76 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 8.1 Hz, 2H), 7.28 (m, 5H), 5.18 (m, 1H), 4.96 (d, J 
= 9.0 Hz, 1H), 3.99 (m, 1H), 3.89 (ddd, J = 2.1, 5.4, 10.5 Hz, 1H), 3.75 (m, 1H), 2.43 (s, 3H), 2.41 
(m, 1H), 2.05 (m, 1H). 
 
N1-{(3R)-2-Oxo-5-[(Z)-1-phenylmethylidene]tetrahydro-3-furanyl}-4-meth-
yl-1-benzenesulfonamide (52). To solution of 33 (355 mg, 0.99 mmol) in 
THF/H2O (25 mL, 1:1 v/v), LiOH (119 mg, 4.97 mmol) was added. The 
reaction mixture was stirred at room temperature for 24 h, after which time 
THF was evaporated from the mixture. The resulting aqueous solution was acidified (pH 1) 
with 1 M HCl and extracted with EtOAc (3 × 25 mL). The combined organic layers were 
dried over MgSO4 and concentrated in vacuo to afford the crude acid 51 (261 mg, 0.76 mmol, 
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77%) as a yellow solid. To a solution of acid 51 (256 mg, 0.75 mmol) in MeCN (10 mL), 
AgOTf (19 mg, 007 mmol) was added and the resulting mixture was heated at reflux for 24 h 
and concentrated in vacuo. Purification by chromatography (EtOAc/heptane 1:2) afforded 52 
(165 mg, 0.48 mmol, 64%) as a white solid. An X-ray crystal structure determination was 
carried out after recrystallization from Et2O. Rf 0.35; [α]D +8.2 (c 0.5, CH2Cl2); mp 169.3 °C; IR 
(neat) 3313, 3023, 2941, 1800, 1692, 1593, 1493; 1H NMR (300 MHz, CDCl3) δ 7.77 (d, J = 8.4 
Hz, 2H), 7.45 (d, J = 8.4 Hz, 2H), 7.25 (m, 5H), 5.61 (d, J = 2.1 Hz, 1H), 5.22 (s, 1H), 4.14 (t, J = 
9.3 Hz, 1H), 3.36 (ddd, J = 0.6, 9.0, 15.9 Hz, 1H), 3.05 (ddd, J = 2.4, 10.5, 15.9 Hz, 1H), 2.43 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 171.6, 144.4, 143.8, 135.6, 132.8, 130.0, 128.5, 128.5, 127.3, 
127.3, 107.1, 51.7, 36.1, 21.9; HRMS (EI) calcd for C18H17NO4S 343.0878, found 343.0880. 
 
 
 
 
 
 
 
Crystallographic data for 52: 
Crystal color    transparent colorless 
Crystal shape    regular thin plate 
Crystal size    0.25 × 0.17 × 0.01 mm 
Empirical formula   C18H17NO4S 
Formula weight   343.39 
Temperature    208(2) K 
Radiation/Wavelength  MoKα (graphite mon.)/0.71073 Å 
Crystal system, space group  Orthorhombic, P212121 
Unit cell dimensions   a = 6.1244(8) Å, α = 90° 
47364 reflections   b = 7.8601(15) Å, β = 90° 
5.000 < θ < 27.490   c = 33.743(8) Å, γ = 90° 
Volume    1624.3(5) Å3 
Z, Calculated density   4, 1.404 Mg/m3 
Absorption coefficient  0.221 mm-1 
Diffractometer/scan   Nonius KappaCCD/area detector ϕ and ω scan 
F(000)    720 
θ range for data collection  3.16 to 27.50° 
Index ranges    −7<=h<=7, −10<=k<=10, −43<=l<=33 
Reflections collected/unique  10574/3551 [R(int) = 0.1454] 
Reflections observed   1657 ([Io>2σ(Io)]) 
Absorption correction   None 
Refinement method   Full-matrix least-squares on F2 
Computing    SHELXL-97 (Sheldrick, 1997) 
Data/restraints/parameters  3551/0/218 
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Goodness-of-fit on F2   1.047 
SHELXL-97 weight parameters 0.036700, 3.350500 
Final R indices [I>2σ(I)]  R1 = 0.1085, wR2 = 0.1645 
R indices (all data)   R1 = 0.2339, wR2 = 0.1992 
Largest diff. peak and hole  0.749 and −0.422 e.A-3 
 
Table 3.4 Bond lengths of the non-hydrogen atoms (Å) of 52 (standard deviations) 
S(1)-O(4) 1.430(5) C(3)-C(4) 1.511(9) C(11)-C(12) 1.376(11) 
S(1)-O(3) 1.437(5) C(4)-C(5) 1.479(9) C(13)-C(18) 1.357(9) 
S(1)-N(1) 1.605(6) C(5)-C(6) 1.328(9) C(13)-C(14) 1.398(10) 
S(1)-C(13) 1.773(7) C(6)-C(7) 1.465(10) C(14)-C(15) 1.358(10) 
O(1)-C(2) 1.364(8) C(7)-C(8) 1.388(11) C(15)-C(16) 1.373(11) 
O(1)-C(5) 1.392(8) C(7)-C(12) 1.408(13) C(16)-C(17) 1.406(12) 
O(2)-C(2) 1.181(8) C(8)-C(9) 1.377(12) C(16)-C(19) 1.483(11) 
N(1)-C(3) 1.412(8) C(9)-C(10) 1.387(14) C(17)-C(18) 1.364(11) 
C(2)-C(3) 1.526(10) C(10)-C(11) 1.357(11)   
 
Table 3.5 Bond angles of the non-hydrogen atoms (°) of 52 (standard deviations) 
O(4)-S(1)-O(3) 118.5(3) C(4)-C(3)-C(2) 102.4(5) C(10)-C(11)-C(12) 123.5(9) 
O(4)-S(1)-N(1) 108.7(3) C(5)-C(4)-C(3) 104.2(6) C(11)-C(12)-C(7) 119.4(8) 
O(3)-S(1)-N(1) 107.0(3) C(6)-C(5)-O(1) 120.4(6) C(18)-C(13)-C(14) 119.1(7) 
O(4)-S(1)-C(13) 105.9(3) C(6)-C(5)-C(4) 129.6(7) C(18)-C(13)-S(1) 121.2(6) 
O(3)-S(1)-C(13) 109.4(3) O(1)-C(5)-C(4) 109.8(6) C(14)-C(13)-S(1) 119.4(6) 
N(1)-S(1)-C(13) 106.8(3) C(5)-C(6)-C(7) 130.7(7) C(15)-C(14)-C(13) 118.4(7) 
C(2)-O(1)-C(5) 110.0(5) C(8)-C(7)-C(12) 117.2(8) C(14)-C(15)-C(16) 123.6(8) 
C(3)-N(1)-S(1) 125.6(5) C(8)-C(7)-C(6) 119.5(8) C(15)-C(16)-C(17) 117.0(8) 
O(2)-C(2)-O(1) 121.5(7) C(12)-C(7)-C(6) 123.4(8) C(15)-C(16)-C(19) 122.4(8) 
O(2)-C(2)-C(3) 128.9(7) C(9)-C(8)-C(7) 121.6(10) C(17)-C(16)-C(19) 120.5(8) 
O(1)-C(2)-C(3) 109.6(6) C(8)-C(9)-C(10) 121.0(10) C(18)-C(17)-C(16) 119.6(8) 
N(1)-C(3)-C(4) 116.6(6) C(11)-C(10)-C(9) 117.2(9) C(13)-C(18)-C(17) 122.3(8) 
N(1)-C(3)-C(2) 113.9(6)     
 
Methyl (2R,5S)-1-[(4-methylphenyl)sulfonyl]-5-phenyltetrahydro-
1H-2-pyrrolecarboxylate (56). To a solution of 39 (120 mg, 0.34 mmol) 
in CH2Cl2 (6 mL), Et3SiH (0.27 mL, 1.70 mmol), TFAA (0.24 mL, 1.70 
mmol) and TFA (0.13 mL, 1.70 mmol) were added at 0 °C. The reaction mixture was allowed 
to reach room temperature and stirred for 2 h. Upon completion, the reaction mixture was 
concentrated in vacuo and purified by chromatography (EtOAc/heptane 1:4) to afford a 
diastereomeric mixture of 56 and the trans-isomer 57 (56/57 = 9:1, 90 mg, 0.25 mmol, 74%). 
Purification of this mixture by chromatography (EtOAc/heptane 1:5) followed by 
crystallization from Et2O gave diastereomerically pure 56 as colorless crystals. Rf 0.60 
(EtOAc/heptane 1:1); [α]D −68.9 (c 0.5, CH2Cl2); mp 130.3 °C; IR (neat) 1745, 1597, 1495, 1456, 
1344; 1H NMR (300 MHz, CDCl3) δ 7.52 (d, J = 8.4 Hz, 2H), 7.40 (m, 2H), 7.18 (m, 5H), 4.77 (t, 
J = 6.6 Hz, 1H), 4.57 (t, J = 6.3 Hz, 1H), 3.79 (s, 3H), 2.36 (s, 3H), 2.04 (m, 4H); 13C NMR (75 
MHz, CDCl3) δ 172.5, 143.3, 141.1, 135.4, 129.2, 128.1, 127.7, 127.2, 127.0, 65.1, 62.2, 52.7, 36.1, 
29.7, 21.8; HRMS (EI) calcd for C19H21NO4S 359.1191, found 359.1183. 
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Crystallographic data for 56: 
Crystal color    transparent colorless 
Crystal shape    regular fragment 
Crystal size    0.29 × 0.26 × 0.26 mm 
Empirical formula   C19H21NO4S 
Formula weight   359.43 
Temperature    293(2) K 
Radiation/Wavelength  MoKα (graphite mon.)/0.71073 Å 
Crystal system, space group  Orthorhombic, P212121 
Unit cell dimensions   a = 11.940(2) Å, α = 90° 
47364 reflections   b = 12.134(2) Å, β = 90° 
5.000 < θ < 27.490   c = 12.4101(13) Å, γ = 90° 
Volume    1797.9(5) Å3 
Z, Calculated density   4, 1.328 Mg/m3 
Absorption coefficient  0.203 mm-1 
Diffractometer/scan   Enraf-Nonius CAD4/area detector ϕ and ω scan 
F(000)    760 
θ range for data collection  5.00 to 27.49° 
Index ranges    −15<=h<=15, −15<=k<=15, −16<=l<=15 
Reflections collected/unique  47364/4105 [R(int) = 0.0416] 
Reflections observed   3429 ([Io>2σ(Io)]) 
Absorption correction   None 
Refinement method   Full-matrix least-squares on F2 
Computing    SHELXL-97 (Sheldrick, 1997) 
Data/restraints/parameters  4105/0/288 
Goodness-of-fit on F2   1.052 
SHELXL-97 weight parameters 0.047500, 0.283100 
Final R indices [I>2σ(I)]  R1 = 0.0388, wR2 = 0.0853 
R indices (all data)   R1 = 0.0527, wR2 = 0.0908 
Absolute structure parameter  −0.01(7) 
Largest diff. peak and hole  0.256 and −0.223 e.A-3 
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Table 3.6 Bond lengths of the non-hydrogen atoms (Å) of 56 (standard deviations) 
S(1)-O(1) 1.4219(15) C(2)-C(3) 1.518(3) C(23)-C(24) 1.376(3) 
S(1)-O(2) 1.4225(16) C(2)-C(6) 1.521(3) C(23)-C(26) 1.505(3) 
S(1)-N(1) 1.6329(15) C(3)-C(4) 1.503(3) C(24)-C(25) 1.372(3) 
S(1)-C(20) 1.7566(19) C(4)-C(5) 1.528(3) C(10)-C(15) 1.378(3) 
N(1)-C(2) 1.468(3) C(5)-C(10) 1.499(3) C(10)-C(11) 1.383(3) 
N(1)-C(5) 1.494(2) C(20)-C(25) 1.382(3) C(11)-C(12) 1.379(3) 
O(3)-C(6) 1.314(3) C(20)-C(21) 1.383(3) C(12)-C(13) 1.363(3) 
O(3)-C(7) 1.455(3) C(21)-C(22) 1.367(3) C(13)-C(14) 1.366(4) 
O(4)-C(6) 1.182(3) C(22)-C(23) 1.378(3) C(14)-C(15) 1.378(4) 
 
Table 3.7 Bond angles of the non-hydrogen atoms (°) of 56 (standard deviations) 
O(1)-S(1)-O(2) 120.32(10) C(4)-C(3)-C(2) 102.61(18) C(24)-C(23)-C(22) 117.7(2) 
O(1)-S(1)-N(1) 106.59(9) C(3)-C(4)-C(5) 104.45(18) C(24)-C(23)-C(26) 121.6(2) 
O(2)-S(1)-N(1) 106.22(9) N(1)-C(5)-C(10) 113.87(15) C(22)-C(23)-C(26) 120.7(2) 
O(1)-S(1)-C(20) 108.05(10) N(1)-C(5)-C(4) 102.04(16) C(25)-C(24)-C(23) 122.2(2) 
O(2)-S(1)-C(20) 107.70(9) C(10)-C(5)-C(4) 112.18(16) C(24)-C(25)-C(20) 119.1(2) 
N(1)-S(1)-C(20) 107.33(8) O(4)-C(6)-O(3) 123.9(2) C(15)-C(10)-C(11) 118.1(2) 
C(2)-N(1)-C(5) 110.99(15) O(4)-C(6)-C(2) 126.7(2) C(15)-C(10)-C(5) 119.78(17) 
C(2)-N(1)-S(1) 118.14(13) O(3)-C(6)-C(2) 109.41(18) C(11)-C(10)-C(5) 122.00(18) 
C(5)-N(1)-S(1) 118.23(13) C(25)-C(20)-C(21) 119.49(18) C(12)-C(11)-C(10) 120.6(2) 
C(6)-O(3)-C(7) 116.8(2) C(25)-C(20)-S(1) 120.34(15) C(13)-C(12)-C(11) 120.6(2) 
N(1)-C(2)-C(3) 104.01(17) C(21)-C(20)-S(1) 120.12(15) C(12)-C(13)-C(14) 119.4(2) 
N(1)-C(2)-C(6) 110.86(16) C(22)-C(21)-C(20) 120.06(19) C(13)-C(14)-C(15) 120.4(2) 
C(3)-C(2)-C(6) 113.01(18) C(21)-C(22)-C(23) 121.4(2) C(14)-C(15)-C(10) 120.9(2) 
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CHAPTER 4 
 
5-SUBSTITUTED PROLINE ANALOGUES 
 
 
4.1 Introduction 
 
Substituted prolines in general have gained considerable interest in recent years, 
which is reflected by the number of stereoselective syntheses of such prolines that have been 
reported in the literature.1 These unnatural substituted proline analogues can be considered 
as conformationally constrained amino acids and have already been applied in biologically 
active peptidomimetics as tools for establishing structure-activity relationships.2 Some of 
these proline analogues have also been recognized as privileged elements in medicinal 
chemistry among which the 5-aryl-substituted prolines are the most prominent examples.3 
Within this class of proline analogues, cis-5-phenylproline 1 has attracted special interest, 
being a key intermediate in the synthesis of the non-peptide cholecystokinin antagonist (+)-
RP 66803 (Scheme 4.1).4 
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Proline analogue 1 was converted into (+)-RP 66803 via a four step synthetic sequence 
involving coupling of 1 with Boc-protected glycine to afford dipeptide 2 in 89% yield. 
Saponification of 2 gave the corresponding acid 3, which was subsequently treated with 
isobutene under acidic conditions to afford the crude amino ester 4. Finally, amino ester 4 
was condensed with m-toluene isocyanate to give enantiopure (+)-RP 66803. 
In recent years, cis-5-phenylproline 1 has been an important synthetic target and 
consequently a variety of synthetic approaches toward this particular proline analogue have 
been reported in the literature.5 The most prominent synthetic approach toward cis-5-
phenylproline and other cis-5-aryl-substituted proline analogues relies on the selective ring 
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opening of for example pyroglutamate 5 by organometallic reagents and subsequent ring 
closure,6 leading to pyrrolines 6 which can be selectively further hydrogenated to the 
corresponding cis-5-aryl-substituted prolines 7 (Scheme 4.2).7 
 
Scheme 4.2 
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Building on the methodology that has been described in the previous two chapters, 
we envisaged that the 2,5-disubstituted pyrrolines of type 6 might also be readily accessible 
as the corresponding methyl esters 8 starting from the enantiopure propargylglycine 
derivative 10 (Scheme 4.3). 
 
Scheme 4.3 
108 9
H2N CO2Me
N CO2Me
R
R
HN CO2Me
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The pyrrolines 8 might be obtained from the amino esters 9 via an intramolecular 5-endo-dig 
cyclization as the key step. The amino esters 9, in turn, should be easily accessible from 
propargylglycine derivative 10 (see: Chapter 2) via Sonogashira coupling with various aryl 
iodides followed by cleavage of the Boc group. 
Metal-catalyzed intramolecular additions of amines onto substituted acetylenes have 
already been reported in the literature using relatively simple (substituted) alkynylamines as 
the cyclization precursors.8 A representative example is the intramolecular aminopalladation 
of alkyne 11, which upon treatment with PdCl2(MeCN)2 leads to the 5-membered cyclic 
imine 12 in reasonable yield (Scheme 4.4). 
 
Scheme 4.4 
12 (63%)11 H2N
N
PdCl2(MeCN)2
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5-Substituted Proline Analogues 
 
81 
These literature precedents in combination with our relatively facile access to 
enantiopure propargylglycine derivative 10, inspired us to use this amino acid in the 
synthesis of the 2,5-disubstituted pyrrolines 8. This sequence might then eventually serve as 
a novel approach to cis-5-phenylproline 1 and related 5-aryl-substituted proline analogues. 
 
4.2 Metal-Catalyzed Pyrroline Formation 
 
In order to investigate the feasibility of pyrroline formation via a similar Pd-catalyzed 
cyclization, amino acid 13 was synthesized from the enantiopure propargylglycine 
derivative 10 via a Sonogashira-type coupling9 with iodobenzene affording cyclization 
precursor 13 in 91% yield (Scheme 4.5). 
 
Scheme 4.5 
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Subsequent cleavage of the Boc group generated the corresponding free amino ester 14, 
which was immediately exposed to PdCl2(MeCN)2 in refluxing acetonitrile. We were pleased 
to find that these conditions, which were also used in the preceding chapters, led to the rapid 
formation of pyrroline 15 in 47% yield after column chromatography. Furthermore, we 
proved using chiral HPLC (Chiralcel OD) that no (partial) racemization had taken place 
during the whole synthetic sequence. 
Interestingly, the formation of pyrroline 15 could also be accomplished by refluxing 
the amino ester 14 in acetonitrile without the presence of the Pd-catalyst, albeit that the 
reaction did not go to completion even after prolonged reaction times of over 24 h. This 
observation prompted us to investigate the formation of pyrroline 15 more carefully in order 
to optimize the cyclization reaction. Therefore, several other Lewis acidic metal catalysts 
were used in this reaction and compared in terms of yield of 15 and reaction times (Table 
4.1). 
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Table 4.1 
entry catalysta time (h) yield of 15 (%)b
aAll  reactions were conducted in refluxing MeCN using
10 mol% of the indicated catalyst.
bIsolated yield calculated from  precursor 13.
1
2
3
4
5
6
7
8
NaAuCl4 0.5 58
AgOTf 1 67
Cu(OTf)2 1 48
ZnCl2 6 65
AlCl3 24 36
Sn(OTf)2 >24 n.d.
Sc(OTf)3 >24 n.d.
Zn(OTf)2 >24 n.d.
 
 
As can be inferred from Table 4.1, some of the investigated Lewis acids were very 
active in the aforementioned cyclization reaction, leading to the rapid formation of pyrroline 
15 (entries 1-3). From this group of metal salts, NaAuCl4 had previously been shown to be an 
excellent catalyst in similar cycloisomerizations.8c In our case, however, this catalyst turned 
out to be less effective affording 15 in a reasonable yield of 58% (entry 1). The use of AgOTf 
also led to a rapid formation of pyrroline 15, which was isolated in an even higher yield of 
67% (entry 2). Using ZnCl2 as the catalyst, 15 was obtained in a similar yield of 65%, but the 
reaction needed more time to go to completion (entry 4). In addition, Cu(OTf)2 appeared 
equally effective in catalyzing the cycloisomerization of amino ester 14 into 15 compared to 
the initially used Pd-catalyst (entry 3). In the case of AlCl3, a slow reaction was observed 
affording pyrroline 15 in a somewhat lower yield of 36% (entry 5). In all other cases, the 
reaction did not go to completion, even after prolonged reaction times of over 24 h (entries 6-
8) so that the yield eventually was not determined. 
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4.3 Ag-Catalyzed Cyclizations of Several Functionalized Cyclization Precursors 
 
Considering these results, we concluded that AgOTf would be the catalyst of choice 
in the synthesis of other pyrrolines. At this point, bearing in mind the reactivity of the Ag-
catalyst, we reasoned that lowering the reaction temperature might benefit the formation 
and thereby the yield of pyrroline 15. To verify this reasoning, we subjected amino ester 14 
again to 10 mol% of AgOTf in MeCN, but in this case the cyclization was performed at room 
temperature (Scheme 4.6). 
 
Scheme 4.6 
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Indeed, these mild conditions resulted in the formation of 15 in an improved yield of 72%, 
although the reaction needed more time to go to completion. More importantly, a similar 
increase in yield upon lowering the temperature to room temperature was not observed 
using NaAuCl4 as the catalyst. 
Pleased with this result, we set out to gain insight in the scope and limitations of the 
observed cycloisomerization. Therefore, we prepared a variety of cyclization precursors via 
Sonogashira couplings between propargylglycine derivative 10 and several (substituted) aryl 
iodides. The substituted acetylenes 16-20 were thus obtained in good yields and, after 
generation of the corresponding amino esters, subjected to 10 mol% of the Ag-catalyst in 
MeCN at room temperature (Table 4.2). 
As can be seen from Table 4.2, subjection of the amino ester derived from precursor 
16 to the Ag-catalyst led to the formation of the corresponding pyrroline 21 in 65% yield 
(entry 1). Likewise, precursor 17, substituted with an electron donating methoxy group could 
be conveniently converted into pyrroline 22 in 69% yield (entry 2). In addition, acetylene 18 
bearing an electron withdrawing nitro substituent underwent after generation of the amino 
ester a smooth cyclization affording 23 in 80% yield (entry 3), indicating that the cyclization 
reaction is not very sensitive to electronic effects. The sterically more hindered precursor 19 
underwent cyclization to pyrroline 24 in a somewhat lower yield of 54% (entry 4). Finally, 
acetylene 20 containing the pharmaceutically relevant fluorophenyl substituent, could also 
be converted into pyrroline 25 in a reasonable yield of 64% (entry 5). 
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Table 4.2 
entry precursor (yield)a pyrroline yield (%)a
1
aIsolated yield after column chromatography.
HN CO2Me
Boc 16 (92%)
21
65
2
N CO2MeNH2
NH2
HN CO2Me
Boc 17 (80%)
22
69
3
N CO2MeOMe
OMe
HN CO2Me
Boc 18 (81%)
23
80
4
N CO2Me
24
5
HN CO2Me
Boc 19 (89%)
54
N CO2Me
HN CO2Me
Boc 20 (94%)
25
64
N CO2Me
NO2
O2N
Me
Me
F
F
 
 
Encouraged by these results, we started to investigate the feasibility of synthesizing 
optically active cyclic imines starting from the homo- and bishomopropargylglycine 
derivatives 26 and 27 (see: Chapter 2), using the same synthetic pathway. Thus the Pd-
catalyzed Sonogashira coupling of the optically active homo- and bishomopropargylglycine 
derivatives 26 and 27 with iodobenzene afforded the cyclization precursors 28 and 29 in 85 
and 82% yield, respectively (Scheme 4.7). 
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Scheme 4.7 
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n
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First, amino ester 30, derived from precursor 28 via the same synthetic procedure as 
previously outlined for amino ester 14 (see: Scheme 4.5), was subjected to AgOTf in MeCN. 
In this case, the cyclization was performed at reflux temperature since we anticipated that 
the possible formation of a 6-membered ring via a 6-endo-dig cyclization might require higher 
reaction temperatures. Gratifiyingly, these conditions led to a rapid cyclization of 30 leading 
to the formation of pyrroline 31 as the sole product in 52% yield after purification by column 
chromatography (Scheme 4.8). 
 
Scheme 4.8 
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In contrast to the earlier obtained pyrrolines, this benzyl- substituted pyrroline turned out to 
be a labile compound which slowly decomposed. The formation of this product can be 
explained by a Ag-mediated cyclization in an exclusive 5-exo-dig fashion giving an 
intermediate conjugated enamine, followed by isomerization of the exocyclic enamine 
double bond to the apparently thermodynamically more stable imine position. Under the 
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same conditions the homologous precursor 32 cyclized exclusively in a 6-exo-dig manner 
affording the 6-membered cyclic imine 33 as the sole product in an acceptable yield of 48%. 
In this case, the obtained imine proved to be a more stable compound, allowing a thorough 
analysis. In doing this, imine 33 showed no optical activity indicating a significant extent of 
racemization. This might be due to the more basic character of the non-conjugated imine, 
which can cause deprotonation at the α-position. 
 
4.4 Synthesis of Pyridyl-Substituted Pyrrolines 
 
With the successful cyclization conditions in hand, we decided to extend this 
methodology to the synthesis of similar pyrrolines substituted with biologically relevant 
pyridyl moieties. Therefore, propargylglycine derivative 10 was first coupled under the 
usual Sonogashira conditions with 2- and 3-iodopyridine to afford the pyridyl-substituted 
precursors 34 and 35 in 85 and 91% yield, respectively (Scheme 4.9). 
 
Scheme 4.9 
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First, precursor 34 was deprotected in a quantitative fashion, after which the initial liberation 
of the free amine using aqueous NH3 turned out to be troublesome. Fortunately, this 
problem could be overcome by switching to other conditions, i.e. Et3N in chloroform, leading 
to a smooth formation of amino ester 36 (X = N, Y = CH). Subjection of this amino ester to the 
Ag-catalyst at room temperature did not give any reaction, however, heating at reflux 
temperature led to a rapid formation of pyrroline 37 in a somewhat lower yield of 38%. 
Likewise, precursor 35 was converted into the corresponding amino ester 36 (X = CH, Y = 
N), which in contrast to the 2-pyridyl-substituted amino ester, already underwent 
cycloisomerization at room temperature affording pyrroline 38 in a yield of 69%. 
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Interestingly, pyrroline 37 is a derivative of the natural product pyrimine, an Fe(II)-
binding agent which has been isolated from the species Pseudomonas GH.10 In a single 
attempt to convert 37 into the natural product, ester 37 was hydrolyzed under acidic 
conditions (Scheme 4.10). These conditions led to a complete disappearance of ester 37, but in 
the crude product the natural product pyrimine could not be detected as judged by 1H NMR. 
 
Scheme 4.10 
N CO2Me
37
N
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N
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Nevertheless, pyrroline 37 remains an interesting compound since it is potentially a 
chiral metal-chelating ligand, which might be used in asymmetric catalysis. In fact, similar 2-
pyridyl-substituted pyrrolines have recently been used as chiral ligands in asymmetric 
catalysis.11 Compared to pyrroline 37, we envisaged that derivative 39 (Scheme 4.11) might 
even be a more suitable ligand as this compound is configurationally less labile and contains 
an additional steric bulk which might increase its asymmetric inductive potential. We 
anticipated that pyrroline 39 might be readily synthesized from the corresponding protected 
precursor 40 via the previously described methodology. Precursor 40, in turn, should be 
easily accessible from propargylglycine derivative 10 via Sonogashira coupling with 2-
iodopyridine followed by ester reduction and protection of the resulting primary alcohol 
(Scheme 4.11). 
 
Scheme 4.11 
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With compound 34 already in hand, we set out to convert this 2-pyridyl-substituted 
amino acid into the protected cyclization precursor 40. Therefore, amino acid 34 was first 
subjected to LiBH4 in THF at room temperature. Unfortunately, these conditions did not 
afford the corresponding amino alcohol, but instead led within 30 min to complete 
decomposition of the starting material. Subsequent treatment of 34 with DIBAL-H in THF 
led to the formation of a product mixture from which the desired amino alcohol 41 could be 
isolated, albeit in a disappointing yield of 32% (Scheme 4.12). 
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Scheme 4.12 
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In view of the troublesome reduction of 34 and the low yield of amino alcohol 41, we 
decided to alter the sequence of synthetic steps. Thus, the reduction was performed on 
propargylglycine derivative 10 affording the corresponding amino alcohol 42 without any 
difficulty. Subsequently, the crude amino alcohol was converted into silyl ether 43 in 96% 
yield over two steps by treatment with the bulky silylating agent TBDPSCl (Scheme 4.13). 
 
Scheme 4.13 
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At this point, the 2-pyridyl moiety was introduced via Sonogashira coupling of silyl ether 43 
with 2-iodopyridine to give the desired precursor 40 in 64% yield. The successful synthesis of 
40 now set the stage to apply our previously developed methodology. Thus, cleavage of the 
Boc group with liberation of the free amine generated the corresponding amino ester 44, 
which was exposed to AgOTf in refluxing acetonitrile affording pyrroline 39 in a good yield 
of 73%. 
Recently, pyrroline 39 has been evaluated in our group as a chiral ligand in a model 
allylic alkylation reaction. Thus, allylic acetate 45 was alkylated in CH2Cl2 at room 
temperature in the presence of a freshly prepared complex between the Pd-catalyst and 
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pyrroline 39, the nucleophile being generated from dimethyl malonate, 
bis(trimethylsilyl)acetamide (BSA) and a catalytic amount of KOAc (Scheme 4.14).12 
 
Scheme 4.14 
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45 46 (83% crude)
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This catalytic system led to the formation of the alkylated product 46 in a crude yield of 83% 
with a moderate enantioselectivity (30%). Nevertheless, this preliminary result shows the 
possible application of pyrrolines 37 and 39 and derivatives thereof as chiral ligands in 
asymmetric catalysis. 
 
4.5 Hydrogenation to 5-Substituted Proline Analogues 
 
Having explored the cycloisomerization of differently substituted cyclization 
precursors, we turned our attention to the hydrogenation of some of the previously obtained 
pyrrolines to complete the approach to 5-substituted proline analogues. First, the 3-pyridyl- 
substituted pyrroline 38 was subjected to straightforward hydrogenation conditions using 
Pd on carbon under an atmospheric hydrogen pressure (Scheme 4.15). 
 
Scheme 4.15 
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These conditions3a led to a smooth and quantitative conversion of 38, giving the cis-proline 
analogue 47 as the sole product as determined by 1H NMR. Interestingly, this proline can 
also be considered as a nicotine analogue which in general may have biological relevance as 
a ligand for the nicotinic acetylcholine receptor.13 The catalytic hydrogenation of pyrroline 15 
under the same conditions as used for 38, also led to the formation of the desired proline 
analogue 1. However, in that case the reduction of the imine was severely hampered by 
partial hydrogenolysis at the benzylic position. This competitive reaction could be efficiently 
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suppressed by using previously reported conditions,3b leading to the formation of cis-proline 
analogue 1 in a quantitative yield. 
In addition, the 6-membered cyclic imine 33 was subjected to similar hydrogenation 
conditions, but this did not lead to clean formation of the corresponding pipecolic acid 
analogue 48. Instead, imine 33 proved to be a labile compound under these conditions 
leading, beside 48, to several unidentifiable side products. Luckily, pipecolic acid 48 could be 
isolated from this product mixture by column chromatography in 40% yield as a single 
diastereoisomer according to 1H and 13C NMR (Scheme 4.16). 
 
Scheme 4.16 
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By analogy to the stereochemistry in the reduction of the aforementioned pyrrolines, the 
configuration of 48 is most likely to be cis. However, no further studies were conducted to 
unambiguously identify the relative configuration of this diastereoisomer. 
 
4.6 Conclusions 
 
In this chapter a novel approach toward 5-substituted proline analogues is described. 
We have shown that the synthesis of the 2,5-disubstituted pyrrolines 8 can be achieved via a 
mild Ag-catalyzed 5-endo-dig cyclization of the acetylene containing amino acids 9. In most 
cases, the yield of the obtained pyrrolines was satisfactory and in the case of 15 we 
demonstrated that the enantiopurity of the starting material was retained in the product. 
Furthermore, we have demonstrated that the developed methodology could also be 
applied on the homologous systems 28 and 29, leading exclusively to the formation of cyclic 
imines 31 and 33, respectively. In addition, we have shown for two examples that the 
obtained pyrrolines can be easily converted into the corresponding 5-substituted proline 
analogues. 
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4.8 Experimental Section 
 
General information. For general experimental details, see Section 2.8. 
 
General procedure A for the Sonogashira cross-coupling reactions. For a general 
procedure, see Section 2.8. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-phenyl-4-pentynoate (13). 
According to general procedure A, to a solution of 10 (364 mg, 1.60 mmol), 
iodobenzene (398 mg, 1.95 mmol) and Et2NH (0.83 mL, 8.04 mmol) in Et2O 
(18 mL), CuI (31 mg, 0.16 mmol) and PdCl2(PPh3)2 (58 mg, 0.08 mmol) 
were added and the resulting mixture was stirred for 2 h. Work-up and 
purification by chromatography (EtOAc/heptane 1:6) afforded 13 (444 mg, 1.46 mmol, 91%) 
as a yellow oil. Rf 0.28 (EtOAc/heptane 1:4); [α]D +71.3 (c 1.0, CH2Cl2); IR (neat) 3375, 2977, 
1747, 1716, 1598; 1H NMR (300 MHz, CDCl3) δ 7.38 (m, 2H), 7.28 (m, 3H), 5.42 (d, J = 8.3 Hz, 
1H), 4.56 (m, 1H), 3.79 (s, 3H), 2.95 (m, 2H), 1.46 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 171.1, 
154.9, 131.5, 128.0, 127.6, 122.8, 83.7, 83.4, 79.8, 52.3, 52.1, 28.1, 23.6; HRMS (EI) calcd for 
C17H21NO4 303.1471, found 303.1471. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-(2-methoxyphenyl)-4-
pentynoate (17). According to general procedure A, to a solution of 10 
(281 mg, 1.24 mmol), 2-iodoanisole (358 mg, 1.53 mmol) and Et2NH (0.64 
mL, 6.23 mmol) in Et2O (18 mL), CuI (24 mg, 0.13 mmol) and PdCl2(PPh3)2 
(44 mg, 0.06 mmol) were added and the resulting mixture was stirred for 
2 h. Work-up and purification by chromatography (EtOAc/heptane 1:4) 
afforded 17 (330 mg, 0.99 mmol, 80%) as a yellow oil. Rf 0.56 (EtOAc/heptane 1:1); [α]D +53.9 
(c 0.5, CH2Cl2); IR (neat) 3379, 2970, 1745, 1712, 1493; 1H NMR (300 MHz, CDCl3) δ 7.29 (m, 
2H), 6.86 (m, 2H), 5.62 (d, J = 8.4 Hz, 1H), 4.58 (m, 1H), 3.89 (s, 3H), 3.78 (s, 3H), 3.04 (dd, J = 
4.2, 17.1 Hz, 1H), 2.95 (dd, J = 5.1, 16.8 Hz, 1H), 1.47 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 
171.5, 160.3, 155.4, 133.3, 129.6, 120.5, 112.3, 110.6, 88.3, 80.3, 80.2, 55.8, 52.7, 52.3, 28.5, 24.2; 
HRMS (EI) calcd for C18H23NO5 333.1576, found 333.1573. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-(4-nitrophenyl)-4-
pentynoate (18). According to general procedure A, to a solution of 
10 (267 mg, 1.18 mmol), 1-iodo-4-nitrobenzene (353 mg, 1.42 mmol) 
and Et2NH (0.61 mL, 5.92 mmol) in Et2O (18 mL), CuI (24 mg, 0.13 
mmol) and PdCl2(PPh3)2 (41 mg, 0.06 mmol) were added and the 
resulting mixture was stirred for 2 h. Work-up and purification by 
chromatography (EtOAc/heptane 1:4) afforded 18 (330 mg, 0.95 mmol, 81%) as a light-
yellow solid. Rf 0.15; [α]D +85.1 (c 0.5, CH2Cl2); mp 98.8 °C; IR (neat) 3352, 2978, 2245, 1736, 
1672, 1592, 1523, 1508; 1H NMR (300 MHz, CDCl3) δ 8.16 (d, J = 9.0 Hz, 2H), 7.52 (d, J = 9.0 
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Hz, 2H), 5.38 (d, J = 3.3 Hz, 1H), 4.60 (m, 1H), 3.81 (s, 3H), 2.99 (d, J = 5.1 Hz, 2H), 1.46 (s, 
9H); 13C NMR (75 MHz, CDCl3) δ 171.2, 155.1, 147.1, 132.6, 130.1, 123.6, 90.2, 82.0, 80.5, 52.9, 
52.3, 28.4, 24.3; HRMS (CI) calcd for C17H21N2O6 (MH+) 349.1400, found 349.1406. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-(2-methylphenyl)-4-penty-
noate (19). According to general procedure A, to a solution of 10 (320 mg, 
1.41 mmol), 2-iodotoluene (374 mg, 1.72 mmol) and Et2NH (0.74 mL, 7.11 
mmol) in Et2O (18 mL), CuI (30 mg, 0.16 mmol) and PdCl2(PPh3)2 (53 mg, 
0.08 mmol) were added and the resulting mixture was stirred for 2 h. 
Work-up and purification by chromatography (EtOAc/heptane 1:6) 
afforded 19 (400 mg, 1.26 mmol, 89%) as a brown oil. Rf 0.15; [α]D +79.2 (c 0.3, CH2Cl2); IR 
(neat) 3373, 2976, 1744, 1709, 1493; 1H NMR (300 MHz, CDCl3) δ 7.32 (d, J = 7.5 Hz, 1H), 7.12 
(m, 3H), 5.38 (d, J = 8.1 Hz, 1H), 4.54 (m, 1H), 3.78 (s, 3H), 2.99 (m, 2H), 2.38 (s, 3H) 1.45 (s, 
9H); 13C NMR (75 MHz, CDCl3) δ 171.1, 154.9, 140.0, 131.9, 129.3, 128.1, 125.4, 122.7, 87.8, 
82.6, 80.3, 52.8, 52.6, 28.6, 24.3, 21.0; HRMS (EI) calcd for C18H23NO4 317.1627, found 317.1626. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-(4-fluorophenyl)-4-pen-
tynoate (20). According to general procedure A, to a solution of 10 (336 
mg, 1.48 mmol), 1-fluoro-4-iodobenzene (409 mg, 1.84 mmol) and 
Et2NH (0.79 mL, 7.62 mmol) in Et2O (18 mL), CuI (30 mg, 0.16 mmol) 
and PdCl2(PPh3)2 (56 mg, 0.08 mmol) were added and the resulting 
mixture was stirred for 2 h. Work-up and purification by 
chromatography (EtOAc/heptane 1:5) afforded 20 (448 mg, 1.39 mmol, 94%) as a light-
yellow oil. Rf 0.15; [α]D +67.2 (c 0.5, CH2Cl2); IR (neat) 3378, 2976, 1748, 1714, 1597, 1502; 1H 
NMR (300 MHz, CDCl3) δ 7.33 (m, 2H), 6.95 (t, J = 8.7 Hz, 2H), 5.36 (d, J = 7.8 Hz, 1H), 4.54 
(m, 1H), 3.78 (s, 3H), 2.92 (m, 2H), 1.45 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 171.1, 163.8, 
161.6, 154.9, 133.5, 133.4, 115.6, 115.3, 83.7, 82.7, 80.3, 52.6, 52.5, 28.6, 24.2; HRMS (EI) calcd for 
C17H20NO4F 321.1376, found 321.1376. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-6-phenyl-5-hexynoate (28). 
According to general procedure A, to a solution of 26 (348 mg, 1.44 mmol), 
iodobenzene (359 mg, 1.76 mmol) and Et2NH (0.75 mL, 7.26 mmol) in Et2O (18 
mL), CuI (31 mg, 0.16 mmol) and PdCl2(PPh3)2 (50 mg, 0.07 mmol) were added 
and the resulting mixture was stirred for 2 h. Work-up and purification by 
chromatography (EtOAc/heptane 1:6) afforded 28 (389 mg, 1.23 mmol, 85%) 
as a brown oil. Rf 0.26 (EtOAc/heptane 1:4); [α]D +18.4 (c 1.0, CH2Cl2); IR (neat) 
3390, 2974, 1743, 1714, 1506, 1491; 1H NMR (300 MHz, CDCl3) δ 7.38 (m, 2H), 
7.25 (m, 3H), 5.31 (d, J = 7.7 Hz, 1H), 4.42 (m, 1H), 3.71 (s, 3H), 2.48 (t, J = 7.1 Hz, 2H), 2.15 (m, 
1H), 1.97 (m, 1H), 1.43 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 172.8, 155.4, 131.6, 128.2, 127.8, 
123.6, 88.4, 81.6, 80.0, 53.0, 52.4, 31.4, 28.3, 15.9; HRMS (EI) calcd for C18H23NO4 317.1627, 
found 317.1631. 
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Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-7-phenyl-6-heptynoate 
(29). According to general procedure A, to a solution of 27 (209 mg, 0.82 
mmol), iodobenzene (200 mg, 0.98 mmol) and Et2NH (0.43 mL, 4.17 
mmol) in Et2O (16 mL), CuI (17 mg, 0.09 mmol) and PdCl2(PPh3)2 (29 
mg, 0.04 mmol) were added and the resulting mixture was stirred for 4 
h. Work-up and purification by chromatography (EtOAc/heptane 1:6) 
afforded 29 (223 mg, 0.67 mmol, 82%) as a brown oil. Rf 0.23 
(EtOAc/heptane 1:4); [α]D +10.6 (c 1.0, CH2Cl2); IR (neat) 3359, 2976, 1741, 1711, 1511, 1491; 
1H NMR (300 MHz, CDCl3) δ 7.39 (m, 2H), 7.27 (m, 3H), 5.04 (d, J = 7.5 Hz, 1H), 4.34 (m, 1H), 
3.75 (s, 3H), 2.45 (t, J = 6.9 Hz, 2H), 2.00 (m, 1H), 1.86-1.61 (m, 3H), 1.45 (s, 9H); 13C NMR (75 
MHz, CDCl3) δ 173.3, 155.5, 131.7, 128.3, 127.8, 123.9, 89.2, 81.4, 80.0, 53.3, 52.4, 32.1, 28.4, 24.7, 
19.2; HRMS (CI) calcd for C19H26NO4 (MH+) 332.1862, found 332.1849. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-(2-pyridyl)-4-pentynoate 
(34). According to general procedure A, to a solution of 10 (358 mg, 1.57 
mmol), 2-iodopyridine (387 mg, 1.27 mmol) and Et2NH (0.81 mL, 7.86 
mmol) in Et2O (18 mL), CuI (30 mg, 0.15 mmol) and PdCl2(PPh3)2 (57 mg, 
0.08 mmol) were added and the resulting mixture was stirred for 2 h. 
Work-up and purification by chromatography (EtOAc/heptane 1:1) 
afforded 34 (405 mg, 1.33 mmol, 85%) as a light-yellow oil. Rf 0.25; [α]D +74.8 (c 0.5, CH2Cl2); 
IR (neat) 2975, 1744, 1709, 1583, 1507, 1462; 1H NMR (300 MHz, CDCl3) δ 8.53 (m, 1H), 7.62 
(dt, J = 1.8, 7.5 Hz, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.21 (m, 1H) 5.67 (d, J = 8.1 Hz, 1H), 4.58 (m, 
1H), 3.79 (s, 3H), 3.01 (d, J = 4.8 Hz, 2H), 1.45 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 170.9, 
154.9, 149.7, 142.9, 136.0, 127.2, 122.7, 84.6, 83.1, 80.3, 52.9, 52.3, 28.6, 24.1; HRMS (EI) calcd for 
C16H20N2O4 304.1423, found 304.1426. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-(3-pyridyl)-4-pentynoate 
(35). According to general procedure A, to a solution of 10 (310 mg, 1.38 
mmol), 3-iodopyridine (336 mg, 1.64 mmol) and Et2NH (0.72 mL, 6.97 
mmol) in Et2O (18 mL), CuI (28 mg, 0.15 mmol) and PdCl2(PPh3)2 (50 mg, 
0.07 mmol) were added and the resulting mixture was stirred for 2 h. 
Work-up and purification by chromatography (EtOAc/heptane 1:1) 
afforded 35 (384 mg, 1.26 mmol, 91%) as a yellow oil. Rf 0.22; [α]D +74.7 (c 0.5, CH2Cl2); IR 
(neat) 2976, 1748, 1709, 1506, 1472; 1H NMR (300 MHz, CDCl3) δ 8.59 (m, 1H), 8.49 (d, J = 4.2 
Hz, 1H), 7.64 (m, 1H), 7.22 (m, 1H), 5.43 (d, J = 7.5 Hz, 1H) 4.57 (m, 1H), 3.79 (s, 3H), 2.97 (d, J 
= 4.8 Hz, 2H), 1.46 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 170.9, 154.9, 151.7, 148.1, 144.8, 138.8, 
123.0, 88.0, 80.4, 80.3, 52.9, 52.4, 28.6, 24.3; HRMS (EI) calcd for C16H20N2O4 304.1423, found 
304.1424. 
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tert-Butyl N-[(1S)-1-({[1-(tert-butyl)-1,1-diphenylsilyl]oxy}methyl]-4-(2-
pyridyl)-3-butynyl]carbamate (40). To a solution of 10 (439 mg, 1.93 
mmol) in THF (20 mL), LiBH4 (2M in THF, 1.9 mL, 3.86 mmol) was added 
at 0 °C. The reaction mixture was allowed to reach room temperature and 
stirred for 20 h. Upon completion, the reaction mixture was quenched by 
adding water (1 mL) and stirred further for 15 min at room temperature, 
after which time the mixture was poured into water (30 mL). The aqueous solution was 
extracted with EtOAc (100 mL) and the organic layer was washed with water (2 × 30 mL), 
brine (2 × 30 mL), dried over MgSO4 and concentrated in vacuo to afford the amino alcohol 
42. To a solution of the crude amino alcohol 42 in CH2Cl2 (10 mL), Et3N (0.32 mL, 2.32 mmol), 
DMAP (235 mg, 1.92 mmol) and TBDPSCl (637 mg, 2.32 mmol) were added at 0 °C. The 
reaction mixture was allowed to reach room temperature and stirred for 18 h. Upon 
completion, the reaction mixture was diluted with CH2Cl2 (20 mL) and washed with water (2 
× 10 mL), brine (10 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by chromatography (EtOAc/heptane 1:12) to afford the silyl ether 43 (809 mg, 1.85 
mmol, 96%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.66 (m, 4H), 7.37 (m, 6H), 4.79 
(d, J = 8.7 Hz, 1H), 3.88 (br s, 1H), 3.78 (m, 1H), 3.66 (m, 1H), 2.54 (m, 2H), 1.93 (t, J = 2.7 Hz, 
1H), 1.43 (s, 9H), 1.06 (s, 9H). According to general procedure A, to a solution of 43 (540 mg, 
1.23 mmol), 2-iodopyridine (305 mg, 1.49 mmol) and Et2NH (0.64 mL, 6.21 mmol) in Et2O (18 
mL), CuI (23 mg, 0.12 mmol) and PdCl2(PPh3)2 (45 mg, 0.06 mmol) were added and the 
resulting mixture was stirred for 4 h. Work-up and purification by chromatography 
(EtOAc/heptane 1:3) afforded 40 (406 mg, 0.79 mmol, 64%) as a light-yellow oil. Rf 0.20; [α]D 
+8.8 (c 0.6, CH2Cl2); IR (neat) 3071, 2958, 2928, 2855, 1709, 1584, 1558; 1H NMR (300 MHz, 
CDCl3) δ 8.51 (m, 1H), 7.60 (m, 5H), 7.28 (m, 7H), 7.18 (m, 1H) 4.89 (d, J = 7.8 Hz, 1H), 4.00 (br 
s, 1H), 3.86 (m, 1H), 3.74 (m, 1H), 2.81 (m, 2H), 1.43 (s, 9H), 1.07 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 155.0, 149.7, 143.4, 135.9, 135.5, 135.5, 129.7, 127.7, 127.0, 122.5, 86.8, 82.4, 79.6, 64.3, 
50.7, 28.7, 27.2, 22.6, 19.7; HRMS (EI) calcd for C31H38N2O3Si 514.2652, found 514.2656. 
 
General procedure B for the preparation of the cyclic imines. To a solution of the 
Boc-protected cyclization precursor in EtOAc (0.25M), a solution of HCl in EtOAc (∼3M, 5 
equiv) was added dropwise at room temperature. The mixture was stirred at room 
temperature and monitored with TLC. After complete conversion of the starting material, the 
mixture was concentrated in vacuo to afford the corresponding HCl-salt. A solution of the 
HCl-salt in dioxane/water (0.08M, 1:1 v/v) was treated dropwise at room temperature with 
25% aqueous NH4OH until the mixture had reached pH 10. The aqueous solution was 
extracted with CH2Cl2 (3 ×) and the combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The remaining crude amino ester was subsequently dissolved in 
MeCN (0.1M) and AgOTf (10 mol%) was added. The mixture was stirred at room or reflux 
temperature under N2-atmosphere and monitored by TLC. Upon completion, the reaction 
mixture was concentrated in vacuo and purified by flash chromatography to afford the pure 
product. 
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Methyl (2S)-5-phenyl-3,4-dihydro-2H-2-pyrrolecarboxylate (15). 
According to general procedure B, precursor 13 (383 mg, 1.26 mmol) 
afforded 15 (185 mg, 0.91 mmol, 72%) as a light-yellow oil after 
purification by chromatography (EtOAc/heptane 1:3). Rf 0.42 (EtOAc/heptane 1:1); [α]D 
+104.1 (c 1.0, CH2Cl2); IR (neat) 2951, 1734, 1612, 1574, 1433; 1H NMR (300 MHz, CDCl3) δ 
7.84 (dd, J = 1.5, 7.8 Hz, 2H), 7.38 (m, 3H), 4.89 (m, 1H), 3.76 (s, 3H), 3.14 (m, 1H), 2.98 (m, 
1H), 2.29 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 175.7, 173.0, 133.6, 130.8, 128.3, 127.9, 74.6, 
52.4, 35.6, 26.6; HRMS (EI) calcd for C12H13NO2 203.0946, found 203.0948. 
 
Methyl (2S)-5-(2-aminophenyl)-3,4-dihydro-2H-2-pyrrolecarboxylate 
(21). According to general procedure B, precursor 16 (535 mg, 1.68 
mmol) afforded 21 (240 mg, 1.10 mmol, 65%) as a white solid after 
purification by chromatography (EtOAc/heptane 1:4). Rf 0.20; [α]D 
−26.0 (c 0.5, CH2Cl2); mp 71.2 °C; IR (neat) 3417, 3284, 2954, 1726, 1612, 1554; 1H NMR (300 
MHz, CDCl3) δ 7.38 (m, 1H), 7.17 (m, 1H), 6.68 (m, 2H), 6.49 (br s, 2H), 4.97 (m, 1H), 3.76 (s, 
3H), 3.22 (m, 1H), 3.04 (m, 1H), 2.23 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 176.5, 172.8, 148.1, 
130.6, 130.2, 115.2, 114.8, 114.2, 73.6, 51.3, 35.6, 24.5; HRMS (EI) calcd for C12H14N2O2 218.1055, 
found 218.1057. 
 
Methyl (2S)-5-(2-methoxyphenyl)-3,4-dihydro-2H-2-pyrrolecarboxy-
late (22). According to general procedure B, precursor 17 (479 mg, 
1.44 mmol) afforded 22 (233 mg, 0.99 mmol, 69%) as a light-yellow oil 
after purification by chromatography (EtOAc/heptane 1:1). Rf 0.29; 
[α]D +65.7 (c 0.5, CH2Cl2); IR (neat) 2951, 2837, 1736, 1599, 1489; 1H NMR (300 MHz, CDCl3) δ 
7.82 (dd, J = 1.8, 7.8 Hz, 1H), 7.35 (m, 1H), 6.91 (m, 2H), 4.79 (m, 1H), 3.83 (s, 3H), 3.76 (s, 3H), 
3.21 (m, 1H), 3.05 (m, 1H), 2.22 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 176.5, 173.3, 158.1, 
131.6, 130.3, 123.8, 120.5, 111.2, 73.4, 55.6, 52.3, 39.0, 27.3; HRMS (EI) calcd for C13H15NO3 
233.1052, found 233.1047. 
 
Methyl (2S)-5-(4-nitrophenyl)-3,4-dihydro-2H-2-pyrrolecarbo-
xylate (23). According to general procedure B, precursor 18 (152 
mg, 0.44 mmol) afforded 23 (87 mg, 0.35 mmol, 80%) as a yellow 
solid after purification by chromatography (EtOAc/heptane 1:2). Rf 0.16; [α]D +83.7 (c 0.5, 
CH2Cl2); mp 87.9 °C; IR (neat) 2950, 1735, 1588, 1524, 1433; 1H NMR (300 MHz, CDCl3) δ 8.22 
(d, J = 9.0 Hz, 2H), 8.02 (d, J = 9.0 Hz, 2H), 4.98 (m, 1H), 3.79 (s, 3H), 3.17 (m, 1H), 3.05 (m, 
1H), 2.37 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 174.0, 172.4, 149.0, 139.2, 128.8, 123.5, 74.9, 
52.5, 35.8, 26.6; HRMS (EI) calcd for C12H12N2O4 248.0797, found 248.0793. 
 
Methyl (2S)-5-(2-methylphenyl)-3,4-dihydro-2H-2-pyrrolecarboxy-
late (24). According to general procedure B, precursor 19 (400 mg, 
1.26 mmol) afforded 24 (147 mg, 0.68 mmol, 54%) as a yellow oil after 
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purification by chromatography (EtOAc/heptane 1:3). Rf 0.22; [α]D +76.4 (c 0.5, CH2Cl2); IR 
(neat) 2954, 1735, 1614, 1558, 1437; 1H NMR (300 MHz, CDCl3) δ 7.40 (d, J = 7.8 Hz, 1H), 7.22 
(m, 3H), 4.93 (m, 1H), 3.76 (s, 3H), 3.04 (m, 2H), 2.52 (s, 3H), 2.25 (m, 2H); 13C NMR (75 MHz, 
CDCl3) δ 177.8, 173.2, 137.3, 134.1, 131.2, 129.4, 128.8, 125.4, 75.1, 52.4, 39.0, 26.7, 21.8; HRMS 
(EI) calcd for C13H15NO2 217.1103, found 217.1104. 
 
Methyl (2S)-5-(4-fluorophenyl)-3,4-dihydro-2H-2-pyrrolecarboxy-
late (25). According to general procedure B, precursor 20 (400 mg, 
1.24 mmol) afforded 25 (174 mg, 0.79 mmol, 64%) as a yellow oil 
after purification by chromatography (EtOAc/heptane 1:3). Rf 0.18; [α]D +97.7 (c 0.5, CH2Cl2); 
IR (neat) 2946, 1735, 1619, 1601, 1506, 1433; 1H NMR (300 MHz, CDCl3) δ 7.85 (dd, J = 5.4, 8.7 
Hz, 2H), 7.06 (t, J = 8.7 Hz, 2H), 4.89 (m, 1H), 3.77 (s, 3H), 3.10 (m, 1H), 2.97 (m, 1H), 2.31 (m, 
2H); 13C NMR (75 MHz, CDCl3) δ 174.6, 173.0, 165.9, 162.6, 130.1, 130.0, 115.6, 115.3, 74.6, 
52.5, 35.7, 26.7; HRMS (EI) calcd for C12H12N2O2F 221.0852, found 221.0851. 
 
Methyl (2S)-5-benzyl-3,4-dihydro-2H-2-pyrrolecarboxylate (31). 
According to general procedure B, precursor 28 (389 mg, 1.23 mmol) 
afforded 31 (140 mg, 0.64 mmol, 52%) as a light-yellow oil after 
purification by chromatography (EtOAc/heptane 1:1) The product 
showed decomposition after being stored at −10 °C for some days. Rf 0.17; IR (neat) 2946, 
1735, 1653, 1593, 1433; 1H NMR (300 MHz, C6D6) δ 7.10 (m, 5H), 4.69 (m, 1H), 3.60 (d, J = 14.1 
Hz, 1H), 3.53 (d, J = 14.4 Hz, 1H), 3.43 (s, 3H), 2.23 (m, 1H), 1.92 (m, 2H), 1.64 (m, 1H); 13C 
NMR (75 MHz, C6D6) δ 179.1, 173.1, 137.1, 129.4, 128.9, 126.9, 74.8, 51.8, 40.8, 37.3, 26.9; 
HRMS (EI) calcd for C13H15NO2 217.1103, found 217.1102. 
 
Methyl 6-benzyl-2,3,4,5-tetrahydro-2-pyridinecarboxylate (33). 
According to general procedure B, precursor 29 (326 mg, 0.98 mmol) 
afforded 33 (108 mg, 0.47 mmol, 48%) as a light-yellow oil after 
purification by chromatography (EtOAc/heptane 1:1). Rf 0.19; IR (neat) 
2943, 1738, 1655, 1587, 1495, 1435; 1H NMR (300 MHz, CDCl3) δ 7.23 (m, 
5H), 4.29 (m, 1H), 3.77 (s, 3H), 3.56 (s, 2H), 2.06 (m, 2H), 1.91 (m, 1H), 1.66 (m, 3H); 13C NMR 
(75 MHz, CDCl3) δ 173.4, 172.1, 137.2, 128.9, 128.5, 126.5, 61.1, 52.4, 48.4, 28.0, 24.7, 18.3; 
HRMS (EI) calcd for C14H17NO2 231.1259, found 231.1265. 
 
General procedure C for the preparation of the pyridyl-substituted pyrrolines. To a 
solution of the Boc-protected cyclization precursor in EtOAc (0.25M), a solution of HCl in 
EtOAc (∼3M, 5 equiv) was added dropwise at room temperature. The mixture was stirred at 
room temperature and monitored with TLC. After complete conversion of the starting 
material, the mixture was concentrated in vacuo to afford the corresponding HCl-salt. A 
suspension of the HCl-salt in CHCl3 (0.12M) was treated dropwise at room temperature with 
Et3N until a clear solution was obtained. This solution was concentrated in vacuo and the 
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precipitate was extracted with Et2O (4 ×). The combined organic layers were concentrated in 
vacuo and the remaining crude amino ester was subsequently dissolved in MeCN (0.1M) and 
AgOTf (10 mol%) was added. The mixture was stirred at room or reflux temperature under 
N2-atmosphere and monitored by TLC. Upon completion, the reaction mixture was 
concentrated in vacuo and purified by flash chromatography to afford the pure product. 
 
Methyl (2S)-5-(2-pyridyl)-3,4-dihydro-2H-2-pyrrolecarboxylate (37). 
According to general procedure C, precursor 34 (313 mg, 1.03 mmol) 
afforded 37 (80 mg, 0.39 mmol, 38%) as a yellow oil after purification 
by chromatography (EtOAc/heptane 1:1). Rf 0.17; [α]D +91.0 (c 0.5, CH2Cl2); IR (neat) 2950, 
1736, 1652, 1612, 1563, 1433; 1H NMR (300 MHz, CDCl3) δ 8.62 (dd, J = 1.1, 3.7 Hz, 1H), 8.18 
(d, J = 7.4 Hz, 1H), 7.72 (m, 1H), 7.32 (m, 1H), 4.96 (m, 1H), 3.78 (s, 3H), 3.30 (m, 1H), 3.14 (m, 
1H), 2.31 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 177.6, 172.8, 152.3, 148.9, 136.2, 125.0, 122.3, 
75.1, 52.4, 35.6, 26.6; HRMS (EI) calcd for C11H12N2O2 204.0899, found 204.0893. 
 
Methyl (2S)-5-(3-pyridyl)-3,4-dihydro-2H-2-pyrrolecarboxylate (38). 
According to general procedure C, precursor 35 (540 mg, 1.77 mmol) 
afforded 38 (250 mg, 1.22 mmol, 69%) as a light-yellow oil after 
purification by chromatography (5% Et3N in EtOAc/heptane 9:1). Rf 
0.37; [α]D +82.7 (c 0.5, CH2Cl2); IR (neat) 2950, 1735, 1619, 1593, 1437; 1H NMR (300 MHz, 
CDCl3) δ 9.03 (s, 1H), 8.65 (dd, J = 1.5, 4.8 Hz, 1H), 8.21 (dt, J = 1.8, 7.8 Hz, 1H), 7.33 (m, 1H), 
4.93 (m, 1H), 3.78 (s, 3H), 3.18 (m, 1H), 3.00 (m, 1H), 2.32 (m, 2H); 13C NMR (75 MHz, CDCl3) 
δ 173.6, 172.7, 151.6, 149.1, 135.0, 129.3, 123.3, 74.6, 52.5, 35.5, 26.5; HRMS (EI) calcd for 
C11H12N2O2 204.0899, found 204.0896. 
 
1-(tert-Butyl)-1,1-diphenylsilyl {[(2S)-5-(3-pyridyl)-3,4-dihydro-
2H-2-pyrrolyl]methyl} ether (39). According to general procedure 
C, precursor 40 (403 mg, 0.78 mmol) afforded 39 (236 mg, 0.57 
mmol, 73%) as a white solid after purification by chromatography (EtOAc/heptane 1:1). Rf 
0.54 (5% Et3N in EtOAc/heptane 1:1); [α]D +53.2 (c 0.5, CH2Cl2); mp 88.1 °C; IR (neat) 2924, 
2850, 1623, 1576, 1554, 1463; 1H NMR (300 MHz, CDCl3) δ 8.60 (dd, J = 0.9, 3.9 Hz, 1H), 8.11 
(d, J = 7.8 Hz, 1H), 7.69 (m, 5H), 7.32 (m, 7H), 4.46 (m, 1H), 3.98 (dd, J = 4.2, 10.2 Hz, 1H), 3.86 
(dd, J = 5.1, 9.9 Hz, 1H), 3.16 (m, 2H), 2.12 (m, 2H), 1.00 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 
175.1, 153.2, 148.9, 136.1, 135.6, 135.5, 133.8, 133.6, 129.5, 129.4, 127.6, 127.5, 124.5, 122.0, 75.4, 
66.9, 35.6, 27.1, 25.5, 19.6; HRMS (EI) calcd for C26H30N2OSi 414.2128, found 414.2119. 
 
Methyl (2S,5R)-5-(3-pyridyl)tetrahydro-1H-2-pyrrolecarboxylate (47). 
To a solution of 38 (120 mg, 0.59 mmol) in iPrOH (3 mL), 10% Pd/C 
(12 mg, 0.01 mmol) was added. The black suspension was subjected to 
hydrogen (1 atm) and stirred for 20 h at room temperature. The reaction mixture was filtered 
over Hyflo and concentrated in vacuo to afford 47 (120 mg, 0.58 mmol, 98%) as a light-yellow 
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oil. An analytically pure sample was obtained after chromatography (CH2Cl2/MeOH 
saturated with NH3 95:5). Rf 0.31 (5% Et3N in EtOAc/heptane 9:1); [α]D +29.1 (c 0.5, CH2Cl2); 
IR (neat) 3339, 2945, 2876, 1731, 1575, 1433; 1H NMR (300 MHz, CDCl3) δ 8.57 (s, 1H), 8.46 
(dd, J = 1.8, 4.8 Hz, 1H), 7.83 (dt, J = 1.8, 7.8 Hz, 1H), 7.24 (m, 1H), 4.24 (dd, J = 5.7, 9.0 Hz, 
1H), 3.95 (dd, J = 5.1, 8.1 Hz, 1H), 3.76 (s, 3H), 2.34 (s, 1H), 2.18 (m, 3H), 1.73 (m, 1H); 13C 
NMR (75 MHz, CDCl3) δ 175.1, 148.6, 148.5, 138.9, 134.1, 123.4, 61.0, 60.0, 52.4, 34.5, 30.5; 
HRMS (CI) calcd for C11H15N2O2 (MH+) 207.1134, found 207.1133. 
 
Methyl (2S,5R)-5-phenyltetrahydro-1H-2-pyrrolecarboxylate (1). To a 
solution of 15 (308 mg, 1.52 mmol) in MeOH (3 mL), PtO2 (10 mg, 0.04 
mmol) was added. The solution was subjected to hydrogen (30 bar) 
and stirred for 3 h at room temperature. The reaction mixture was filtered over Hyflo and 
concentrated in vacuo to afford 1 (308 mg, 1.50 mmol, 99%) as a light-yellow oil. An 
analytically pure sample was obtained after chromatography (EtOAc/heptane 1:2). Rf 0.15; 
[α]D +20.1 (c 1.0, CH2Cl2); IR (neat) 3356, 2950, 1731, 1610, 1502, 1459; 1H NMR (300 MHz, 
CDCl3) δ 7.40 (dd, J = 0.6, 7.5 Hz, 2H), 7.26 (m, 3H), 4.18 (dd, J = 5.7, 9.0 Hz, 1H), 3.92 (dd, J = 
5.1, 8.1 Hz, 1H), 3.76 (s, 3H), 2.17 (m, 4H), 1.72 (m, 1H); 13C NMR (75 MHz, CDCl3) δ 175.3, 
143.2, 128.4, 127.1, 126.7, 63.7, 60.2, 52.3, 34.5, 30.8; HRMS (CI) calcd for C12H16NO2 (MH+) 
206.1181, found 206.1179. 
 
Methyl 6-benzyl-2-piperidinecarboxylate (48). To a solution of 33 (108 
mg, 0.47 mmol) in MeOH (10 mL), 10% Pd/C (15 mg, 0.01 mmol) was 
added. The black suspension was subjected to hydrogen (1 atm) and 
stirred for 2 h at room temperature. The reaction mixture was filtered 
over Hyflo and concentrated in vacuo. Purification by chromatography 
(EtOAc/heptane 1:1) afforded 48 (44 mg, 0.19 mmol, 40%) as a colorless oil. Rf 0.17; IR (neat) 
3332, 2931, 2852, 2791, 1739, 1603, 1495, 1435; 1H NMR (300 MHz, CDCl3) δ 7.25 (m, 2H), 7.18 
(m, 3H), 3.66 (s, 3H), 3.26 (dd, J = 2.7, 10.8 Hz, 1H), 2.70 (m, 3H), 2.03-1.84 (m, 3H), 1.64 (m, 
1H), 1.48-1.14 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 173.3, 138.7, 129.1, 128.4, 126.3, 59.5, 58.0, 
52.1, 43.8, 32.1, 29.3, 24.7; HRMS (EI) calcd for C14H19NO2 233.1371, found 233.1374. 
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CHAPTER 5 
 
FUNCTIONALIZED HETEROCYCLIC ENEDIYNES 
 
 
5.1 Introduction 
 
Enediynes constitute a family of antitumor antibiotics derived from bacterial sources, 
which were discovered in the late 1980s.1 These natural products combine a unique mode of 
action with an extremely potent antitumor activity by virtue of their DNA-cleaving ability, 
which has already led to promising clinical results in cancer chemotherapy.2 
One of the most prominent members of the enediyne class of natural products is 
calicheamicin γI1 (1), isolated from Micromonospora echinospora ssp calichensis along with a 
series of related compounds.3 
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The structure of calicheamicin γI1 and other related enediynes can be roughly divided into 
three domains: (1) the enediyne system (“molecular warhead”) which is the source of 
radicals that damage DNA; (2) the trisulfide moiety (“triggering device”) which, upon 
suitable activation, initiates the formation of the damaging radicals; and (3) the 
oligosaccharide chain (“delivery system”) which delivers the warhead to its target, the DNA. 
As mentioned before, the enediynes exert their biological action by virtue of their 
ability to cleave DNA. This biological activity can be explained by the proposed mechanism 
of action of calicheamicin γI1 which firstly involves the specific binding of the molecule 
within the minor groove of duplex DNA at 5’-TCCT and 5’-TTTT sequences, in which the 
oligosaccharide fragment serves as a recognition and delivery system.4 Before or after 
binding to DNA, a bionucleophile (e.g. glutathione) attacks the trisulfide moiety of 1, 
generating a thiolate species (viz. 2) which adds in a conjugate fashion to the adjacent enone 
system to give the strained tricyclic compound 3 (Scheme 5.1). In this reaction, the sp2 carbon 
at the bridgehead position is converted into an sp3 carbon, which leads to a significant 
shorter distance between the acetylenic carbon atoms c and d (c-d distance, see Scheme 5.1). 
This event facilitates a cycloaromatization of the enediyne system leading to the benzenoid 
diradical 4, which is also known as the Bergman cyclization.5 The reactive diradical 4 is 
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capable of abstracting hydrogen radicals from duplex DNA, leading to cleavage of both 
strands and eventually cell death. 
 
Scheme 5.1 
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The fascinating mode of action and the attractive biological activity of the newly 
discovered enediynes soon stimulated extensive research activities among synthetic chemists 
to develop the chemistry to construct the natural products.6 Additionally, the design and 
synthesis of simple model systems of the naturally occurring enediynes became an important 
research subject to probe and mimic the chemical and biological actions of the natural 
compounds.7 As an example of the latter topic, being part of initial studies regarding the 
reactivity profile of monocyclic enediynes, the conjugated enediyne 6 was designed as a 
potential DNA-cleaving agent in the group of Nicolaou (Scheme 5.2).8 
 
Scheme 5.2 
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Compound 6 was sufficiently stable at room temperature, but underwent cycloaromatization 
at 37 °C in the presence of 1,4-cyclohexadiene leading to product 8 via the benzenoid 
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diradical 7 with a half-life time of 11.8 h. More importantly, enediyne 6 showed DNA 
cleaving properties, resulting in both single and double strand DNA cuts, thereby providing 
the first confirmation for the proposed mode of action of for example the calicheamicins (see: 
Scheme 5.1). As such, enediyne 6 was the first synthetic enediyne to demonstrate DNA 
cleaving properties and these results clearly showed that simple cyclic enediynes could 
spontaneously cleave DNA without the presence of cofactors such as thiols. Therefore, 
enediynes of type 6 might serve as “warheads” in larger designed molecular structures 
equipped with delivery systems to target specific DNA segments or tumor cells. 
Amongst the various simple synthetic enediynes which have been developed so far, 
the nitrogen-containing cyclic enediynes (azaenediynes) have some advantages over their 
carbocyclic8 or sulfur9 containing analogues. These include (1) the facile attachment of side 
chains onto the nitrogen that may provide triggering mechanisms10 for enediyne activation 
or DNA binding agents,11 and (2) a possible enhancement of the tendency to undergo 
Bergman cyclization due to the shorter C-N bond compared to the carbon and sulfur 
analogues. 
In order to study the influence of the nitrogen atom on the cycloaromatization 
reactivity, several monocyclic azaenediynes have recently been synthesized.12 Representative 
compounds are the enediynes 11 and 14 (Scheme 5.3).12b 
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A Pd-catalyzed Sonogashira coupling was used as a key step to construct the enediynes 11 
and 14. The synthesis of 11 commenced with cis-1,2-dichloroethylene (9) which was 
converted into the acyclic enediyne 10 in a linear sequence of 8 steps. Mesylate 10 served as a 
precursor for an intramolecular N-alkylation, using K2CO3 in DMF under high dilution 
(0.006 M) to give the 10-membered azaenediyne 11 in 85% yield. The c-d distance between 
the reacting acetylenic atoms for enediyne 11, based on molecular mechanics calculations, 
turned out to be 3.22 Å which is within the critical range of 3.20-3.31 Å proposed by 
Nicolaou et al.13 for spontaneous cyclization at ambient temperature. Indeed, enediyne 11 
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slowly underwent cycloaromatization in CDCl3 at room temperature leading to the 
tetrahydroisoquinoline system 12 with a half-life time of 72 h. 
The benzene-fused enediyne 14, which was synthesized in a similar fashion starting 
from 1,2-dibromobenzene (13), showed a c-d distance of 3.24 Å which would predict similar 
behavior in a Bergman cyclization. However, the tetrahydrobenzoisoquinoline derivative 15 
could only be obtained after refluxing a solution of 14 in chloroform for 3 days with a half-
life time of 52 h at 65 °C. Thus, the fusion of the aromatic ring on 14 slowed down the 
kinetics of the cycloaromatization, which had also been observed for similar carbocyclic 
systems.14 This could be explained by the lower gain of resonance energy in the naphthalene-
like transition state for the cycloisomerization of 14 compared to a benzenoid transition state 
for the cyclization of 11. 
Inspired by the work of Basak,12a-b,15 who synthesized several non-functionalized 
azaenediynes, we envisaged that 16 and 17 might be readily synthesized from the 
corresponding acyclic enediynes 18 and 19 via the previously reported methodology.12b The 
enediynes 18 and 19, in turn, should be easily accessible from the enantiopure 
propargylglycine derivative 20 using the Pd-catalyzed Sonogashira coupling as the key 
reaction (Scheme 5.4). 
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To the best of our knowledge, the targeted functionalized enediynes 16 and 17 belong to a 
new class of cyclic amino acids possessing besides the nitrogen an ester function, which can 
be used as a handle for the attachment of side chains or the incorporation into peptides. 
 
5.2 Preparation of Functionalized Azaenediynes 
 
In order to investigate the feasibility of forming the functionalized azaenediynes 16 
and 17 via intramolecular N-alkylation (viz. 10→11, Scheme 5.3), propargylglycine derivative 
20 was first reacted under Sonogashira-type conditions16 with aryl iodide 21 which, in turn, 
was obtained via a Sonogashira coupling between 1,2-diiodobenzene and propargyl alcohol 
in 48% yield (Scheme 5.5). 
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Thus, treatment of 20 with aryl iodide 21 led to an efficient coupling at room temperature 
affording the acyclic enediyne 18 in 82% yield. Compound 18 was subsequently reacted with 
MsCl to give the corresponding mesylate 22 in 87% yield, setting the stage for the cyclization 
reaction. Much to our satisfaction, the intramolecular N-alkylation, using K2CO3 (5 equiv) in 
DMF, proceeded smoothly to afford the azaenediyne 16 in 75% yield. 
This compound turned out to be a crystalline solid which to our surprise showed no 
rotation in the polarimeter. This indicates that racemization took place after cyclization of 
precursor 22 into enediyne 16. Apparently, the tosyl protecting group renders the α-amino 
acid proton sufficiently acidic to be prone to deprotonation in the presence of an excess of 
even a mild base. Crystallization of 16 afforded good quality crystals that were subjected to 
an X-ray crystal structure analysis, confirming the formation of the 10-membered ring (Fig. 
5.1).17 
 
 
Figure 5.1 PLATON18 drawing of the unit cell containing the crystal structures of both 
enantiomers of azaenediyne 16. 
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Interestingly, compound 16 showed a c-d distance of 3.23 Å in the crystal structure, which 
corresponds well with the calculated distance of 3.24 Å for enediyne 14 (see: Scheme 5.3). 
Therefore, compound 16 is expected to show similar thermal behavior as 14, although kinetic 
studies will have to be carried out to determine the thermal reactivity of 16 toward 
cycloaromatization. 
Next, we investigated the formation of the 11-membered ring 17 via the same 
synthetic sequence as outlined in Scheme 5.5. Thus, the acyclic enediyne 19, obtained in a 
yield of 90% from propargylglycine derivative 20 via a Sonogashira coupling with the 
appropriate aryl iodide,19 was treated with MsCl affording the mesylate 23 in 91% yield 
(Scheme 5.6). 
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Subsequent treatment of 23 with K2CO3 in DMF under high dilution led to the formation of 
azaenediyne 17 without any difficulty, which was isolated in 76% yield after column 
chromatography. Also in this case, the product did not show any optical activity. 
 
5.3 Preliminary Studies toward Enediyne-Containing Dipeptides 
 
Encouraged by the results described in the previous section, we set out to investigate 
the synthesis of compounds 24 and 25. Clearly, these dipeptides, equipped with a “molecular 
warhead”, might be incorporated in larger peptides, thus making them attractive synthetic 
targets. 
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Literature precedent regarding the synthesis of enediyne-containing dipeptides such as 24 
and 25 is rather scarce. To the best of our knowledge, the only useful procedure involves a 
four step synthetic sequence starting from cis-1,2-dichloroethylene (9, Scheme 5.7).20 
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Scheme 5.7 
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cis-1,2-Dichloroethylene (9) was first coupled under Sonogashira conditions with methyl 5-
hexynoate after which a second Pd-catalyzed coupling reaction afforded the linear enediyne 
27 in good overall yield. Saponification of ester 27 gave the corresponding free acid 28 which 
was subsequently cyclized, by employing 2-fluoro-1-methylpyridinium tosylate as the 
carboxylic acid activating agent, into the targeted lactam 29 in 40% yield. Likewise, the 
corresponding benzene-fused lactam was obtained starting from 1,2-dibromobenzene. 
We realized that this approach may well be the best way to access the enediynes 24 
and 25, since it utilizes the pre-organized conformation of the enediyne system to force the 
lactamization to proceed. Considering that such an approach in case of the dipeptides 24 and 
25 would require an orthogonal protective group strategy, we anticipated that these 
compounds might be more rapidly accessible by first constructing a suitably substituted 
dipeptide unit, which then should undergo an intramolecular Sonogashira coupling reaction. 
To study the intramolecular Sonogashira coupling in the synthesis of dipeptide 24, 
the enantiopure propargylglycine derivative 30 was first coupled with cis-1,2-
dichloroethylene to provide enyne 31 in 69% yield (Scheme 5.8). Subsequent cleavage of the 
Boc group of 31 generated the corresponding amino ester, which was reacted with Boc-
protected propargylglycine 33 under standard peptide coupling conditions to give dipeptide 
32 in 50% yield over two steps. Unfortunately, subjection of dipeptide 32 to standard 
Sonogashira conditions (0.01 M) did not lead to enediyne 24. Instead, a mixture of 
unidentifiable products was obtained probably partially as a result of polymerization of 32. 
The difficulty of intramolecular formation of 24 is understandable since dipeptide 32 most 
likely adopts the more favored s-trans-conformation whereas the s-cis-conformation is 
required to bring both reacting side groups together. 
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Scheme 5.8 
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After this result, we again turned our attention to the approach outlined in Scheme 
5.7 and started to investigate the synthesis of the benzene-fused enediyne 25 via an 
intramolecular peptide coupling of the corresponding acyclic enediyne. This approach also 
requires the use of orthogonally protected propargylglycine derivatives in the Sonogashira 
coupling reactions. Therefore, enantiomerically pure propargylglycine 34 was first converted 
into the corresponding tert-butyl ester and protected with a Ts group to give 
propargylglycine derivative 35 in 54% yield over two steps (Scheme 5.9). 
 
Scheme 5.9 
H2N CO2H
34 35 (54%)
HN CO2
tBu
Ts
1)  isobutene, H2SO4
     dioxane, rt, 90 h
2)  p-TsCl, pyridine
     CH2Cl2, rt, 70 h
 
 
Next, the enantiopure propargylglycine derivative 30 was coupled with 1,2-
diiodobenzene affording amino acid 36 in 54% yield. Subsequent coupling of 36 with 
propargylglycine derivative 35 led to the formation of the desired acyclic enediyne 37 in 74% 
yield after column chromatography (Scheme 5.10). In a single attempt to convert 37 into the 
targeted enediyne 25, compound 37 was first treated with HCl in EtOAc, which led to 
cleavage of the t-butyl ester with concomitant deprotection of the Boc group, thereby 
installing the amine and acid functionalities for the intramolecular peptide coupling. 
Subjection of the deprotected intermediate to standard peptide coupling conditions under 
high dilution (0.006 M) afforded a mixture of products, of which a small fraction was 
identified by 1H NMR as the target product 25. Further evidence for structural proof, 
however, requires additional experimentation and optimization. 
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Scheme 5.10 
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5.4 Conclusions 
 
In this chapter, we described the synthesis of the novel functionalized azaenediynes 
16 and 17. These compounds have been synthesized from the enantiopure propargylglycine 
derivative 20 by using the Sonogashira coupling to construct the enediyne system. The key 
step in these syntheses comprised an efficient base-mediated intramolecular cyclization, 
which allowed the formation of 16 and 17. 
In addition, we investigated two different approaches to access the enediyne-
containing dipeptides 24 and 25. Unfortunately, the synthesis of 24 via the intramolecular 
Sonogashira coupling of dipeptide 32 was unsuccessful most likely due to the unfavorable s-
trans-conformation of the dipeptide. An alternative approach led to the formation of the 
acyclic enediyne 37 which could be converted via an intramolecular peptide coupling into 
enediyne 25, albeit the reaction has to be further optimized. 
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tert-Butyl (2S)-2-{[(4-methylphenyl)sulfonyl]amino}-4-pentynoate (35). To a 
suspension of 34 (353 mg, 3.12 mmol) in dioxane (20 mL), conc. H2SO4 (1.5 mL, 
27.0 mmol) and isobutene (20 mL) were added. The resulting mixture was 
stirred for 90 h at room temperature after which it was poured into a cooled 
solution of Et2O/1M NaOH (100 mL, 1:1 v/v). The layers were separated and the aqueous 
phase was extracted with Et2O (3 × 50 mL). The combined organic layers were dried over 
MgSO4 and concentrated in vacuo to give the crude amino ester. The crude residue was 
dissolved in CH2Cl2 (50 mL), pyridine (0.75 mL, 9.36 mmol) and p-TsCl (1.19 g, 6.24 mmol) 
were added and the reaction mixture was stirred for 70 h at room temperature. Saturated 
aqueous CuSO4 (100 mL) was added to the reaction mixture and the layers were separated. 
The aqueous layer was extracted with CH2Cl2 (3 × 50 mL) and the combined organic layers 
were washed with saturated aqueous NaHCO3 (50 mL), brine (50 mL), dried over MgSO4 
and concentrated in vacuo. The crude product was purified by chromatography 
(EtOAc/heptane 1:5) to afford 35 (540 mg, 1.67 mmol, 54%) as a white solid. Rf 0.22 
(EtOAc/heptane 1:4); [α]D +8.7 (c 1.0, CH2Cl2); mp 77.5 °C; IR (neat) 3283, 2980, 1727, 1593, 
1437; 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.3 Hz, 2H), 5.37 (d, J = 
8.7 Hz, 1H), 3.94 (m, 1H), 2.65 (m, 2H), 2.40 (s, 3H), 2.01 (t, J = 2.7 Hz, 1H), 1.32 (s, 9H); 13C 
NMR (75 MHz, CDCl3) δ 168.2, 143.5, 136.8, 129.6, 127.2, 83.3, 77.9, 72.2, 54.5, 28.0, 24.7, 21.8; 
HRMS (CI) calcd for C16H22NO4S (MH+) 324.1270, found 324.1272. 
 
General procedure A for the Sonogashira cross-coupling reactions. For a general 
procedure, see Section 2.8. 
 
3-(2-Iodophenyl)-2-propyn-1-ol (21). According to general procedure A, 
to a solution of 2-propyn-1-ol (264 mg, 4.71 mmol), 1,2-diiodobenzene 
(1.01 g, 3.06 mmol) and Et2NH (1.59 mL, 15.4 mmol) in Et2O (40 mL), CuI 
(87 mg, 0.46 mmol) and PdCl2(PPh3)2 (109 mg, 0.16 mmol) were added and 
the resulting mixture was stirred for 20 h. Work-up and purification by chromatography 
(EtOAc/heptane 1:4) afforded 21 (380 mg, 1.47 mmol, 48%) as a brown oil. Rf 0.20; 1H NMR 
(300 MHz, CDCl3) δ 7.79 (dd, J = 1.2, 8.1 Hz, 1H), 7.41 (dd, J = 1.5, 7.8 Hz, 1H), 7.25 (dt, J = 
1.2, 7.5 Hz, 1H), 6.96 (dt, J = 1.8, 7.8 Hz, 1H), 4.54 (s, 2H), 2.20 (br s, 1H). 
 
Methyl (2R)-5-[2-(3-hydroxy-1-propynyl)phenyl]-2-{[(4-methylphe-
nyl)sulfonyl]amino}-4-pentynoate (18). According to general 
procedure A, to a solution of 20 (375 mg, 1.33 mmol), 21 (412 mg, 
1.60 mmol) and Et2NH (0.69 mL, 6.74 mmol) in Et2O (18 mL), CuI (37 
mg, 0.19 mmol) and PdCl2(PPh3)2 (48 mg, 0.07 mmol) were added and the resulting mixture 
was stirred for 3 h. Work-up and purification by chromatography (EtOAc/heptane 2:3) 
afforded 18 (449 mg, 1.09 mmol, 82%) as a yellow oil. Rf 0.20; [α]D −4.1 (c 0.5, CH2Cl2); IR 
(neat) 3484, 3276, 2952, 1737, 1635, 1592, 1477, 1439; 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 
8.1 Hz, 2H), 7.39 (m, 1H), 7.30 (m, 1H), 7.22 (m, 4H), 6.19 (d, J = 8.7 Hz, 1H) 4.59 (d, J = 5.4 
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Hz, 2H), 4.21 (m, 1H), 3.63 (s, 3H), 3.23 (br m, 1H), 2.98 (dd, J = 4.2, 17.1 Hz, 1H), 2.90 (dd, J = 
5.1, 17.1 Hz, 1H), 2.37 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 170.1, 143.6, 136.9, 132.0, 131.7, 
129.6, 127.9, 127.9, 127.1, 125.3, 125.1, 91.6, 86.8, 84.0, 83.2, 54.3, 53.2, 51.6, 25.4, 21.8; HRMS 
(EI) calcd for C22H21NO5S 411.1140, found 411.1136. 
 
Methyl (2R)-5-[2-(4-hydroxy-1-butynyl)phenyl]-2-{[(4-methylphe-
nyl)sulfonyl]amino}-4-pentynoate (19). According to general 
procedure A, to a solution of 20 (380 mg, 1.35 mmol), 4-(2-
iodophenyl)-3-butyn-1-ol (448 mg, 1.65 mmol) and Et2NH (0.70 mL, 
6.84 mmol) in Et2O (18 mL), CuI (27 mg, 0.14 mmol) and 
PdCl2(PPh3)2 (47 mg, 0.07 mmol) were added and the resulting mixture was stirred for 3 h. 
Work-up and purification by chromatography (EtOAc/heptane 2:3) afforded 19 (516 mg, 
1.21 mmol, 90%) as a light-yellow oil. Rf 0.15; [α]D +2.6 (c 0.5, CH2Cl2); IR (neat) 3495, 3266, 
2955, 1736, 1584, 1473, 1438; 1H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 8.4 Hz, 2H), 7.36 (m, 
1H), 7.22 (m, 5H), 6.12 (d, J = 8.7 Hz, 1H) 4.17 (m, 1H), 3.86 (m, 2H), 3.61 (s, 3H), 3.00-2.73 (m, 
4H), 2.55 (t, J = 6.0 Hz, 1H), 2.34 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 170.0, 143.5, 136.9, 
131.9, 131.7, 129.5, 127.9, 127.5, 127.1, 125.9, 125.2, 91.3, 86.7, 83.2, 81.4, 61.1, 54.5, 53.0, 25.3, 
24.2, 21.8; HRMS (EI) calcd for C23H23NO5S 425.1297, found 425.1309. 
 
Methyl (2S,6Z)-2-[(tert-butoxycarbonyl)amino]-7-chloro-6-hepten-4-ynoate 
(31). According to general procedure A, to a solution of 30 (391 mg, 1,72 
mmol), cis-1,2-dichloroethylene (830 mg, 8.57 mmol) and nPrNH2 (512 mg, 8.67 
mmol) in Et2O (18 mL), CuI (51 mg, 0.27 mmol) and PdCl2(PPh3)2 (61 mg, 0.09 
mmol) were added. Work-up and purification by chromatography 
(EtOAc/heptane 1:8) afforded 31 (342 mg, 1.19 mmol, 69%) as a yellow oil. Rf 
0.28 (EtOAc/heptane 1:4); [α]D +74.8 (c 1.0, CH2Cl2); IR (neat) 3375, 3085, 2977, 1747, 1717; 1H 
NMR (300 MHz, CDCl3) δ 6.37 (d, J = 7.4 Hz, 1H), 5.83 (d, J = 7,4 Hz, 1H), 5.41 (d, J = 8.0 Hz, 
1H), 4.53 (m, 1H), 3.79 (s, 3H), 2.95 (m, 2H), 1.46 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 170.8, 
154.8, 128.16, 111.6, 92.5, 79.7, 77.2, 52.3, 51.8, 27.9, 23.6. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-(2-iodophenyl)-4-pentyno-
ate (36). According to general procedure A, to a solution of 30 (403 mg, 
1.77 mmol), 1,2-diiodobenzene (698 mg, 2.12 mmol) and Et2NH (0.91 mL, 
8.87 mmol) in Et2O (18 mL), CuI (33 mg, 0.17 mmol) and PdCl2(PPh3)2 (63 
mg, 0.09 mmol) were added and the resulting mixture was stirred for 3 h. 
Work-up and purification by chromatography (EtOAc/heptane 1:4) afforded 36 (413 mg, 
0.96 mmol, 54%) as a yellow oil. Rf 0.64 (EtOAc/heptane 1:1); [α]D +47.5 (c 0.5, CH2Cl2); IR 
(neat) 3395, 2971, 1744, 1709, 1498; 1H NMR (300 MHz, CDCl3) δ 7.78 (dd, J = 1.2, 7.8 Hz, 1H), 
7.37 (dd, J = 1.8, 7.8 Hz, 1H), 7.24 (dt, J = 1.2, 7.5 Hz, 1H), 6.96 (dt, J = 1.8, 7.8 Hz, 1H), 5.56 (br 
d, J = 7.5 Hz, 1H), 4.57 (br m, 1H), 3.79 (s, 3H), 3.02 (m, 2H), 1.46 (s, 9H); 13C NMR (75 MHz, 
CO2Me
HN
Ts
OH
HN CO2Me
Boc
I
Chapter 5 
 
112 
CDCl3) δ 171.0, 155.0, 138.5, 132.7, 129.5, 129.3, 127.7, 100.8, 88.3, 85.7, 80.3, 53.0, 52.3, 28.7, 
24.2; HRMS (EI) calcd for C17H20NO4I 429.0437, found 429.0438. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-[2-((3S)-4-(tert-buto-
xy)-3-{[(4-methylphenyl)-sulfonyl]amino}-4-oxo-1-butynyl)-phenyl]-
4-pentynoate (37). According to general procedure A, to a solution of 
35 (218 mg, 0.68 mmol), 36 (348 mg, 0.81 mmol) and Et2NH (0.35 mL, 
3.39 mmol) in Et2O (18 mL), CuI (14 mg, 0.07 mmol) and PdCl2(PPh3)2 
(25 mg, 0.04 mmol) were added and the resulting mixture was stirred for 22 h. Work-up and 
purification by chromatography (EtOAc/heptane 1:3) afforded 37 (310 mg, 0.50 mmol, 74%) 
as a brown oil. Rf 0.14; [α]D +8.8 (c 0.6, CH2Cl2); IR (neat) 3274, 2954, 2920, 1714, 1593, 1498, 
1480, 1437; 1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 8.1 Hz, 2H), 7.35 (m, 1H), 7.23 (m, 5H), 
5.68 (d, J = 9.0 Hz, 1H) 5.49 (d, J = 8.7 Hz, 1H), 4.59 (m, 1H), 4.08 (m, 1H), 3.78 (s, 3H), 3.11-
2.87 (m, 4H), 2.35 (s, 3H), 1.67 (s, 9H), 1.45 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 171.3, 168.6, 
155.1, 143.3, 137.1, 132.1, 132.0, 129.5, 127.7, 127.7, 127.2, 125.4, 125.2, 88.2, 87.3, 83.0, 82.9, 
82.5, 80.3, 55.0, 52.9, 52.4, 28.6, 28.0, 24.3, 23.0, 21.8. 
 
Methyl 4-[(4-methylphenyl)sulfonyl]-1,2,7,8-tetradehydro-3,4,5,6-
tetrahydro-4-benzacecine-5-carboxylate (16). To a solution of 18 
(338 mg, 0.82 mmol) in CH2Cl2 (15 mL), MsCl (0.13 mL, 1.67 mmol) 
and Et3N (0.23 mL, 1.66 mmol) were added at 0 °C. The reaction 
mixture was allowed to reach room temperature and stirred for 4 h after which it was 
poured into a solution of CH2Cl2/water (80 mL, 1:1 v/v). The layers were separated and the 
organic layer was washed with water (2 × 40 mL), dried over MgSO4 and concentrated in 
vacuo. Purification by chromatography (EtOAc/heptane 2:3) afforded the mesylate 22 (347 
mg, 0.71 mmol, 87%) as a yellow oil. Rf 0.22; 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 8.2 Hz, 
2H), 7.43 (m, 1H), 7.29 (m, 5H), 5.68 (d, J = 8.4 Hz, 1H) 5.22 (dd, J = 15.9, 17.4 Hz, 2H), 4.14 
(m, 1H), 3.62 (s, 3H), 3.19 (s, 3H), 2.97 (d, J = 4.8 Hz, 2H), 2.38 (s, 3H). To a solution of the 
mesylate 22 (334 mg, 0.68 mmol) in DMF (115 mL), K2CO3 (470 mg, 3.40 mmol) was added 
and the reaction mixture was stirred for 2 h at room temperature. The mixture was poured 
into a solution of EtOAc/water (600 mL; 1:1 v/v) and the layers were separated. The organic 
layer was washed with water (3 × 300 mL), dried over MgSO4 and concentrated in vacuo. 
Purification by chromatography (EtOAc/heptane 1:4) afforded 16 (201 mg, 0.51 mmol, 75%) 
as a white solid. An X-ray crystal structure determination was carried out after 
recrystallization from EtOAc/heptane. Rf 0.19; IR (neat) 2958, 1735, 1593, 1459, 1433; 1H NMR 
(300 MHz, CDCl3) δ 7.78 (dd, J = 1.8, 6.6 Hz, 2H), 7.22 (m, 4H), 7.09 (m, 2H), 4.74 (d, J = 19.2 
Hz, 1H) 4.29 (dd, J = 3.9, 10.5 Hz, 1H), 4.18 (d, J = 19.2 Hz, 1H), 3.82 (s, 3H), 3.29 (dd, J = 10.2, 
18.3 Hz, 1H), 3.20 (dd, J = 3.9, 18.3 Hz, 1H), 2.22 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 169.8, 
143.4, 137.6, 129.3, 128.7, 128.1, 128.0, 127.7, 127.5, 127.5, 127.2, 95.3, 92.8, 87.3, 84.1, 64.4, 53.2, 
42.6, 21.9, 21.7; HRMS (EI) calcd for C22H19NO4S 393.1035, found 393.1038. 
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Crystallographic data for 16: 
Crystal color    transparent colorless 
Crystal shape    regular fragment 
Crystal size    0.31 × 0.15 × 0.15 mm 
Empirical formula   C22H19NO4S 
Formula weight   339.44 
Temperature    208(2) K 
Radiation/Wavelength  MoKα (graphite mon.)/0.71073 Å 
Crystal system, space group  Triclinic, P–1 
Unit cell dimensions   a = 6.8047(2) Å; α = 111.921(6)° 
23786 reflections   b = 11.9451(7) Å; β = 94.992(5)° 
3.020 < θ < 27.500   c = 12.7864(9) Å; γ = 92.605(4)° 
Volume    957.09(9) Å3 
Z, Calculated density   2, 1.365 Mg/m3 
Absorption coefficient  0.198 mm–1 
Diffractometer/scan   Nonius KappaCCD/area detector ϕ and ω scan 
F(000)    412 
θ range for data collection  3.02 to 27.50° 
Index ranges    −8<=h<=8, −15<=k<=15, −16<=l<=16 
Reflections collected/unique  23786/4377 [R(int) = 0.0249] 
Reflections observed   3612 ([Io>2σ(Io)]) 
Absorption correction   None 
Refinement method   Full-matrix least-squares on F2 
Computing    SHELXL-97 (Sheldrick, 1997) 
Data/restraints/parameters  4377/0/329 
Goodness-of-fit on F2   1.038 
SHELXL-97 weight parameters 0.050000, 0.309900 
Final R indices [I>2σ(I)]  R1 = 0.0373, wR2 = 0.0935 
R indices (all data)   R1 = 0.0494, wR2 = 0.0995 
Largest diff. peak and hole  0.367 and −0.341 e.A–3 
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Table 5.1 Bond lengths of the non-hydrogen atoms (Å) of 16 (standard deviations) 
S(1)-O(1) 1.4294(11) C(2)-C(3) 1.190(2) C(11)-C(12) 1.457(2) 
S(1)-O(2) 1.4301(11) C(3)-C(4) 1.433(2) C(12)-C(13) 1.5364(19) 
S(1)-N(1) 1.6324(12) C(4)-C(5) 1.392(2) C(13)-C(14) 1.528(2) 
S(1)-C(16) 1.7620(15) C(4)-C(9) 1.417(2) C(16)-C(21) 1.380(2) 
O(3)-C(14) 1.1985(18) C(5)-C(6) 1.385(3) C(16)-C(17) 1.392(2) 
O(4)-C(14) 1.3246(18) C(6)-C(7) 1.376(3) C(17)-C(18) 1.381(2) 
O(4)-C(15) 1.451(2) C(7)-C(8) 1.381(3) C(18)-C(19) 1.384(3) 
N(1)-C(13) 1.4716(17) C(8)-C(9) 1.392(2) C(19)-C(20) 1.384(2) 
N(1)-C(1) 1.4774(18) C(9)-C(10) 1.432(2) C(19)-C(22) 1.512(3) 
C(1)-C(2) 1.466(2) C(10)-C(11) 1.192(2) C(20)-C(21) 1.386(2) 
 
Table 5.2 Bond angles of the non-hydrogen atoms (°) of 16 (standard deviations) 
O(1)-S(1)-O(2) 120.63(7) C(5)-C(4)-C(3) 123.70(15) C(14)-C(13)-C(12) 109.02(11) 
O(1)-S(1)-N(1) 105.59(6) C(9)-C(4)-C(3) 116.53(13) O(3)-C(14)-O(4) 125.09(14) 
O(2)-S(1)-N(1) 106.59(7) C(6)-C(5)-C(4) 119.39(18) O(3)-C(14)-C(13) 123.97(13) 
O(1)-S(1)-C(16) 107.93(7) C(7)-C(6)-C(5) 120.97(18) O(4)-C(14)-C(13) 110.88(12) 
O(2)-S(1)-C(16) 107.49(7) C(6)-C(7)-C(8) 120.56(18) C(21)-C(16)-C(17) 120.54(15) 
N(1)-S(1)-C(16) 108.07(7) C(7)-C(8)-C(9) 119.91(17) C(21)-C(16)-S(1) 119.97(11) 
C(14)-O(4)-C(15) 116.40(13) C(8)-C(9)-C(4) 119.41(15) C(17)-C(16)-S(1) 119.44(12) 
C(13)-N(1)-C(1) 118.37(12) C(8)-C(9)-C(10) 123.81(14) C(18)-C(17)-C(16) 118.91(16) 
C(13)-N(1)-S(1) 120.34(9) C(4)-C(9)-C(10) 116.77(13) C(17)-C(18)-C(19) 121.41(15) 
C(1)-N(1)-S(1) 120.38(10) C(11)-C(10)-C(9) 165.94(15) C(20)-C(19)-C(18) 118.73(16) 
C(2)-C(1)-N(1) 112.00(12) C(10)-C(11)-C(12) 177.03(14) C(20)-C(19)-C(22) 120.0(2) 
C(3)-C(2)-C(1) 171.78(15) C(11)-C(12)-C(13) 113.37(12) C(18)-C(19)-C(22) 121.31(19) 
C(2)-C(3)-C(4) 166.01(15) N(1)-C(13)-C(14) 111.43(11) C(19)-C(20)-C(21) 120.85(16) 
C(5)-C(4)-C(9) 119.77(15) N(1)-C(13)-C(12) 117.03(12) C(16)-C(21)-C(20) 119.47(15) 
 
Methyl 5-[(4-methylphenyl)sulfonyl]-1,2,8,9-tetradehydro-4,5,6,7-
tetrahydro-3H-5-benzazacycloundecine-4-carboxylate (17). To a 
solution of 19 (460 mg, 1.08 mmol) in CH2Cl2 (20 mL), MsCl (0.17 
mL, 2.18 mmol) and Et3N (0.30 mL, 2.16 mmol) were added at 0 °C. 
The reaction mixture was allowed to reach room temperature and stirred for 3 h after which 
it was poured into a solution of CH2Cl2/water (100 mL, 1:1 v/v). The layers were separated 
and the organic layer was washed with water (2 × 50 mL), dried over MgSO4 and 
concentrated in vacuo. Purification by chromatography (EtOAc/heptane 2:3) afforded the 
mesylate 23 (495 mg, 0.98 mmol, 91%) as a yellow oil. Rf 0.15; 1H NMR (300 MHz, CDCl3) δ 
7.73 (d, J = 8.4 Hz, 2H), 7.38 (m, 1H), 7.24 (m, 5H), 5.60 (d, J = 9.0 Hz, 1H) 4.46 (t, J = 6.6 Hz, 
2H), 4.17 (m, 1H), 3.62 (s, 3H), 3.08 (s, 3H), 3.02 (t, J = 6.6 Hz, 2H), 2.93 (t, J = 4.5 Hz, 2H), 2.38 
(s, 3H). To a solution of the mesylate 23 (480 mg, 0.95 mmol) in DMF (160 mL), K2CO3 (658 
mg, 4.77 mmol) was added and the reaction mixture was stirred for 2 h at room temperature. 
The mixture was poured into a solution of EtOAc/water (800 mL; 1:1 v/v) and the layers 
were separated. The organic layer was washed with water (3 × 400 mL), dried over MgSO4 
and concentrated in vacuo. Purification by chromatography (EtOAc/heptane 1:4) afforded 17 
(295 mg, 0.72 mmol, 76%) as a colorless oil. Rf 0.14; IR (neat) 3270, 2949, 2915, 1740, 1593, 
1480, 1442; 1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 6.4 Hz, 2H), 7.37 (m, 1H), 7.26 (m, 5H), 
6.10 (dd, J = 11.1, 17.4 Hz, 1H) 5.78 (dd, J = 2.1, 17.4 Hz, 1H), 5.58 (dd, J = 2.1, 11.1 Hz, 1H), 
N
CO2Me
Ts
Functionalized Heterocyclic Enediynes 
 
115 
5.51 (d, J = 9.0 Hz, 1H), 4.20 (m, 1H), 3.61 (s, 3H), 2.98 (dd, J = 4.5, 16.8 Hz, 1H), 2.88 (dd, J = 
5.4, 17.1 Hz, 1H), 2.37 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 169.9, 143.6, 136.9, 132.1, 131.9, 
129.6, 127.9, 127.9, 127.6, 127.1, 125.6, 124.9, 117.2, 92.0, 88.7, 86.9, 83.0, 54.5, 53.1, 25.5, 21.8; 
HRMS (EI) calcd for C23H21NO4S 407.1191, found 407.1193. 
 
Methyl (2R)-2-({(2S,6Z)-2-[(tert-butoxycarbonyl)amino]-7-chloro-6-
hepten-4-ynoyl}amino)-4-pentynoate (32). To a solution of enyne 31 
(308 mg, 1.07 mmol) in CH2Cl2 (8 mL), TFA (8 mL) was added and 
the reaction mixture was stirred at room temperature for 3 h, after 
which time the reaction mixture was concentrated in vacuo. The 
crude product was suspended in EtOAc (20 mL), i-Pr2NH (0.50 mL, 
2.68 mmol) was added and the resulting mixture was stirred for 30 
min at room temperature. Then, 33 (342 mg, 1.61 mmol) was added followed by addition of 
HOBt (289 mg, 2.14 mmol) and DCC (243 mg, 1.18 mmol), and the resulting mixture was 
stirred further at room temperature. Upon completion, the reaction mixture was filtered, 
diluted with EtOAc (20 mL), washed with water (2 × 10 mL), 10% aqueous Na2CO3 (2 × 10 
mL), water (2 × 10 mL), brine (2 × 10 mL), dried over Na2SO4 and concentrated in vacuo. 
Purification by chromatography (EtOAc/heptane 1:3) afforded 32 (205 mg, 0.54 mmol, 50%) 
as a colorless oil. Rf 0.24 (EtOAc/heptane 1:2); [α]D +75.1 (c 1.0, CH2Cl2); IR (neat) 3296, 3084, 
2977, 1746, 1716, 1672, 1519; 1H NMR (200 MHz, CDCl3) δ 7.16 (d, J = 7.5 Hz, 1H), 6.35 (d, J = 
7.3 Hz, 1H), 5.80 (dt, J = 1.9, 7.4 Hz, 1H), 5.32 (d, J = 6.9 Hz, 1H), 4.77 (m, 1H), 4.34 (br m, 1H), 
3.77 (s, 3H), 2.97 (dd, J = 1.8, 4.5 Hz, 2H), 2.83 (ddd, J = 2.2, 4.6, 19.2 Hz, 1H), 2.61 (ddd, J = 
2.6, 6.4, 17.0 Hz, 1H), 2.07 (t, J = 3.8 Hz, 1H), 1.45 (s, 9H); HRMS (EI) calcd for C18H23N2O5Cl 
382.1295, found 382.1295. 
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SUMMARY 
 
SYNTHESIS OF MULTI-FUNCTIONAL BUILDING BLOCKS 
FROM ACETYLENE-CONTAINING α-AMINO ACIDS 
 
 
The proteinogenic α-amino acids are cheap and readily available chiral building 
blocks, which have been used for many years as enantiomerically pure starting materials for 
a variety of (bio)synthetic purposes. These amino acids, however, incorporate a relatively 
small set of functional groups in the side chain, which still limits their synthetic utility. 
Therefore, non-proteinogenic α-amino acids in general have recently become more and more 
important as building block in synthetic routes as they offer, by virtue of the non-natural 
functionality in the side chain, additional possibilities for structural modification, compared 
to the proteinogenic amino acids. 
Following this perspective, this thesis details the application of the enantiomerically 
pure acetylene-containing α-amino acids 1-3 in the synthesis of functionalized heterocyclic 
building blocks, with a focus on transition metal-catalyzed transformations. 
 
1 2 3
H2N CO2H H2N CO2HH2N CO2H
 
 
In Chapter 1, a number of recent applications of acetylene-containing α-amino acids 
in (bio)organic chemistry are summarized. 
Chapter 2 describes the synthesis of both unsaturated proline derivatives as well as 
novel optically active tryptophan analogues via Pd- or Ag-catalyzed cyclization reactions of 
aniline-containing acetylenic amino acids (viz. 5, Scheme 1). The cyclization precursors 5, 
obtained from the protected amino acids 1-3 via a Pd-catalyzed Sonogashira coupling with 2-
iodoaniline, underwent in the presence of a Pd(II)-catalyst a rapid cycloisomerization to give 
either the tryptophan analogues 6 or proline derivative 4. The mode of cyclization in these 
reactions turned out to be strongly dependent on the side chain length of the cyclization 
precursor. By simply switching to AgOTf as the catalyst, precursor 5 (n = 1) could be 
selectively transformed into the corresponding tryptophan analogue 7, without formation of 
pyrroline 4 (Scheme 1). 
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In addition, the oxygen-containing tryptophan analogue 9 was directly obtained from 
enantiopure propargylglycine derivative 8 via a tandem Sonogashira cross-coupling 
cyclization reaction with 2-iodophenol (Scheme 2). 
 
Scheme 2 
HN CO2Me
Ts
8
HN CO2Me
O
Ts
9
2-iodophenol
PdCl2(PPh3)2, CuI
Et2NH, reflux
 
 
Chapter 3 utilizes the reaction conditions described in Chapters 2 and 4 in cyclo-
isomerizations of substituted acetylenic amino acids, leading to the formation of several 
enantiomerically pure functionalized heterocycles. As an example, the enantiopure phenyl-
substituted propargylglycine derivative 11 (R = Me) underwent a Pd-catalyzed cyclization to 
afford the 2,5-disubstituted pyrroline 12 without detectable racemization (Scheme 3). By 
using the carboxylic acid moiety as the nucleophile, cyclization precursor 11 (R = H) was 
transformed into the corresponding lactone 10 via a Ag-catalyzed cycloisomerization. In 
order to demonstrate the synthetic utility of pyrrolines such as 12, it was also shown that this 
compound could be efficiently transformed into the corresponding saturated proline 
derivatives 13 and 14. 
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Chapter 4 deals with a novel approach toward 5-aryl-substituted proline analogues, 
involving a mild Ag-catalyzed 5-endo-dig cyclization of enantiomerically pure aryl-
substituted acetylenic amino acids. An example of this approach is shown in Scheme 4, in 
which the enantiopure phenyl-substituted propargylglycine derivative 15 undergoes a Ag-
catalyzed cycloisomerization to give the 2,5-disubstituted pyrroline 16. Pyrrolines such as 16 
can be easily transformed into the corresponding 5-aryl-substituted proline analogues as 
demonstrated by the efficient conversion of 16 into cis-5-phenylproline derivative 17. 
 
Scheme 4 
17
H2N CO2Me
15
N CO2Me
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Finally, Chapter 5 discloses the synthesis of novel heterocyclic functionalized 
enediynes by using enantiopure propargylglycine derivatives in the construction of the 
targeted enediyne functionality. Among the selected target compounds were the nitrogen-
containing cyclic enediynes (azaenediynes) 22, which were synthesized starting from 
propargylglycine derivative 18 (Scheme 5). In this pathway, propargylglycine derivative 18 
was first coupled under Sonogashira-type conditions with the appropriate aryl iodides 19 to 
afford the acyclic enediynes 20. These compounds were then reacted with MsCl to give the 
corresponding mesylates 21, which subsequently underwent an intramolecular base-
mediated cyclization to provide the desired azaenediynes 22. 
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SAMENVATTING 
 
SYNTHESE VAN MULTI-FUNCTIONELE BOUWSTENEN 
UITGAANDE VAN ACETYLEENHOUDENDE α-AMINOZUREN 
 
 
De natuurlijke α-aminozuren zijn goedkope en eenvoudig verkrijgbare chirale 
bouwstenen, die al vele jaren zijn gebruikt als enantiomeerzuivere uitgangsstoffen voor 
uiteenlopende (bio)synthetische doeleinden. Deze aminozuren bevatten echter een relatief 
kleine verscheidenheid aan functionele groepen in de zijketen, waardoor hun synthetische 
bruikbaarheid nog steeds enigszins beperkt is. α-Aminozuren met niet-natuurlijke 
functionele groepen in de zijketen zijn daarom de afgelopen jaren steeds belangrijker 
geworden als veelzijdige bouwsteen in syntheseroutes. De niet-natuurlijke functionele groep 
in de zijketen van deze aminozuren biedt immers, in vergelijking tot de natuurlijke 
aminozuren, nieuwe mogelijkheden voor structurele veranderingen van de aminozuren zelf. 
Vanuit dit perspectief gaat in dit proefschrift de aandacht uit naar de toepassing van 
de enantiomeerzuivere acetyleenhoudende α-aminozuren 1-3 in de metaal-gekatalyseerde 
synthese van gefunctionaliseerde heterocyclische bouwstenen. 
 
1 2 3
H2N CO2H H2N CO2HH2N CO2H
 
 
In Hoofdstuk 1 wordt een aantal recente toepassingen van acetyleenhoudende α-
aminozuren in de (bio)organische chemie samengevat. 
Hoofdstuk 2 beschrijft de synthese van onverzadigde prolinederivaten en nieuwe 
optisch actieve tryptofaananaloga uitgaande van de aniline-bevattende aminozuren 5 
(Schema 1), gebruikmakend van Pd- of Ag-gekatalyseerde cyclisatiereacties. De aminozuren 
5, verkregen uitgaande van de beschermde aminozuren 1-3 via een Pd-gekatalyseerde 
Sonogashira koppeling met 2-joodaniline, ondergingen in aanwezigheid van een Pd(II)-
katalysator een snelle cycloisomerisatie, waarbij enerzijds de tryptofaananaloga 6 en 
anderzijds prolinederivaat 4 werden verkregen. De wijze van cyclisatie in deze reacties bleek 
sterk afhankelijk te zijn van de lengte van de zijketen van de aminozuren 5. Door 
eenvoudigweg gebruik te maken van AgOTf als katalysator kon aminozuur 5 (n = 1) selectief 
worden omgezet in het overeenkomstige tryptofaananalogon 7, zonder de vorming van 
pyrroline 4 (Schema 1). 
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Tevens werd het zuurstof-bevattende tryptofaananalogon 9 direct verkregen 
uitgaande van enantiomeerzuiver propargylglycine 8 via een tandem Sonogashira 
koppeling/cyclisatiereactie met 2-joodfenol (Schema 2). 
 
Schema 2 
HN CO2Me
Ts
8
HN CO2Me
O
Ts
9
2-iodophenol
PdCl2(PPh3)2, CuI
Et2NH, reflux
 
 
Hoofdstuk 3 gebruikt de cyclisatiecondities, welke zijn beschreven in Hoofdstukken 2 
en 4, voor de synthese van diverse enantiomeerzuivere heterocyclische verbindingen via 
cycloisomerisaties van acetyleenhoudende aminozuren. Het enantiomeerzuivere fenyl-
gesubstitueerde propargylglycine 11 (R = Me) onderging bijvoorbeeld een Pd-gekatalyseerde 
cyclisatie, waarbij het 2,5-digesubstitueerde pyrroline 12 zonder racemisatie werd verkregen 
(Schema 3). Door gebruik te maken van de carbonzuurfunctie als nucleofiel werd aminozuur 
11 (R = H) omgezet in het overeenkomstige lacton 10 via een Ag-gekatalyseerde cyclo-
isomerisatie. Om de synthetische bruikbaarheid van pyrrolines zoals 12 aan te tonen, werd 
deze verbinding tevens op een efficiënte wijze omgezet in de verzadigde prolinederivaten 13 
en 14. 
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Hoofdstuk 4 behandelt een nieuwe methode voor de synthese van 5-aryl-gesub-
stitueerde proline-analoga, waarin gebruik wordt gemaakt van een Ag-gekatalyseerde 5-
endo-dig cyclisatie van enantiomeerzuivere acetyleenhoudende aminozuren. In Schema 4 is 
een voorbeeld van deze methode weergegeven waarin het enantiomeerzuivere fenyl-
gesubstitueerde propargylglycine 15 onder invloed van de Ag-katalysator cycliseert tot het 
2,5-digesubstitueerde pyrroline 16. 
 
Schema 4 
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Tenslotte beschrijft Hoofdstuk 5 de synthese van nieuwe heterocyclische gefunctio-
naliseerde eendiynen door gebruik te maken van enantiomeerzuivere propargyl-
glycinederivaten in de opbouw van het gewenste eendiynsysteem. Onder de geselecteerde 
doelverbindingen bevonden zich de stikstof-bevattende cyclische eendiynen (azaeendiynen) 
22, welke werden gesynthetiseerd uitgaande van propargylglycine 18 (Schema 5). In deze 
route werd propargylglycine 18 eerst gekoppeld onder Sonogashira-condities met de 
aryljodides 19 waarbij de acyclische eendiynen 20 werden verkregen. Deze verbindingen 
werden dan omgezet in de overeenkomstige mesylaten 21, die vervolgens onder invloed van 
een base een intramoleculaire cyclisatie ondergingen waarbij de gewenste azaeendiynen 22 
werden gevormd. 
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